| Drug |
paclitaxel |
357 |
2015 |
| Drug |
trastuzumab |
320 |
2015 |
| Drug |
cyclophosphamide |
314 |
2014 |
| Drug |
docetaxel |
261 |
2015 |
| placebo |
placebo |
251 |
2014 |
| Other |
laboratory biomarker analysis |
245 |
2015 |
| Drug |
capecitabine |
169 |
2015 |
| Drug |
letrozole |
169 |
2015 |
| Drug |
carboplatin |
165 |
2017 |
| Drug |
fulvestrant |
136 |
2015 |
| Other |
questionnaire administration |
122 |
2014 |
| Other |
quality-of-life assessment |
107 |
2014 |
| Drug |
exemestane |
105 |
2015 |
| Radiation |
radiotherapy |
100 |
2014 |
| Drug |
bevacizumab |
97 |
2014 |
| Drug |
anastrozole |
96 |
2015 |
| Drug |
doxorubicin |
92 |
2018 |
| Drug |
pertuzumab |
88 |
2015 |
| Drug |
epirubicin |
82 |
2014 |
| Drug |
palbociclib |
81 |
2014 |
| Drug |
gemcitabine |
79 |
2014 |
| Drug |
tamoxifen |
79 |
2015 |
| Drug |
lapatinib |
76 |
2009 |
| Drug |
doxorubicin hydrochloride |
64 |
2009 |
| Drug |
pembrolizumab |
64 |
2018 |
| Other |
pharmacological study |
63 |
2010 |
| Drug |
tamoxifen citrate |
60 |
2014 |
| Drug |
nab-paclitaxel |
56 |
2015 |
| Drug |
vinorelbine |
52 |
2015 |
| Biological |
filgrastim |
51 |
2017 |
| Drug |
cisplatin |
49 |
2014 |
| Drug |
everolimus |
47 |
2014 |
| Other |
standard care |
42 |
2015 |
| Procedure |
conventional surgery |
40 |
2011 |
| Procedure |
therapeutic conventional surgery |
40 |
2015 |
| Drug |
fluorouracil |
39 |
2016 |
| Drug |
atezolizumab |
37 |
2019 |
| Other |
questionnaire |
37 |
2015 |
| Drug |
zoledronic acid |
37 |
2010 |
| Procedure |
adjuvant therapy |
35 |
2008 |
| Drug |
herceptin |
35 |
2010 |
| Drug |
epirubicin hydrochloride |
34 |
2008 |
| Other |
educational intervention |
33 |
2010 |
| Drug |
ixabepilone |
32 |
2009 |
| Drug |
pegfilgrastim |
32 |
2017 |
| Drug |
methotrexate |
31 |
2014 |
| Behavioral |
exercise intervention |
30 |
2014 |
| Drug |
olaparib |
30 |
2014 |
| Procedure |
biopsy |
29 |
2016 |
| Drug |
eribulin |
29 |
2015 |
| Drug |
chemotherapy |
28 |
2014 |
| Drug |
goserelin |
28 |
2015 |
| Drug |
ribociclib |
28 |
2015 |
| Procedure |
peripheral blood stem cell transplantation |
26 |
1999 |
| Procedure |
surgery |
26 |
2009 |
| Other |
exercise |
25 |
2018 |
| Drug |
lapatinib ditosylate |
25 |
2008 |
| Drug |
trastuzumab emtansine |
25 |
2010 |
| Procedure |
neoadjuvant therapy |
24 |
2018 |
| Biological |
sargramostim |
24 |
2016 |
| Procedure |
care |
23 |
2009 |
| Drug |
neratinib |
23 |
2014 |
| Drug |
nivolumab |
23 |
2014 |
| Procedure |
psychosocial assessment |
23 |
2009 |
| Procedure |
psychosocial assessment/care |
23 |
2009 |
| Drug |
5-fluorouracil |
22 |
2019 |
| Drug |
abemaciclib |
22 |
2019 |
| Drug |
durvalumab |
22 |
2019 |
| Drug |
endocrine therapy |
21 |
2009 |
| Drug |
metformin |
21 |
2009 |
| Procedure |
positron emission tomography |
21 |
2018 |
| Drug |
eribulin mesylate |
20 |
2014 |
| Other |
immunohistochemistry staining method |
19 |
2010 |
| Other |
counseling intervention |
18 |
2009 |
| Procedure |
magnetic resonance imaging |
18 |
2011 |
| Drug |
t-dm1 |
18 |
2014 |
| Drug |
thiotepa |
18 |
2007 |
| Other |
acupuncture |
17 |
2015 |
| Drug |
abraxane |
16 |
2014 |
| Other |
control |
16 |
2018 |
| Drug |
pyrotinib |
16 |
2018 |
| Dietary Supplement |
vitamin d |
16 |
2010 |
| Radiation |
whole breast irradiation |
16 |
2018 |
| Drug |
celecoxib |
15 |
2013 |
| Drug |
entinostat |
15 |
2016 |
| Drug |
gefitinib |
15 |
2008 |
| Other |
informational intervention |
15 |
2020 |
| Drug |
veliparib |
15 |
2013 |
| Drug |
apatinib |
14 |
2010 |
| Drug |
aromatase inhibitor |
14 |
2011 |
| Drug |
bkm120 |
14 |
2014 |
| Drug |
dasatinib |
14 |
2008 |
| Drug |
gemcitabine hydrochloride |
14 |
2016 |
| Other |
best available therapy |
13 |
2019 |
| Procedure |
computed tomography |
13 |
2018 |
| Drug |
ipatasertib |
13 |
2014 |
| Drug |
ipilimumab |
13 |
2017 |
| Procedure |
management of therapy complications |
13 |
2010 |
| Device |
mri |
13 |
2014 |
| Drug |
pegylated liposomal doxorubicin |
13 |
2010 |
| Behavioral |
physical activity |
13 |
2017 |
| Drug |
talazoparib |
13 |
2014 |
| Drug |
taxotere |
13 |
2016 |
| Radiation |
accelerated partial breast irradiation |
12 |
2018 |
| Device |
ct-scan |
12 |
2013 |
| Drug |
goserelin acetate |
12 |
2014 |
| Drug |
irinotecan hydrochloride |
12 |
2017 |
| Drug |
pegylated liposomal doxorubicin hydrochloride |
12 |
2009 |
| Procedure |
blood draw |
11 |
2018 |
| Drug |
enzalutamide |
11 |
2016 |
| Drug |
etoposide |
11 |
2019 |
| Drug |
paclitaxel albumin-stabilized nanoparticle formulation |
11 |
2012 |
| Drug |
pemetrexed |
11 |
2015 |
| Procedure |
sentinel lymph node biopsy |
11 |
2014 |
| Procedure |
axillary lymph node dissection |
10 |
2009 |
| Drug |
byl719 |
10 |
2014 |
| Drug |
cholecalciferol |
10 |
2010 |
| Drug |
cmf regimen |
10 |
1999 |
| Other |
flow cytometry |
10 |
2009 |
| Biological |
her-2 |
10 |
2011 |
| Procedure |
mammography |
10 |
2017 |
| Drug |
saline |
10 |
2018 |
| Behavioral |
telephone-based intervention |
10 |
2009 |
| Behavioral |
yoga |
10 |
2010 |
| Biological |
aldesleukin |
9 |
2010 |
| Procedure |
autologous bone marrow transplantation |
9 |
1999 |
| Behavioral |
behavioral dietary intervention |
9 |
2013 |
| Drug |
bevacizumab [avastin] |
9 |
2013 |
| Biological |
blood sample |
9 |
2009 |
| Genetic |
gene expression analysis |
9 |
2009 |
| Radiation |
hypofractionated radiation therapy |
9 |
2017 |
| Other |
immunoenzyme technique |
9 |
2009 |
| Drug |
indocyanine green |
9 |
2014 |
| Other |
internet-based intervention |
9 |
2017 |
| Drug |
melphalan |
9 |
2007 |
| Drug |
sunitinib |
9 |
2009 |
| Drug |
vinorelbine tartrate |
9 |
2010 |
| Drug |
vorinostat |
9 |
2010 |
| Other |
NA |
8 |
2014 |
| Drug |
adriamycin |
8 |
2015 |
| Behavioral |
aerobic exercise |
8 |
2019 |
| Drug |
alpelisib |
8 |
2018 |
| Drug |
capecitabine [xeloda] |
8 |
2013 |
| Drug |
denosumab |
8 |
2018 |
| Drug |
dexamethasone |
8 |
2017 |
| Drug |
erlotinib hydrochloride |
8 |
2008 |
| Drug |
irinotecan |
8 |
2014 |
| Drug |
kg |
8 |
2014 |
| Procedure |
lumpectomy |
8 |
2020 |
| Procedure |
mastectomy |
8 |
2020 |
| Drug |
abi-007 |
7 |
2008 |
| Procedure |
acupuncture therapy |
7 |
2009 |
| Drug |
avelumab |
7 |
2018 |
| Other |
demographic variables |
7 |
2009 |
| Procedure |
dynamic contrast-enhanced magnetic resonance imaging |
7 |
2016 |
| Biological |
her-2/neu peptide vaccine |
7 |
2011 |
| Radiation |
intraoperative radiation therapy |
7 |
2009 |
| Radiation |
intraoperative radiotherapy |
7 |
2010 |
| Drug |
lee011 |
7 |
2015 |
| Procedure |
management |
7 |
2009 |
| Other |
mass spectrometry |
7 |
2008 |
| Drug |
midazolam |
7 |
2017 |
| Biological |
neu peptide vaccine |
7 |
2011 |
| Drug |
niraparib |
7 |
2017 |
| Dietary Supplement |
omega-3 fatty acid |
7 |
2013 |
| Device |
pet |
7 |
2009 |
| Genetic |
protein expression analysis |
7 |
2010 |
| Drug |
sorafenib |
7 |
2009 |
| Other |
study of socioeconomic |
7 |
2009 |
| Other |
study of socioeconomic/demographic variables |
7 |
2009 |
| Drug |
temsirolimus |
7 |
2010 |
| Drug |
tipifarnib |
7 |
2007 |
| Drug |
afatinib |
6 |
2015 |
| Drug |
aromatase inhibitors |
6 |
2016 |
| Procedure |
assessment of therapy complications |
6 |
2011 |
| Procedure |
axillary dissection |
6 |
2019 |
| Drug |
bibw 2992 |
6 |
2009 |
| Drug |
bicalutamide |
6 |
2014 |
| Procedure |
breast surgery |
6 |
2013 |
| Biological |
cetuximab |
6 |
2010 |
| Dietary Supplement |
curcumin |
6 |
2013 |
| Drug |
cytoxan |
6 |
2009 |
| Device |
dbt |
6 |
2014 |
| Drug |
doxil |
6 |
2008 |
| Behavioral |
education |
6 |
2016 |
| Drug |
erlotinib |
6 |
2012 |
| Procedure |
fatigue assessment |
6 |
2009 |
| Procedure |
fatigue assessment/management |
6 |
2009 |
| Radiation |
fludeoxyglucose f 18 |
6 |
2012 |
| Other |
immunologic technique |
6 |
2009 |
| Drug |
mifepristone |
6 |
2014 |
| Device |
molecular breast imaging |
6 |
2017 |
| Drug |
oxaliplatin |
6 |
2014 |
| Drug |
palbociclib 125mg |
6 |
2018 |
| Drug |
pazopanib |
6 |
2012 |
| Other |
pharmacogenomic studies |
6 |
2010 |
| Drug |
propofol |
6 |
2013 |
| Radiation |
radiation |
6 |
2018 |
| Radiation |
stereotactic radiosurgery |
6 |
2015 |
| Biological |
talimogene laherparepvec |
6 |
2018 |
| Drug |
taselisib |
6 |
2014 |
| Drug |
temozolomide |
6 |
2009 |
| Drug |
toremifene |
6 |
2015 |
| Drug |
trastuzumab [herceptin] |
6 |
2009 |
| Drug |
alisertib |
5 |
2014 |
| Drug |
aromatase inhibition therapy |
5 |
2013 |
| Drug |
atorvastatin |
5 |
2013 |
| Drug |
avastin |
5 |
2008 |
| Drug |
azd5363 |
5 |
2014 |
| Drug |
bez235 |
5 |
2010 |
| Drug |
bp-c1 |
5 |
2020 |
| Radiation |
brachytherapy |
5 |
2009 |
| Procedure |
breast imaging study |
5 |
2008 |
| Dietary Supplement |
calcium carbonate |
5 |
2006 |
| Drug |
capivasertib |
5 |
2019 |
| Drug |
cediranib maleate |
5 |
2015 |
| Other |
counseling |
5 |
2016 |
| Other |
cytology specimen collection procedure |
5 |
2013 |
| Behavioral |
diet |
5 |
2012 |
| Dietary Supplement |
dietary intervention |
5 |
2016 |
| Procedure |
digital mammography |
5 |
2010 |
| Radiation |
external beam radiation therapy |
5 |
2016 |
| Radiation |
f-18 16 alpha-fluoroestradiol |
5 |
2014 |
| Drug |
gm-csf |
5 |
2014 |
| Biological |
gm-csf vaccine |
5 |
2009 |
| Biological |
herceptinâ® |
5 |
2018 |
| Drug |
letrozole 2.5mg |
5 |
2019 |
| Drug |
leuprolide acetate |
5 |
2016 |
| Drug |
loperamide |
5 |
2017 |
| Drug |
metformin hydrochloride |
5 |
2016 |
| Drug |
mitoxantrone hydrochloride |
5 |
1999 |
| Drug |
oral vinorelbine |
5 |
2016 |
| Drug |
rad001 |
5 |
2010 |
| Drug |
raloxifene |
5 |
2005 |
| Radiation |
sbrt |
5 |
2018 |
| Procedure |
sham acupuncture |
5 |
2012 |
| Drug |
simvastatin |
5 |
2018 |
| Drug |
standard chemotherapy |
5 |
2016 |
| Procedure |
standard follow-up care |
5 |
2013 |
| Radiation |
stereotactic body radiotherapy |
5 |
2018 |
| Procedure |
surgical procedure |
5 |
2015 |
| Radiation |
technetium tc 99m sulfur colloid |
5 |
2007 |
| Drug |
trastuzumab emtansine [kadcyla] |
5 |
2009 |
| Drug |
triptorelin |
5 |
2013 |
| Drug |
tucatinib |
5 |
2018 |
| Procedure |
tumor biopsy |
5 |
2012 |
| Device |
ultrasound |
5 |
2016 |
| Drug |
xeloda |
5 |
2016 |
| Drug |
5-fluoruracil |
4 |
2016 |
| Drug |
akt inhibitor mk2206 |
4 |
2010 |
| Biological |
allogeneic gm-csf-secreting breast cancer vaccine |
4 |
2009 |
| Drug |
amifostine trihydrate |
4 |
1999 |
| Drug |
anastrazole |
4 |
2009 |
| Drug |
azd2014 |
4 |
2014 |
| Other |
behavioral, psychological |
4 |
2018 |
| Other |
behavioral, psychological/informational intervention |
4 |
2018 |
| Procedure |
bone marrow ablation with stem cell support |
4 |
1999 |
| Drug |
busulfan |
4 |
2016 |
| Drug |
cabozantinib |
4 |
2014 |
| Drug |
calcium |
4 |
2018 |
| Drug |
carvedilol |
4 |
2019 |
| Drug |
cobimetinib |
4 |
2017 |
| Procedure |
cryoablation |
4 |
2016 |
| Drug |
ctx |
4 |
2019 |
| Drug |
cyclosporine |
4 |
2010 |
| Drug |
day |
4 |
2014 |
| Drug |
ds-8201a |
4 |
2017 |
| Drug |
e7389 |
4 |
2011 |
| Other |
enzyme-linked immunosorbent assay |
4 |
2009 |
| Drug |
epirubicin/cyclophosphamide |
4 |
2010 |
| Drug |
epirubicine |
4 |
2009 |
| Biological |
epoetin alfa |
4 |
2001 |
| Drug |
estradiol |
4 |
2014 |
| Drug |
everolimus (rad001) |
4 |
2013 |
| Drug |
f-627 |
4 |
2017 |
| Procedure |
fdg-pet |
4 |
2007 |
| Device |
ffdm |
4 |
2015 |
| Drug |
fludarabine |
4 |
2018 |
| Drug |
gabapentin |
4 |
2017 |
| Drug |
ganetespib |
4 |
2012 |
| Drug |
gedatolisib |
4 |
2016 |
| Behavioral |
healing touch |
4 |
2008 |
| Drug |
hormone therapy |
4 |
2015 |
| Drug |
imatinib mesylate |
4 |
2006 |
| Drug |
iniparib |
4 |
2009 |
| Drug |
isosulfan blue |
4 |
2013 |
| Drug |
ketamine |
4 |
2018 |
| Drug |
leuprolide |
4 |
2009 |
| Drug |
liposomal doxorubicin |
4 |
2012 |
| Procedure |
lymphangiography |
4 |
2019 |
| Procedure |
lymphoscintigraphy |
4 |
2012 |
| Drug |
medi4736 |
4 |
2014 |
| Other |
medical chart review |
4 |
2019 |
| Drug |
melatonin |
4 |
2013 |
| Drug |
mesna |
4 |
1999 |
| Drug |
methylprednisolone |
4 |
2010 |
| Genetic |
microarray analysis |
4 |
2010 |
| Drug |
myocet |
4 |
2013 |
| Drug |
navelbine |
4 |
2007 |
| Drug |
neulasta |
4 |
2017 |
| Procedure |
oophorectomy |
4 |
2006 |
| Biological |
panitumumab |
4 |
2009 |
| Radiation |
partial breast irradiation |
4 |
2009 |
| Drug |
pd-0332991 |
4 |
2012 |
| Procedure |
physical therapy |
4 |
2010 |
| Other |
physiologic testing |
4 |
2009 |
| Biological |
qs21 |
4 |
2007 |
| Biological |
recombinant interleukin-12 |
4 |
2000 |
| Behavioral |
resistance exercise |
4 |
2016 |
| Drug |
ridaforolimus |
4 |
2010 |
| Drug |
rucaparib |
4 |
2018 |
| Drug |
ruxolitinib |
4 |
2014 |
| Drug |
sacituzumab govitecan |
4 |
2019 |
| Drug |
sar439859 |
4 |
2017 |
| Drug |
sevoflurane |
4 |
2013 |
| Drug |
sgn-liv1a |
4 |
2013 |
| Procedure |
sham intervention |
4 |
2009 |
| Drug |
sorafenib tosylate |
4 |
2009 |
| Procedure |
study of high risk factors |
4 |
2009 |
| Drug |
su011248 |
4 |
2005 |
| Drug |
sunitinib malate |
4 |
2015 |
| Drug |
systemic chemotherapy |
4 |
2009 |
| Drug |
taxol |
4 |
2006 |
| Biological |
therapeutic autologous dendritic cells |
4 |
2007 |
| Biological |
therapeutic estradiol |
4 |
2019 |
| Drug |
trastuzumab iv |
4 |
2018 |
| Drug |
trastuzumab sc |
4 |
2017 |
| Biological |
tremelimumab |
4 |
2017 |
| Procedure |
ultrasound imaging |
4 |
2011 |
| Drug |
vinflunine |
4 |
2010 |
| Drug |
vinorelbine ditartrate |
4 |
2010 |
| Drug |
zoledronate |
4 |
2017 |
| Radiation |
3-dimensional conformal accelerated partial breast irradiation |
3 |
2008 |
| Radiation |
3-dimensional conformal radiation therapy |
3 |
2018 |
| Drug |
abiraterone acetate |
3 |
2008 |
| Drug |
abt-888 |
3 |
2011 |
| Drug |
ac |
3 |
2019 |
| Drug |
ac regimen |
3 |
2007 |
| Behavioral |
acceptance |
3 |
2020 |
| Other |
additional blood sample |
3 |
2016 |
| Biological |
ado-trastuzumab emtansine |
3 |
2014 |
| Drug |
ai |
3 |
2012 |
| Drug |
albumin-bound paclitaxel |
3 |
2019 |
| Drug |
anastrozole 1mg |
3 |
2019 |
| Drug |
anthracycline |
3 |
2019 |
| Drug |
aprepitant |
3 |
2011 |
| Drug |
arzoxifene hydrochloride |
3 |
2005 |
| Drug |
atezolizumab (mpdl3280a), an engineered anti-pdl1 antibody |
3 |
2015 |
| Procedure |
axillary reverse mapping |
3 |
2019 |
| Drug |
azd4547 |
3 |
2014 |
| Drug |
azd8931 |
3 |
2014 |
| Drug |
bavituximab |
3 |
2011 |
| Drug |
bendamustine |
3 |
2013 |
| Drug |
binimetinib |
3 |
2015 |
| Other |
biomarker analysis |
3 |
2008 |
| Drug |
bortezomib |
3 |
2008 |
| Procedure |
breast biopsy |
3 |
2009 |
| Drug |
carmustine |
3 |
2016 |
| Drug |
chemotherapy drugs, cancer |
3 |
2020 |
| Drug |
cisplatin-docetaxel â± trastuzumab |
3 |
2007 |
| Procedure |
cognitive assessment |
3 |
2008 |
| Other |
cognitive intervention |
3 |
2013 |
| Procedure |
comparison of screening methods |
3 |
1999 |
| Drug |
copanlisib |
3 |
2019 |
| Radiation |
copper cu 64-dota-trastuzumab |
3 |
2010 |
| Procedure |
cryosurgery |
3 |
2016 |
| Drug |
dalotuzumab |
3 |
2010 |
| Drug |
darbepoetin alfa |
3 |
2005 |
| Other |
decision aid |
3 |
2017 |
| Drug |
decitabine |
3 |
2017 |
| Drug |
dexmedetomidine |
3 |
2017 |
| Other |
diagnostic laboratory biomarker analysis |
3 |
2007 |
| Procedure |
diffusion-weighted magnetic resonance imaging |
3 |
2012 |
| Radiation |
digital breast tomosynthesis |
3 |
2017 |
| Drug |
doxorubicin/cyclophosphamide |
3 |
2018 |
| Drug |
endotag-1 |
3 |
2016 |
| Procedure |
evaluation of cancer risk factors |
3 |
2006 |
| Drug |
exemestane (aromasin) |
3 |
2010 |
| Drug |
exemestane 25 mg |
3 |
2019 |
| Behavioral |
exercise training |
3 |
2019 |
| Drug |
fec |
3 |
2009 |
| Drug |
fenretinide |
3 |
1999 |
| Procedure |
fine needle aspiration |
3 |
2010 |
| Drug |
fludeoxyglucose f-18 |
3 |
2018 |
| Procedure |
fna |
3 |
2017 |
| Drug |
g-csf |
3 |
2007 |
| Drug |
gdc-0941 |
3 |
2012 |
| Procedure |
general anesthesia |
3 |
2019 |
| Drug |
granulocyte-colony stimulating growth factor |
3 |
2013 |
| Drug |
gw572016 |
3 |
2007 |
| Biological |
her-2 pulsed dendritic cell vaccine |
3 |
2014 |
| Biological |
her-2/neu intracellular domain protein |
3 |
2006 |
| Drug |
hki-272 |
3 |
2011 |
| Drug |
hormonal therapy |
3 |
2010 |
| Behavioral |
hypnosis |
3 |
2020 |
| Radiation |
hypofractionated radiotherapy |
3 |
2016 |
| Radiation |
hypofractionation |
3 |
2017 |
| Drug |
imiquimod |
3 |
2009 |
| Radiation |
imrt |
3 |
2008 |
| Procedure |
in vitro-treated peripheral blood stem cell transplantation |
3 |
1999 |
| Drug |
interleukin-2 |
3 |
2010 |
| Drug |
lapatinib (gw572016) |
3 |
2003 |
| Drug |
larotaxel (xrp9881) |
3 |
2007 |
| Drug |
lhrh agonist |
3 |
2019 |
| Behavioral |
lifestyle intervention |
3 |
2011 |
| Other |
liquid chromatography |
3 |
2008 |
| Drug |
ljm716 |
3 |
2014 |
| Radiation |
low-let electron therapy |
3 |
2009 |
| Radiation |
low-let photon therapy |
3 |
2009 |
| Behavioral |
low fat diet |
3 |
2016 |
| Drug |
lymphoseek |
3 |
2010 |
| Biological |
margetuximab |
3 |
2020 |
| Drug |
megestrol acetate |
3 |
2014 |
| Drug |
methylene blue |
3 |
2018 |
| Behavioral |
mindfulness-based stress reduction |
3 |
2014 |
| Drug |
mm-121 |
3 |
2010 |
| Procedure |
modified radical mastectomy |
3 |
2019 |
| Device |
monitoring device |
3 |
2016 |
| Drug |
motexafin gadolinium |
3 |
2005 |
| Drug |
nab paclitaxel |
3 |
2018 |
| Biological |
neu intracellular domain protein |
3 |
2006 |
| Drug |
neulastaâ® |
3 |
2018 |
| Drug |
nktr-102 |
3 |
2011 |
| Behavioral |
nonlinear aerobic training |
3 |
2010 |
| Drug |
omeprazole |
3 |
2016 |
| Drug |
paclitaxel 80 mg |
3 |
2016 |
| Drug |
pamidronate |
3 |
2016 |
| Drug |
pd0332991 |
3 |
2013 |
| Behavioral |
pedometer |
3 |
2016 |
| Drug |
peg-rhg-csf |
3 |
2016 |
| Drug |
pertuzumab iv |
3 |
2018 |
| Other |
physical exercise |
3 |
2016 |
| Drug |
physician’s choice |
3 |
2017 |
| Drug |
poly iclc |
3 |
2009 |
| Procedure |
positron emission tomography (pet) |
3 |
2013 |
| Radiation |
post-operative radiotherapy |
3 |
2009 |
| Drug |
prednisone |
3 |
2016 |
| Radiation |
proton beam radiation therapy |
3 |
2010 |
| Procedure |
radiofrequency ablation |
3 |
2010 |
| Procedure |
radiomammography |
3 |
2003 |
| Procedure |
radionuclide imaging |
3 |
2004 |
| Other |
realrisks |
3 |
2018 |
| Biological |
recombinant fowlpox-cea(6d) |
3 |
2005 |
| Biological |
recombinant fowlpox-cea(6d)/tricom vaccine |
3 |
2005 |
| Genetic |
reverse transcriptase-polymerase chain reaction |
3 |
2010 |
| Drug |
rintatolimod |
3 |
2018 |
| Drug |
risedronate sodium |
3 |
2004 |
| Drug |
selumetinib |
3 |
2014 |
| Drug |
shr-1210 |
3 |
2018 |
| Drug |
shr6390 |
3 |
2018 |
| Dietary Supplement |
soy isoflavones |
3 |
2010 |
| Drug |
spi-2012 |
3 |
2016 |
| Behavioral |
support group |
3 |
2011 |
| Procedure |
support group therapy |
3 |
2009 |
| Procedure |
supportive care |
3 |
2019 |
| Drug |
tesetaxel |
3 |
2019 |
| Behavioral |
therapeutic education |
3 |
2018 |
| Procedure |
therapeutic surgical procedure |
3 |
2015 |
| Device |
tomosynthesis |
3 |
2010 |
| Drug |
trastuzumab deruxtecan |
3 |
2018 |
| Biological |
tricom vaccine |
3 |
2005 |
| Procedure |
ultrasonography |
3 |
2014 |
| Drug |
utomilumab |
3 |
2017 |
| Procedure |
vacuum-assisted biopsy |
3 |
2016 |
| Drug |
venetoclax |
3 |
2018 |
| Dietary Supplement |
vitamin e |
3 |
2019 |
| Behavioral |
walking |
3 |
2015 |
| Behavioral |
weight loss intervention |
3 |
2014 |
| Drug |
z-endoxifen hydrochloride |
3 |
2017 |
| Drug |
zoladex |
3 |
2015 |
| Drug |
zometa |
3 |
2005 |
| Drug |
18f-fdg |
2 |
2015 |
| Drug |
18f-flt |
2 |
2011 |
| Drug |
5-fluorouracil (5fu) |
2 |
2008 |
| Drug |
6 inhibitor |
2 |
2017 |
| Drug |
68ganota-anti-her2 vhh1 |
2 |
2017 |
| Procedure |
89zr-trastuzumab |
2 |
2014 |
| Behavioral |
acceptance/commitment therapy |
2 |
2015 |
| Drug |
acetaminophen |
2 |
2017 |
| Device |
active breathing coordinator (abc) |
2 |
2016 |
| Biological |
ad5cmv-p53 gene |
2 |
1999 |
| Drug |
adriamycin/cytoxan |
2 |
2005 |
| Behavioral |
aerobic exercise intervention |
2 |
2016 |
| Behavioral |
aerobic exercise training |
2 |
2019 |
| Behavioral |
aerobic training |
2 |
2013 |
| Drug |
afimoxifene |
2 |
2009 |
| Biological |
alemtuzumab |
2 |
2006 |
| Drug |
alendronate sodium |
2 |
2005 |
| Procedure |
alternative medicine procedure |
2 |
2008 |
| Drug |
alvocidib |
2 |
2001 |
| Dietary Supplement |
american ginseng |
2 |
2018 |
| Drug |
amg 386 |
2 |
2007 |
| Drug |
anastrozole (arimidex) |
2 |
2008 |
| Behavioral |
art therapy |
2 |
2017 |
| Drug |
aspirin |
2 |
2016 |
| Behavioral |
attention control |
2 |
2016 |
| Biological |
autologous, lethally irradiated breast cancer cells |
2 |
2009 |
| Drug |
auy922 |
2 |
2010 |
| Drug |
avb-620 |
2 |
2017 |
| Procedure |
axillary lymph node dissection (alnd) |
2 |
2013 |
| Procedure |
axillary reverse mapping (arm) |
2 |
2017 |
| Procedure |
axillary surgery |
2 |
2010 |
| Drug |
azd2281 |
2 |
2008 |
| Drug |
azd6738 |
2 |
2017 |
| Drug |
azd9496 |
2 |
2017 |
| Drug |
azd9833 |
2 |
2018 |
| Drug |
bazedoxifene |
2 |
2015 |
| Behavioral |
behavioral intervention |
2 |
2017 |
| Drug |
bexarotene |
2 |
1999 |
| Drug |
bintrafusp alfa |
2 |
2018 |
| Biological |
biological collection |
2 |
2017 |
| Procedure |
biospecimen collection |
2 |
2018 |
| placebo |
bkm120 matching placebo |
2 |
2012 |
| Biological |
blood |
2 |
2016 |
| Other |
blood test |
2 |
2013 |
| Other |
bnav |
2 |
2017 |
| Procedure |
bone marrow aspiration |
2 |
2004 |
| Procedure |
boost |
2 |
2005 |
| Procedure |
breast-conserving surgery |
2 |
2017 |
| Device |
breast cancer locator (bcl) |
2 |
2018 |
| Drug |
broccoli sprout extract |
2 |
2009 |
| Drug |
buparlisib |
2 |
2013 |
| Combination Product |
bupivacaine |
2 |
2017 |
| Drug |
cabazitaxel |
2 |
2014 |
| Drug |
calcitriol |
2 |
2009 |
| Dietary Supplement |
calcium-rich diet |
2 |
2003 |
| Dietary Supplement |
calcium citrate |
2 |
2006 |
| Drug |
calcium gluconate |
2 |
2006 |
| Procedure |
cam exercise therapy |
2 |
2009 |
| Drug |
candesartan |
2 |
2020 |
| Drug |
cap |
2 |
2017 |
| Drug |
capecitabine tablets |
2 |
2013 |
| Diagnostic Test |
cardiac mri |
2 |
2016 |
| Device |
cardiopulmonary exercise testing (cpet) |
2 |
2012 |
| Other |
care-as-usual |
2 |
2018 |
| Drug |
cdx-011 |
2 |
2013 |
| Drug |
cediranib |
2 |
2015 |
| Drug |
cefazolin |
2 |
2016 |
| Drug |
cfi-400945 |
2 |
2018 |
| Drug |
ci-1040 |
2 |
2002 |
| Biological |
cixutumumab |
2 |
2008 |
| Behavioral |
cognitive behavioral stress management (cbsm) |
2 |
2009 |
| Behavioral |
cognitive behavioral therapy |
2 |
2016 |
| Behavioral |
cognitive behavioral therapy for insomnia |
2 |
2018 |
| Drug |
cohort a |
2 |
2018 |
| Behavioral |
combined training |
2 |
2017 |
| Behavioral |
commitment therapy |
2 |
2015 |
| Procedure |
complementary |
2 |
2008 |
| Procedure |
complementary/alternative medicine procedure |
2 |
2008 |
| Behavioral |
comprehensive geriatric assessment |
2 |
2016 |
| Device |
compression |
2 |
2017 |
| Behavioral |
compression garment |
2 |
2017 |
| Drug |
conjugated estrogens |
2 |
2001 |
| Device |
conventional |
2 |
2019 |
| Device |
conventional mammography |
2 |
2013 |
| Drug |
copanlisib hydrochloride |
2 |
2015 |
| Procedure |
core biopsy |
2 |
2018 |
| Other |
correlative studies |
2 |
2013 |
| Drug |
crofelemer |
2 |
2016 |
| Procedure |
cryotherapy |
2 |
2018 |
| Radiation |
ct imaging |
2 |
2013 |
| Device |
ct scan |
2 |
2018 |
| Drug |
custirsen sodium |
2 |
2007 |
| Drug |
cyclophosphamide (ac) |
2 |
2005 |
| Drug |
cyclophosphamide 50mg |
2 |
2017 |
| Other |
daily log |
2 |
2013 |
| Drug |
darolutamide |
2 |
2016 |
| Drug |
ddp |
2 |
2016 |
| Other |
dedicated |
2 |
2017 |
| Procedure |
delayed breast reconstruction |
2 |
2010 |
| Biological |
denileukin diftitox |
2 |
2005 |
| Drug |
digoxin |
2 |
2013 |
| Drug |
dinaciclib |
2 |
2012 |
| Drug |
disulfiram |
2 |
2017 |
| Drug |
docetaxel sequential |
2 |
2007 |
| Drug |
docetaxel, doxorubicin, cyclophosphamide |
2 |
2016 |
| Drug |
docetaxel/capecitabine |
2 |
2007 |
| Drug |
dose-dense doxorubicin |
2 |
2016 |
| Drug |
dose dense ac |
2 |
2016 |
| Drug |
doxorubicin, docetaxel |
2 |
2007 |
| Drug |
doxycycline |
2 |
2016 |
| Procedure |
dual x-ray absorptometry |
2 |
2009 |
| Drug |
duration of treatment: 3 days |
2 |
2004 |
| Biological |
e75 |
2 |
2009 |
| Biological |
e75 / gm-csf vaccine |
2 |
2009 |
| Other |
early physical therapy |
2 |
2008 |
| Other |
early physical therapy/educational strategy |
2 |
2008 |
| Drug |
ec-t |
2 |
2010 |
| Drug |
edotecarin |
2 |
2003 |
| Behavioral |
educational information |
2 |
2013 |
| Behavioral |
educational materials |
2 |
2012 |
| Other |
educational strategy |
2 |
2008 |
| Drug |
elacestrant |
2 |
2014 |
| Behavioral |
emdr psychotherapy |
2 |
2017 |
| Drug |
endostar |
2 |
2019 |
| Drug |
enzastaurin |
2 |
2007 |
| Drug |
epidoxorubicin |
2 |
2007 |
| Drug |
epirubicin, cyclophosphamide |
2 |
2010 |
| Biological |
epothilone b |
2 |
2007 |
| Drug |
erdafitinib |
2 |
2017 |
| Procedure |
erythromycin breath test (ermbt) |
2 |
2005 |
| Drug |
estetrol |
2 |
2016 |
| Other |
european organization for research |
2 |
2017 |
| placebo |
everolimus placebo |
2 |
2009 |
| Biological |
ex vivo-expanded her2-specific t cells |
2 |
2005 |
| Device |
exablate mrgfus |
2 |
2016 |
| Behavioral |
exercise behavior change |
2 |
2008 |
| Other |
exercise treatment |
2 |
2020 |
| Drug |
famitinib |
2 |
2019 |
| Drug |
faslodex |
2 |
2015 |
| Drug |
fdc of pertuzumab |
2 |
2018 |
| Drug |
fdc of pertuzumab/trastuzumab sc |
2 |
2018 |
| Diagnostic Test |
fdg-pet/ct |
2 |
2017 |
| Drug |
fentanyl |
2 |
2017 |
| Device |
ffdm/dbt |
2 |
2015 |
| Biological |
filgrastim (g-csf) |
2 |
1999 |
| Dietary Supplement |
fish oil |
2 |
2015 |
| Behavioral |
fitbit |
2 |
2019 |
| Dietary Supplement |
flaxseed |
2 |
2009 |
| Behavioral |
flexibility training |
2 |
2008 |
| Drug |
fludarabine phosphate |
2 |
2001 |
| Drug |
fluoroestradiol (18f) |
2 |
2018 |
| Drug |
fluorothymidine f-18 |
2 |
2013 |
| Drug |
fluorouracile |
2 |
2009 |
| Drug |
fluzoparib |
2 |
2017 |
| Behavioral |
focus group |
2 |
2019 |
| Drug |
foretinib |
2 |
2010 |
| Other |
free-breathing |
2 |
2018 |
| Drug |
gadobutrol (gadavist, gadovist, bay86-4875) |
2 |
2010 |
| Other |
gas chromatography |
2 |
2009 |
| Drug |
gdc-0077 |
2 |
2016 |
| Drug |
gdc-0980 |
2 |
2010 |
| Drug |
gdc-9545 |
2 |
2017 |
| Drug |
gemcitabine,cisplatin |
2 |
2015 |
| Drug |
gemcitabine/carboplatin |
2 |
2009 |
| Genetic |
genetic testing |
2 |
2019 |
| Dietary Supplement |
genistein |
2 |
2006 |
| Dietary Supplement |
glutamine |
2 |
2008 |
| Drug |
gnrh analogue |
2 |
2017 |
| Drug |
goserelin (zoladex) |
2 |
2012 |
| Biological |
gp2 peptide |
2 |
2017 |
| Behavioral |
group phone calls |
2 |
2017 |
| Drug |
gw572016 oral tablets |
2 |
2006 |
| Behavioral |
health coaching |
2 |
2015 |
| Drug |
hemay022 |
2 |
2017 |
| Other |
high performance liquid chromatography |
2 |
2008 |
| Procedure |
histopathologic examination |
2 |
2008 |
| Behavioral |
home-based exercise |
2 |
2017 |
| Drug |
hormonotherapy |
2 |
2012 |
| Biological |
htert |
2 |
2012 |
| Drug |
huaier |
2 |
2015 |
| Drug |
hydroxychloroquine |
2 |
2017 |
| Procedure |
hyperthermia treatment |
2 |
2019 |
| Behavioral |
hypnotherapy |
2 |
2008 |
| Radiation |
hypofractionated |
2 |
2019 |
| Procedure |
hypofractionated stereotactic body radiation therapy |
2 |
2005 |
| Biological |
î³î´ t cells |
2 |
2017 |
| Device |
ice-sense3tm |
2 |
2012 |
| Drug |
ifosfamide |
2 |
2000 |
| Procedure |
im-slnb |
2 |
2018 |
| Radiation |
image-guided radiation therapy |
2 |
2009 |
| Diagnostic Test |
imaging |
2 |
2017 |
| Drug |
imatinib |
2 |
2005 |
| Device |
implanted medical device |
2 |
2017 |
| Biological |
incomplete freund’s adjuvant |
2 |
2008 |
| Radiation |
intensity-modulated radiation therapy |
2 |
2018 |
| Behavioral |
intervention |
2 |
2015 |
| Radiation |
intracavitary balloon brachytherapy |
2 |
2009 |
| Drug |
ipi-549 |
2 |
2019 |
| Dietary Supplement |
isoflavones |
2 |
2005 |
| Drug |
isosulfan blue dye |
2 |
2015 |
| Drug |
iv paclitaxel |
2 |
2017 |
| Drug |
ixabepilone / capecitabine |
2 |
2004 |
| Behavioral |
iyengar yoga |
2 |
2019 |
| Drug |
ketoconazole |
2 |
2018 |
| Other |
kinesio taping |
2 |
2017 |
| Drug |
kn026 |
2 |
2019 |
| Drug |
la-ep2006 |
2 |
2012 |
| Biological |
lag525 |
2 |
2018 |
| Procedure |
laser |
2 |
2019 |
| Device |
laser therapy |
2 |
2013 |
| Drug |
lde225 |
2 |
2013 |
| placebo |
lee011 placebo |
2 |
2013 |
| Drug |
letrozole (femara) |
2 |
2010 |
| Drug |
letrozole 2.5mg tablet |
2 |
2017 |
| Drug |
letrozole/anastrozole |
2 |
2019 |
| Drug |
leucovorin |
2 |
2017 |
| Procedure |
leukapheresis |
2 |
2006 |
| Drug |
leuprorelin |
2 |
2015 |
| Drug |
leuprorelin acetate |
2 |
2019 |
| Drug |
levobupivacaine |
2 |
2013 |
| Drug |
lfa102 |
2 |
2011 |
| Drug |
lidocaine |
2 |
2018 |
| Procedure |
light-scattering spectroscopy |
2 |
2012 |
| Drug |
liposomal cytarabine |
2 |
2012 |
| Behavioral |
living healthy together |
2 |
2016 |
| Biological |
lmb-9 immunotoxin |
2 |
2001 |
| Other |
local therapy |
2 |
2009 |
| Drug |
lonafarnib |
2 |
2004 |
| Drug |
lovazaâ„¢ |
2 |
2010 |
| Behavioral |
low carbohydrate diet |
2 |
2016 |
| Drug |
low dose doxorubicin |
2 |
2019 |
| Procedure |
lumpectomy/mastectomy |
2 |
2012 |
| Procedure |
lymph node biopsy |
2 |
2014 |
| Drug |
m^2 |
2 |
2018 |
| Drug |
m2 |
2 |
2012 |
| Drug |
m2) |
2 |
2018 |
| Procedure |
magnetic resonance spectroscopic imaging |
2 |
2009 |
| Biological |
mammaglobin-a dna vaccine |
2 |
2014 |
| Diagnostic Test |
mammaprint |
2 |
2019 |
| Other |
mammography/ultrasound |
2 |
2013 |
| Other |
manual lymphatic drainage |
2 |
2009 |
| Biological |
mcs110 |
2 |
2018 |
| Behavioral |
mediterranean diet |
2 |
2018 |
| Drug |
medroxyprogesterone |
2 |
2001 |
| Drug |
megestrol acetate 40 mg |
2 |
2017 |
| Device |
mepitel film |
2 |
2019 |
| Drug |
methylthioninium |
2 |
2012 |
| Behavioral |
mindfulness |
2 |
2014 |
| Behavioral |
mindfulness based meditation program |
2 |
2006 |
| Drug |
minocycline hydrochloride |
2 |
2014 |
| Device |
mira device imaging |
2 |
2017 |
| Biological |
mirvetuximab soravtansine |
2 |
2016 |
| Drug |
mitomycin c |
2 |
2014 |
| Drug |
mk-3475 |
2 |
2014 |
| Drug |
mk0869, aprepitant |
2 |
2004 |
| Drug |
mk0869, aprepitant / duration of treatment: 3 days |
2 |
2004 |
| Drug |
mln0128 |
2 |
2016 |
| Drug |
mm-111 |
2 |
2009 |
| Device |
mobile community |
2 |
2018 |
| Behavioral |
motivational interviewing |
2 |
2017 |
| Procedure |
mr |
2 |
2013 |
| Other |
mri scan |
2 |
2013 |
| Device |
mrs |
2 |
2010 |
| Biological |
muc-1 peptide vaccine |
2 |
2009 |
| Biological |
multi-epitope folate receptor alpha peptide vaccine |
2 |
2016 |
| Dietary Supplement |
multivitamin |
2 |
2016 |
| Biological |
mva-bn-her2 |
2 |
2010 |
| Drug |
nab-paclitaxel / carboplatin |
2 |
2019 |
| Drug |
naltrexone |
2 |
2014 |
| Procedure |
nausea |
2 |
2006 |
| Procedure |
nausea/vomiting therapy |
2 |
2006 |
| Procedure |
needle biopsy |
2 |
2007 |
| Drug |
neo-adjuvant chemotherapy |
2 |
2017 |
| Drug |
neoadjuvant docetaxel |
2 |
2015 |
| Biological |
neuvax vaccine |
2 |
2014 |
| Drug |
nintedanib |
2 |
2015 |
| Procedure |
nipple sparing mastectomy |
2 |
2009 |
| Biological |
nk immunotherapy |
2 |
2016 |
| Drug |
nk012 |
2 |
2009 |
| Other |
no axillary lymph node dissection |
2 |
2012 |
| Other |
no intervention |
2 |
2014 |
| Drug |
non-pegylated liposomal doxorubicin |
2 |
2014 |
| Other |
observation |
2 |
2014 |
| Diagnostic Test |
odour sampling |
2 |
2018 |
| Drug |
olanzapine |
2 |
2017 |
| Drug |
oleclumab |
2 |
2018 |
| Dietary Supplement |
omega-3 fatty acids |
2 |
2014 |
| Procedure |
omission of axillary clearance |
2 |
2014 |
| Drug |
onalespib |
2 |
2016 |
| Procedure |
oncoplastic breast surgery |
2 |
2017 |
| Drug |
ondansetron |
2 |
2018 |
| Behavioral |
optimune |
2 |
2018 |
| Drug |
oraxol |
2 |
2018 |
| Drug |
oxygen |
2 |
2019 |
| Drug |
paclitaxel / carboplatin |
2 |
2017 |
| Drug |
paclitaxel infusion |
2 |
2006 |
| Drug |
paclitaxel injection |
2 |
2017 |
| Drug |
palbociclib 100mg |
2 |
2018 |
| Drug |
palonosetron hydrochloride |
2 |
2006 |
| Drug |
panobinostat |
2 |
2010 |
| Procedure |
paravertebral block |
2 |
2008 |
| Procedure |
partial mastectomy |
2 |
2016 |
| Other |
patient-reported outcomes measurement information system (promis)-cancer-fatigue |
2 |
2017 |
| Other |
patient-reported outcomes measurement information system (promis)-sleep disturbance |
2 |
2017 |
| Other |
patient observation |
2 |
2018 |
| Other |
pecs block |
2 |
2020 |
| Behavioral |
peer support |
2 |
2017 |
| Drug |
pertuzumab [perjeta] |
2 |
2015 |
| Procedure |
pet scan |
2 |
2014 |
| Diagnostic Test |
pet/mri |
2 |
2012 |
| Biological |
pf-05280014 |
2 |
2014 |
| Other |
pharmacokinetic study |
2 |
2018 |
| Other |
phase ii - preoperative radiation followed by lumpectomy. |
2 |
2009 |
| Radiation |
photon |
2 |
2015 |
| Behavioral |
physical activity intervention |
2 |
2005 |
| Behavioral |
physical activity intervention (pai) |
2 |
2019 |
| Drug |
pi3k inhibitor byl719 |
2 |
2014 |
| Device |
picc |
2 |
2015 |
| Drug |
pictilisib |
2 |
2009 |
| Drug |
pirarubicin |
2 |
2015 |
| Other |
pittsburgh sleep quality index (psqi) |
2 |
2015 |
| placebo |
placebo (saline) |
2 |
2014 |
| placebo |
placebo capsule |
2 |
2014 |
| Behavioral |
plant-based diet |
2 |
2017 |
| Drug |
plx3397 |
2 |
2012 |
| Device |
positron emission mammography |
2 |
2009 |
| Drug |
poziotinib |
2 |
2016 |
| Drug |
prednisolone |
2 |
2014 |
| Drug |
pregabalin |
2 |
2018 |
| Combination Product |
prehabilitation |
2 |
2018 |
| Radiation |
proton radiotherapy |
2 |
2012 |
| Drug |
ps-341 |
2 |
2005 |
| Other |
psychosocial support for caregiver |
2 |
2010 |
| Biological |
pvx-410 |
2 |
2016 |
| Drug |
pyrazoloacridine |
2 |
1999 |
| Dietary Supplement |
pyridoxine hydrochloride |
2 |
2006 |
| Drug |
pyrotinib/with capecitabine |
2 |
2014 |
| Other |
quality of life assessment |
2 |
2010 |
| Other |
quality of life questionnaires |
2 |
2017 |
| Drug |
radium-223 dichloride (xofigo, bay88-8223) |
2 |
2014 |
| Biological |
ramucirumab (imc-1121b) |
2 |
2011 |
| Drug |
rapamycin |
2 |
2015 |
| Biological |
recombinant interferon alfa-2b |
2 |
2018 |
| Biological |
recombinant interferon gamma |
2 |
2001 |
| Behavioral |
relaxation |
2 |
2017 |
| Behavioral |
relaxation training |
2 |
2014 |
| Drug |
reparixin |
2 |
2015 |
| Procedure |
research blood sample |
2 |
2016 |
| Other |
resistance training |
2 |
2010 |
| Drug |
rg1507 |
2 |
2008 |
| Drug |
ribociclib (lee011) |
2 |
2013 |
| placebo |
ribociclib placebo |
2 |
2015 |
| Drug |
ridaforolimus / dalotuzumab |
2 |
2010 |
| Drug |
risedronate |
2 |
2009 |
| Genetic |
rna analysis |
2 |
2010 |
| Drug |
romidepsin |
2 |
2012 |
| Drug |
ropivacaine |
2 |
2015 |
| Behavioral |
routine care |
2 |
2014 |
| Drug |
sapanisertib |
2 |
2015 |
| Dietary Supplement |
selenium supplementation |
2 |
2019 |
| Behavioral |
self-regulation condition |
2 |
2018 |
| Drug |
selinexor |
2 |
2013 |
| Procedure |
sentinel lymph node biopsy (slnb) |
2 |
2018 |
| Diagnostic Test |
sentinel node |
2 |
2019 |
| Procedure |
sentinel node biopsy |
2 |
2020 |
| Drug |
sequential |
2 |
2011 |
| Device |
sham laser |
2 |
2019 |
| Drug |
simvastatin 40mg |
2 |
2020 |
| Procedure |
single photon emission computed tomography |
2 |
2009 |
| Drug |
sirolimus |
2 |
2012 |
| Drug |
sorafenib (nexavar, bay43-9006) |
2 |
2010 |
| Dietary Supplement |
soy |
2 |
2007 |
| Dietary Supplement |
soy protein |
2 |
2002 |
| Biological |
spartalizumab |
2 |
2018 |
| Drug |
standard adjuvant endocrine therapy |
2 |
2017 |
| Procedure |
stem cell transplant |
2 |
2007 |
| Radiation |
stereotactic body radiation therapy |
2 |
2010 |
| Drug |
sulindac |
2 |
2005 |
| Behavioral |
supervised exercise |
2 |
2017 |
| Other |
supervised progressive resistance training |
2 |
2011 |
| Device |
supine mri |
2 |
2016 |
| Behavioral |
supportive-expressive group therapy |
2 |
2005 |
| Drug |
suramin |
2 |
1999 |
| Procedure |
surgical resection |
2 |
2018 |
| Other |
survivorship care plan |
2 |
2012 |
| Biological |
sv-br-1-gm |
2 |
2017 |
| Radiation |
synthetic mammography |
2 |
2018 |
| Drug |
t |
2 |
2016 |
| Drug |
tac |
2 |
2007 |
| Drug |
tak-228 |
2 |
2016 |
| Drug |
tamoxifen (nolvadex) |
2 |
2009 |
| Drug |
tanespimycin |
2 |
2008 |
| Drug |
taxane |
2 |
2011 |
| Drug |
taxanes |
2 |
2014 |
| Diagnostic Test |
tchp |
2 |
2020 |
| Drug |
technetium (99mtc) sestamibi |
2 |
2013 |
| Drug |
telapristone acetate |
2 |
2014 |
| Behavioral |
telephone genetic counseling |
2 |
2019 |
| Drug |
testosterone |
2 |
2012 |
| Other |
text message |
2 |
2019 |
| Biological |
therapeutic allogeneic lymphocytes |
2 |
2003 |
| Biological |
therapeutic autologous lymphocytes |
2 |
2001 |
| Biological |
therapeutic tumor infiltrating lymphocytes |
2 |
2006 |
| Drug |
tibolone |
2 |
2008 |
| Drug |
tki258 |
2 |
2012 |
| Drug |
tocilizumab |
2 |
2017 |
| Drug |
trametinib |
2 |
2013 |
| Drug |
trastuzumab-mcc-dm1 |
2 |
2009 |
| Drug |
trastuzumab (herceptinâ®) |
2 |
2008 |
| Drug |
trastuzumab deruxtecan (ds-8201a) |
2 |
2018 |
| Drug |
trastuzumab, docetaxel |
2 |
2011 |
| Drug |
trc105 |
2 |
2015 |
| Biological |
tx05 (trastuzumab) |
2 |
2018 |
| Drug |
uft (uracil, tegafur) |
2 |
2005 |
| Diagnostic Test |
ultrasound tomography |
2 |
2017 |
| Drug |
valspodar |
2 |
1999 |
| Drug |
vandetanib |
2 |
2014 |
| Drug |
venlafaxine |
2 |
2005 |
| Drug |
verteporfin |
2 |
2016 |
| Procedure |
vomiting therapy |
2 |
2006 |
| Behavioral |
waitlist control |
2 |
2017 |
| Radiation |
wbi |
2 |
2018 |
| Device |
wire localization |
2 |
2018 |
| Drug |
with capecitabine |
2 |
2014 |
| Behavioral |
written materials |
2 |
2011 |
| Drug |
xentuzumab |
2 |
2018 |
| Drug |
xl147 (sar245408) |
2 |
2010 |
| Procedure |
yoga therapy |
2 |
2007 |
| Radiation |
yttrium y 90-edotreotide |
2 |
2000 |
| Drug |
zn-c5 |
2 |
2018 |
| Biological |
zw25 |
2 |
2020 |
| Combination Product |
- bevacizumab |
1 |
2018 |
| Procedure |
- complementary axillary lymphadenectomy |
1 |
2014 |
| Drug |
“investigator’s choice” chemotherapy |
1 |
2010 |
| Behavioral |
“oncotool” control (health |
1 |
2019 |
| Behavioral |
“oncotool” control (health /ht education) |
1 |
2019 |
| Behavioral |
“oncotool” intervention (mbsr |
1 |
2019 |
| Behavioral |
“oncotool” intervention (mbsr / ht education) |
1 |
2019 |
| Drug |
(vic-)trastuzumab duocarmazine |
1 |
2017 |
| Drug |
(will be assigned based on molecular profile |
1 |
2010 |
| Drug |
(will be assigned based on molecular profile/rpma) |
1 |
2010 |
| Diagnostic Test |
[1-13c]pyruvate along with mri imaging |
1 |
2019 |
| Biological |
[131i]-sgmib anti-her2 vhh1 |
1 |
2016 |
| Drug |
[18f]fes |
1 |
2015 |
| Drug |
[18f]flt |
1 |
2015 |
| Drug |
[18f]fluoroestradiol (fes) |
1 |
2013 |
| Drug |
[18f]fluorthanatrace |
1 |
2017 |
| Radiation |
[18f]ge-226 |
1 |
2019 |
| Drug |
[18f]iso-1 |
1 |
2014 |
| Drug |
[68ga]aby-025 |
1 |
2013 |
| Drug |
0.04 mg |
1 |
2002 |
| Drug |
0.04 mg/kg cpg 7909 |
1 |
2002 |
| Drug |
0.08 mg |
1 |
2002 |
| Drug |
0.08 mg/kg cpg 7909 |
1 |
2002 |
| Drug |
0.1% uracil cream |
1 |
2010 |
| Drug |
0.12 mg |
1 |
2002 |
| Drug |
0.12 mg/kg cpg 7909 |
1 |
2002 |
| Drug |
0.16 mg |
1 |
2002 |
| Drug |
0.16 mg/kg cpg 7909 |
1 |
2002 |
| Drug |
0.5% lignocaine 60mm |
1 |
2013 |
| Drug |
1-methyl-d-tryptophan |
1 |
2010 |
| Radiation |
1 week rt |
1 |
2018 |
| Drug |
1.7 ml subcutaneous solution [xgeva] |
1 |
2018 |
| Radiation |
10 fractions |
1 |
2008 |
| Behavioral |
10 week behavioral intervention program |
1 |
2006 |
| Behavioral |
10,000 steps |
1 |
2017 |
| Biological |
100 î¼g) |
1 |
2012 |
| Drug |
111-in-aby-025 |
1 |
2010 |
| Radiation |
11c-metformin |
1 |
2016 |
| Procedure |
14 sessions of manual lymphatic drainage technique |
1 |
2019 |
| Drug |
15 |
1 |
2012 |
| Drug |
153 sm-edtmp |
1 |
2007 |
| Drug |
17b-estradiol |
1 |
2014 |
| Radiation |
18 gy radiation |
1 |
2011 |
| Drug |
18f-al-nota-prgd2 pet |
1 |
2015 |
| Drug |
18f-al-nota-prgd2 pet/ct |
1 |
2015 |
| Device |
18f-fes-pet |
1 |
2018 |
| Drug |
18f-fes pet |
1 |
2018 |
| Drug |
18f-ffnp |
1 |
2015 |
| Radiation |
18f-flt-pet |
1 |
2009 |
| Device |
18f-flt-pet imaging |
1 |
2012 |
| Radiation |
18f-flt-pet/ct imaging |
1 |
2009 |
| Drug |
18f-fludeoxyglucose (18f-fdg) |
1 |
2013 |
| Diagnostic Test |
18f-fluorestradiol pet |
1 |
2018 |
| Diagnostic Test |
18f-fluorestradiol pet/ct scan |
1 |
2018 |
| Other |
18f-fluoromisonidazole |
1 |
2015 |
| Diagnostic Test |
18f-fluorothymidine |
1 |
2020 |
| Drug |
18f-fpprgd2 |
1 |
2013 |
| Drug |
18f-fspg |
1 |
2015 |
| Drug |
18f-î±vî²6-bp |
1 |
2017 |
| Device |
2-dimensional mammogram |
1 |
2017 |
| Dietary Supplement |
2-week ketogenic diet |
1 |
2019 |
| Other |
2 fes-pet imaging will be performed: |
1 |
2018 |
| Radiation |
2 gy targeted radiotherapy |
1 |
2016 |
| Other |
20-30 mmhg compression sleeve |
1 |
2017 |
| Other |
20-30 mmhg compression sleeve/gauntlet |
1 |
2017 |
| Radiation |
21 gy radiation |
1 |
2011 |
| Procedure |
24hour blood pressure |
1 |
2015 |
| Diagnostic Test |
2d-ffdm |
1 |
2017 |
| Device |
2d mammography |
1 |
2012 |
| Other |
3’-deoxy-3’-[18f]fluorothymidine |
1 |
2007 |
| Other |
3 days sie |
1 |
2018 |
| Other |
3 days sie/3 weeks pre |
1 |
2018 |
| Other |
3 days sie/4 weeks pre |
1 |
2018 |
| Device |
3 dimensional breast ultrasound |
1 |
2014 |
| Behavioral |
3 month physical activity intervention |
1 |
2010 |
| Radiation |
3 week rt |
1 |
2018 |
| Drug |
3 weeks conventional everolimus dosing |
1 |
2015 |
| Drug |
3 weeks dose induction of everolimus |
1 |
2015 |
| Other |
3 weeks pre |
1 |
2018 |
| Drug |
3 x fec 3 x doc |
1 |
2008 |
| Drug |
3 x fec 3 x doc / gemcitabine |
1 |
2008 |
| Drug |
350 mg leronlimab |
1 |
2019 |
| Radiation |
3d |
1 |
2007 |
| Radiation |
3d-conformal external beam |
1 |
2010 |
| Radiation |
3d-conformal techniques |
1 |
2010 |
| Radiation |
3d-crt (photon) apbi |
1 |
2015 |
| Radiation |
3d-proton |
1 |
2011 |
| Radiation |
3d-proton only |
1 |
2011 |
| Radiation |
3d-proton/conventional plan/3d-proton only |
1 |
2011 |
| Radiation |
3d-rt |
1 |
2011 |
| Radiation |
3d-rt/imrt |
1 |
2011 |
| Radiation |
3d conformal external beam irradiation |
1 |
2018 |
| Device |
3d mr fingerprinting scan |
1 |
2018 |
| Other |
3d printed bolus |
1 |
2015 |
| Procedure |
3d scanning |
1 |
2019 |
| Procedure |
3d shear wave elastography (swe) |
1 |
2016 |
| Device |
3d ultrasound elastography by means of shear wave propagation into breast tissue |
1 |
2012 |
| Device |
3m cavilon no sting barrier film |
1 |
2013 |
| Drug |
4- [f-18] fluoropaclitaxel |
1 |
2007 |
| Procedure |
4 ec q 2 weeks followed by 4 txt q 2 weeks |
1 |
2005 |
| Radiation |
4 gy targeted radiotherapy |
1 |
2016 |
| Procedure |
4 txt q 2 weeks followed by 4 ec q 2 weeks |
1 |
2005 |
| Other |
4 weeks pre |
1 |
2018 |
| Drug |
420mg |
1 |
2018 |
| Radiation |
4d conformal image-guided partial breast rt |
1 |
2012 |
| Biological |
4scar t cells |
1 |
2020 |
| Behavioral |
5-element music therapy |
1 |
2020 |
| Drug |
5-fluoro-2’-deoxycytidine (fdcyd) |
1 |
2009 |
| Drug |
5-fluoro-2’-deoxycytidine (fdcyd) / tetrahydrouridine (thu) |
1 |
2009 |
| Drug |
5-fu |
1 |
2015 |
| Drug |
5-fu, epirubicin |
1 |
2019 |
| Drug |
5-fu, epirubicin, cyclophosphamide, docetaxel |
1 |
2007 |
| Drug |
5-fu, epirubicin, cyclophosphamide, docetaxel, zoledronic acid |
1 |
2007 |
| Drug |
5-fu, epirubicin/cyclophosphamide |
1 |
2019 |
| Drug |
5-fu(intravenous bolus) |
1 |
2010 |
| Drug |
5-fu(intravenous bolus)/epirubicin/cyclophosphamide |
1 |
2010 |
| Drug |
5-fu(intravenous infusion) |
1 |
2010 |
| Drug |
5-fu(intravenous infusion)/epirubicin/cyclophosphamide |
1 |
2010 |
| Radiation |
5 fraction stereotactic body radiation therapy |
1 |
2018 |
| Drug |
50,000 iu vitamin d supplement |
1 |
2013 |
| Drug |
500 mg of depot hydroxy-progesterone |
1 |
2005 |
| Drug |
525 mg leronlimab |
1 |
2019 |
| Drug |
6-mercaptopurine |
1 |
2011 |
| Drug |
6 (cdk4 |
1 |
2017 |
| Radiation |
6 gy |
1 |
2016 |
| Radiation |
6 gy/ fraction |
1 |
2016 |
| Drug |
6 mg |
1 |
2018 |
| Procedure |
6 tec q 3 weeks |
1 |
2005 |
| Drug |
6) inhibitor |
1 |
2017 |
| Other |
68ga-nota-ae105 |
1 |
2016 |
| Drug |
7-hydroxystaurosporine |
1 |
2002 |
| Other |
7 days sie |
1 |
2018 |
| Other |
7 days sie/3 weeks pre |
1 |
2018 |
| Other |
7 days sie/4 weeks pre |
1 |
2018 |
| Drug |
700 mg leronlimab |
1 |
2019 |
| Radiation |
8 fractions |
1 |
2008 |
| Other |
8 week waiting period |
1 |
2019 |
| Other |
8 week waiting period / optional acupuncture |
1 |
2019 |
| Drug |
800 iu vitamin d supplement |
1 |
2013 |
| Other |
89zr-atezolizumab pet scans |
1 |
2019 |
| Drug |
89zr-bevacizumab |
1 |
2013 |
| Other |
89zr-bevacizumab pet |
1 |
2009 |
| Radiation |
89zr-pertuzumab |
1 |
2014 |
| Drug |
89zr-trastuzumab injection |
1 |
2013 |
| Drug |
9-cis-retinoic acid |
1 |
1999 |
| Drug |
9-ing-41 |
1 |
2018 |
| Radiation |
9 fractions |
1 |
2008 |
| Biological |
9 peptides from her-2 |
1 |
2009 |
| Biological |
9 peptides from her-2/neu, cea,/cta |
1 |
2009 |
| Drug |
95 regimen |
1 |
2006 |
| Drug |
99m-tc-nm-02 injection |
1 |
2019 |
| Radiation |
99mtc-3prgd2 |
1 |
2016 |
| Biological |
99mtc-abh2 |
1 |
2018 |
| Drug |
99mtc-hpark2 |
1 |
2020 |
| Radiation |
99mtc-labeled sulfur colloid |
1 |
2012 |
| Drug |
99mtc-rwy |
1 |
2020 |
| Radiation |
99mtc-sc |
1 |
2012 |
| Drug |
99technetium-sulfur colloid radiolabel |
1 |
2013 |
| Other |
a high-intensity interval exercise group |
1 |
2016 |
| placebo |
a placebo in combination with weekly paclitaxel. |
1 |
2012 |
| Behavioral |
a psycho-educational control |
1 |
2011 |
| Drug |
a.i. |
1 |
2019 |
| Device |
â® (smart phone app) |
1 |
2015 |
| Drug |
a1: pyrotinib with capecitabine |
1 |
2020 |
| Drug |
a166 |
1 |
2018 |
| Drug |
a2: nab-paclitaxel |
1 |
2020 |
| Other |
â²â¹â²pb-tcmc-trastuzumab |
1 |
2011 |
| Drug |
ab-101 |
1 |
2018 |
| Drug |
ab928 |
1 |
2018 |
| Drug |
abbv-085 |
1 |
2015 |
| Drug |
abi-007 (abraxane) |
1 |
2007 |
| Biological |
abi-007/carboplatin/trastuzumab |
1 |
1999 |
| Drug |
abiraterone acetate / prednisone/ prednisolone / exemestane |
1 |
2011 |
| Drug |
abiraterone acetate / prednisone/prednisolone |
1 |
2011 |
| Other |
ablation |
1 |
2017 |
| Drug |
abp 980 |
1 |
2013 |
| Drug |
abraxane / tigatuzumab |
1 |
2011 |
| Drug |
abraxane alone |
1 |
2011 |
| Drug |
abraxane,cyclophosphamide,carboplatin |
1 |
2014 |
| Drug |
abraxane/cisplatin combination |
1 |
2010 |
| Drug |
abraxane/gemcitabine |
1 |
2012 |
| Drug |
abt-751 |
1 |
2003 |
| Drug |
abt-869 |
1 |
2008 |
| Drug |
abx, cisplatin |
1 |
2015 |
| Diagnostic Test |
aby-pet |
1 |
2018 |
| Drug |
ac-t chemotherapy regimen |
1 |
2019 |
| Drug |
ac (adm 40mg |
1 |
2005 |
| Drug |
ac (adm 40mg/m2/cpa 500mg/m2) q21 days x 6 cycles |
1 |
2005 |
| Drug |
ac [adriamycin (a) (also known as doxorubicin) |
1 |
2007 |
| Drug |
ac [adriamycin (a) (also known as doxorubicin)/cyclophosphamide (c)] followed by paclitaxel (p) |
1 |
2007 |
| Drug |
ac/docetaxel 60mg/m2 alternately q21 days for 6 cycles |
1 |
2005 |
| Drug |
ac4-cddp4 |
1 |
2012 |
| Radiation |
accelerated external beam 3-d conformal radiotherapy |
1 |
2005 |
| Radiation |
accelerated hypofractionated radiotherapy (ahf-rt) |
1 |
2011 |
| Radiation |
accelerated partial breast irradiation - 3d-conformal planning |
1 |
2010 |
| Radiation |
accelerated partial breast irradiation - imrt planning |
1 |
2010 |
| Radiation |
accelerated partial breast irradiation (apbi) |
1 |
2014 |
| Radiation |
accelerated partial breast irradiation (apbi) to region of tumour bed using 3d conformal radiation therapy (3d crt) |
1 |
2007 |
| Radiation |
acceleration |
1 |
2017 |
| Behavioral |
acceptance/commitment therapy (act) |
1 |
2020 |
| Other |
accessory joint mobilization |
1 |
2015 |
| Procedure |
accupuncture |
1 |
2006 |
| Dietary Supplement |
acetyl-l-carnitine hydrochloride |
1 |
2008 |
| Device |
achieva, philips medical systems (3t magnet) |
1 |
2016 |
| Drug |
acolbifene hydrochloride |
1 |
2009 |
| Device |
actigraph |
1 |
2007 |
| Other |
action group |
1 |
2009 |
| Biological |
activated cik |
1 |
2018 |
| Biological |
activated cik/cd3-muc1 bispecific antibody in treating breast cancer |
1 |
2018 |
| Other |
active breathing control |
1 |
2016 |
| Device |
active breathing coordinator |
1 |
2006 |
| Behavioral |
active living counseling |
1 |
2016 |
| Behavioral |
active neurofeedback training |
1 |
2009 |
| Other |
active provider intervention |
1 |
2013 |
| Other |
active surveillance |
1 |
2004 |
| Behavioral |
active video game-based intervention |
1 |
2016 |
| Behavioral |
active video game teleconference support group |
1 |
2020 |
| Other |
activity-oriented proprioceptive antiedema therapy (tapa) |
1 |
2018 |
| Behavioral |
activity monitoring |
1 |
2013 |
| Device |
activity monitoring device |
1 |
2016 |
| Behavioral |
activity program |
1 |
2018 |
| Behavioral |
acts intervention |
1 |
2010 |
| Device |
acupression’s bracelet |
1 |
2005 |
| Behavioral |
acupressure intervention |
1 |
2017 |
| Procedure |
acupressure therapy |
1 |
2002 |
| Other |
acupuncture/moxibustion |
1 |
2009 |
| Dietary Supplement |
acute tryptophan depletion |
1 |
2005 |
| Drug |
acy-1215 |
1 |
2015 |
| Genetic |
ad-rts-hil-12 |
1 |
2012 |
| Genetic |
ad-rts-hil-12/veledimex |
1 |
2012 |
| Biological |
adagloxad simolenin |
1 |
2018 |
| Biological |
adagloxad simolenin/with obi-821 |
1 |
2018 |
| Drug |
adavosertib |
1 |
2015 |
| Drug |
adavosertib 150 mg bd |
1 |
2017 |
| Drug |
adavosertib 150 mg bd / olaparib 200 mg bd (21-day cycle). |
1 |
2017 |
| Other |
additional measurement |
1 |
2012 |
| Procedure |
additional shave margin |
1 |
2016 |
| Biological |
adenoviral vector encoding rat her-2 |
1 |
2006 |
| Biological |
adenoviral vector encoding rat her-2/neu |
1 |
2006 |
| Biological |
adenovirus-mediated human interleukin-12 |
1 |
2009 |
| Biological |
adenovirus-p53 transduced dendritic cell (dc) vaccine |
1 |
2010 |
| Biological |
adher-2 |
1 |
2005 |
| Biological |
adher-2/neu transduced dendritic cells |
1 |
2005 |
| Biological |
adher2 |
1 |
2012 |
| Biological |
adher2/neu dc vaccine |
1 |
2012 |
| Drug |
adi-peg 20 |
1 |
2013 |
| Behavioral |
adjustable compression wrap |
1 |
2016 |
| Drug |
adjuvant capecitabine |
1 |
2005 |
| Drug |
adjuvant chemotherapy |
1 |
2008 |
| Drug |
adjuvant endocrine therapy |
1 |
2017 |
| Drug |
adjuvant epirubicin |
1 |
2015 |
| Drug |
adjuvant epirubicin/ cyclophosphamide |
1 |
2015 |
| Combination Product |
adjuvant hypofractionated radiation |
1 |
2016 |
| Drug |
adjuvant letrozole (postmenopausal women) |
1 |
2015 |
| Drug |
adjuvant palbociclib (if palbociclib given neoadjuvant) |
1 |
2015 |
| Drug |
adjuvant tamoxifen |
1 |
2015 |
| Drug |
adjuvant tamoxifen / goserelin (premenopausal women) |
1 |
2015 |
| Drug |
adjuvant trastuzumab |
1 |
2015 |
| Drug |
ado-trastuzumab emtansine (t-dm1) |
1 |
2018 |
| Drug |
ado trastuzumab emtansine |
1 |
2013 |
| Procedure |
adrc-enhanced autologous fat transplant |
1 |
2008 |
| Drug |
adriamycin (doxorubicin), docetaxel, tamoxifen |
1 |
2008 |
| Drug |
adriamycin (doxorubicin), docetaxel, tamoxifen, cyclophosphamid |
1 |
2008 |
| Drug |
adriamycin/cytoxan (ac) |
1 |
2006 |
| Drug |
adriamycine |
1 |
2005 |
| Biological |
adv |
1 |
2016 |
| Biological |
adv/hsv-tk |
1 |
2016 |
| Biological |
ae37 |
1 |
2007 |
| Biological |
ae37 / gm-csf vaccine |
1 |
2007 |
| Biological |
ae37 peptide vaccine |
1 |
2019 |
| Behavioral |
aerobic exercise only |
1 |
2018 |
| Behavioral |
aerobic exercise/relaxation |
1 |
2018 |
| Behavioral |
aerobic training - fixed schedule |
1 |
2016 |
| Behavioral |
aerobic training - flexible schedule |
1 |
2016 |
| Other |
aerobic training home-based |
1 |
2018 |
| Other |
aerobic training presential |
1 |
2018 |
| Device |
aeroform breast tissue expander |
1 |
2013 |
| Drug |
afatinib 40mg once daily (od) |
1 |
2011 |
| Drug |
afatinib dimaleate |
1 |
2015 |
| Drug |
afatinib once daily (od) |
1 |
2011 |
| Drug |
aflibercept |
1 |
2013 |
| Drug |
afp464 |
1 |
2006 |
| Drug |
ag-013736 (axitinib) |
1 |
2004 |
| Other |
ah-ha tool in the epic ehr |
1 |
2019 |
| Drug |
ai adjuvant therapy |
1 |
2012 |
| Drug |
ai/chemotherapy adjuvant therapy |
1 |
2012 |
| Drug |
ai/dimethyldiguanide |
1 |
2012 |
| Drug |
akt inhibitor gsk2141795 |
1 |
2013 |
| Drug |
albumin bound (nab)-paclitaxel |
1 |
2019 |
| Drug |
albumin bound (nab)-paclitaxel/with carboplatin followed by epirubicin/cyclophosphamide |
1 |
2019 |
| Drug |
albumin bound paclitaxel |
1 |
2020 |
| Drug |
albumin paclitaxel |
1 |
2019 |
| Drug |
alcohol-free dexamethasone mouth rinse |
1 |
2012 |
| Drug |
aldoxorubicin hcl |
1 |
2017 |
| Drug |
alimta |
1 |
2004 |
| Drug |
alimta (pemetrexed) |
1 |
2010 |
| Drug |
alimta/epirubicin |
1 |
2004 |
| Dietary Supplement |
alkaline water |
1 |
2011 |
| Drug |
alkylating agent of physician choice registered in cancer |
1 |
2010 |
| Drug |
all-trans retinoic acid |
1 |
2019 |
| Device |
alloderm rtu |
1 |
2013 |
| Biological |
allogeneic tumor cell vaccine |
1 |
1999 |
| Other |
alloplastic free rom |
1 |
2015 |
| Other |
alloplastic limited rom |
1 |
2015 |
| Procedure |
alnd) |
1 |
2016 |
| Procedure |
aloe barbadensis topical application in a moisturizing cream vehicle. |
1 |
2005 |
| Drug |
alpelisib (byl719) |
1 |
2014 |
| placebo |
alpelisib placebo |
1 |
2015 |
| Dietary Supplement |
alpha-lipoic acid |
1 |
2019 |
| Drug |
alpha-tocopheryloxyacetic acid |
1 |
2019 |
| Biological |
alt-p7 (hm2-mmae) |
1 |
2017 |
| Radiation |
alternate bolus |
1 |
2013 |
| Biological |
alvac-cea vaccine |
1 |
1999 |
| Drug |
alvespimycin |
1 |
2008 |
| Drug |
alvespimycin hydrochloride |
1 |
2004 |
| Other |
ambulatory surgery |
1 |
2012 |
| Drug |
american ginseng root |
1 |
2008 |
| Drug |
amg 162 |
1 |
2004 |
| Drug |
amg 162 / denosumab |
1 |
2004 |
| Drug |
amg 386 10 mg |
1 |
2008 |
| Drug |
amg 386 10 mg/kg, capecitabine/lapatinib |
1 |
2008 |
| Drug |
amg 386 10 mgkg, paclitaxel |
1 |
2008 |
| Drug |
amg 386 10 mgkg, paclitaxel/trastuzumab |
1 |
2008 |
| Drug |
amg 386 30 mg |
1 |
2008 |
| Drug |
amg 386 30 mg/kg, capecitabine/lapatinib |
1 |
2008 |
| Drug |
amg 386 30 mg/kg, paclitaxel/trastuzumab |
1 |
2008 |
| placebo |
amg 386 placebo |
1 |
2007 |
| Drug |
amg 386 with |
1 |
2009 |
| Drug |
amg 386 with/without trastuzumab |
1 |
2009 |
| Drug |
amg 386/trastuzumab |
1 |
2009 |
| Drug |
amg 479 |
1 |
2008 |
| Drug |
amg 479 (ganitumab) |
1 |
2009 |
| Drug |
amg 479 (ganitumab)/metformin |
1 |
2009 |
| Drug |
amg 479/placebo administered with either exemestane/fulvestrant |
1 |
2008 |
| Drug |
amg 706 |
1 |
2006 |
| Drug |
amifostine |
1 |
2004 |
| Drug |
aminoglutethimide |
1 |
2006 |
| Drug |
amlodipine |
1 |
2016 |
| Drug |
amonafide dihydrochloride |
1 |
2003 |
| Drug |
ampicillin |
1 |
2006 |
| Drug |
ampicillin/sulbactam |
1 |
2006 |
| Drug |
amrubicin |
1 |
2009 |
| Other |
an attention-control group |
1 |
2016 |
| Drug |
anastozole (arimidex) |
1 |
2009 |
| placebo |
anastozole (arimidex) placebo |
1 |
2009 |
| Drug |
anastrazole (arimidex) |
1 |
2008 |
| Drug |
anastrazole (arimidexâ®) |
1 |
2001 |
| Drug |
anastrozole 1mg tablet |
1 |
2017 |
| Drug |
anastrozole tablets |
1 |
2019 |
| Drug |
anastrozole/fulvestrant |
1 |
2008 |
| Drug |
anastrozole/goserelin |
1 |
2005 |
| Drug |
anastrozole/letrozole/exemestane |
1 |
2016 |
| Procedure |
anatomo-pathologic procedure |
1 |
2006 |
| Device |
andullation |
1 |
2019 |
| Drug |
ang1005 |
1 |
2014 |
| Device |
angiodynamics (previously rita med,inc) radiofrequency delivery system (consisting of a generator |
1 |
2007 |
| Device |
angiodynamics (previously rita med,inc) radiofrequency delivery system (consisting of a generator/starburst xl probe) |
1 |
2007 |
| Drug |
anlotinib hydrochioride capsules |
1 |
2019 |
| Drug |
anlotinib hydrochloride |
1 |
2019 |
| Other |
annual invitation to mammography |
1 |
2015 |
| Drug |
anthra |
1 |
2015 |
| Drug |
anthracycline-based |
1 |
2007 |
| Drug |
anthracycline (doxorubicin) |
1 |
2015 |
| Drug |
anthracycline, cyclophosphamide, docetaxel, capecitabine |
1 |
2006 |
| Drug |
anthracycline/taxane based chemotherapy |
1 |
2015 |
| Drug |
anthracyclines |
1 |
2014 |
| Biological |
anti-b7h1 monoclonal antibody medi4736 |
1 |
2015 |
| Drug |
anti-egfr-il-dox |
1 |
2016 |
| Drug |
anti-nausea therapy |
1 |
2013 |
| Biological |
anti-ox40 antibody pf-04518600 |
1 |
2019 |
| Drug |
anti-pd-l1 |
1 |
2018 |
| Drug |
anti-pd-l1/tgfbetarii fusion protein m7824 |
1 |
2018 |
| Drug |
anti-thymocyte globulin |
1 |
2006 |
| Drug |
anti pd-1 with nab-paclitaxel |
1 |
2019 |
| Drug |
antibody-drug conjugates |
1 |
2015 |
| Drug |
antidepressant |
1 |
2004 |
| Procedure |
antiestrogen therapy |
1 |
2002 |
| Drug |
antiperspirant cream f511 |
1 |
2009 |
| Device |
antiseptic occlusive dressing group |
1 |
2017 |
| Other |
anxiety questionnaire administration |
1 |
2018 |
| Other |
anxiety self-management techniques |
1 |
2018 |
| Drug |
ap1903 |
1 |
2016 |
| Other |
apa |
1 |
2018 |
| Other |
apad |
1 |
2019 |
| Drug |
apatinib/oral etoposide |
1 |
2017 |
| Radiation |
apbi |
1 |
2018 |
| Radiation |
apbi 27gy in 5 fractions |
1 |
2016 |
| Radiation |
apbi utilizing 3d-crt radiation |
1 |
2006 |
| Radiation |
apbi: 27.5 gy |
1 |
2015 |
| Radiation |
apbi: 30 gy |
1 |
2015 |
| Drug |
apis mellifica |
1 |
2018 |
| Behavioral |
app |
1 |
2017 |
| Behavioral |
app-based mindfulness training |
1 |
2015 |
| Behavioral |
app notifications |
1 |
2017 |
| Behavioral |
app/ |
1 |
2017 |
| Drug |
ar inhibitor with cdk4 |
1 |
2019 |
| Drug |
ar inhibitor with cdk4/6 inhibitor |
1 |
2019 |
| Drug |
aranesp |
1 |
2005 |
| Other |
archived tissue collection |
1 |
2015 |
| Drug |
arcoxia, 120 mg |
1 |
2017 |
| Procedure |
areola sparing mastectomy |
1 |
2017 |
| Procedure |
argon plasma coagulation |
1 |
2015 |
| Drug |
arimidex |
1 |
2007 |
| Drug |
arimidex (anastrazole) |
1 |
2005 |
| Drug |
arimidex 1mg |
1 |
2012 |
| Drug |
arimidex dummy |
1 |
2012 |
| placebo |
arimidex placebo |
1 |
2008 |
| Radiation |
arm 1 600 cgy x 5 fractions |
1 |
2015 |
| Procedure |
arm 1: sentinel node biopsy |
1 |
2014 |
| Radiation |
arm 2 800 cgy x 3 fractions |
1 |
2015 |
| Other |
arm 2: exercise |
1 |
2003 |
| Other |
arm 2: exercise / calcium-rich diet |
1 |
2003 |
| Drug |
arm a |
1 |
2010 |
| Other |
arm a directed exercise program |
1 |
2014 |
| Drug |
arm a vinorelbine (navelbine oral) capecitabine (xeloda) |
1 |
2012 |
| Other |
arm a: adapted physical activity |
1 |
2014 |
| Other |
arm a: adapted physical activity / enhanced geriatric follow-up |
1 |
2014 |
| Drug |
arm b |
1 |
2010 |
| Drug |
arm b vinorelbine (navelbine oral) capecitabine (xeloda) |
1 |
2012 |
| Other |
arm b, tumor markers assessment |
1 |
2014 |
| Drug |
arm c |
1 |
2010 |
| Behavioral |
arm precaution |
1 |
2015 |
| Drug |
aromasin (exemestane) |
1 |
2010 |
| Drug |
aromatase inhibition |
1 |
2002 |
| Drug |
aromatase inhibitor / palbociclib |
1 |
2015 |
| Drug |
aromatase inhibitor/palbociclib |
1 |
2017 |
| Drug |
aromatase inhibitors (arimidex) |
1 |
2016 |
| Drug |
aromatase inhibitors (aromasin) |
1 |
2016 |
| Drug |
aromatase inhibitors (femara) |
1 |
2016 |
| Drug |
aromatase inhibitors, non steroideal |
1 |
2019 |
| Drug |
arry-380 once daily |
1 |
2013 |
| Drug |
arry-380 twice daily dosage |
1 |
2013 |
| Other |
art-therapie |
1 |
2011 |
| Drug |
artesunate |
1 |
2008 |
| Drug |
arv-471 |
1 |
2019 |
| Drug |
arx788 |
1 |
2017 |
| Drug |
arzoxifene |
1 |
2000 |
| Drug |
as15 |
1 |
2015 |
| Biological |
as15 asci |
1 |
2009 |
| Procedure |
aspiration of breast |
1 |
2018 |
| Behavioral |
assessment |
1 |
2016 |
| Other |
assessment of dietary intake |
1 |
2013 |
| Drug |
astx727 |
1 |
2019 |
| Drug |
atamestane |
1 |
2002 |
| Drug |
atezolizumab (mpdl3280a), an engineered anti-programmed death-ligand 1 (pd-l1) antibody |
1 |
2017 |
| placebo |
atezolizumab placebo |
1 |
2017 |
| Other |
atope-b |
1 |
2018 |
| Other |
atope-i |
1 |
2018 |
| Drug |
atorvastatin 80mg |
1 |
2017 |
| Drug |
atorvastatin calcium |
1 |
2008 |
| Drug |
atropine |
1 |
2016 |
| Behavioral |
attention control condition |
1 |
2019 |
| Behavioral |
attention control group (acg) |
1 |
2012 |
| Drug |
auc 5 carboplatin |
1 |
2019 |
| Procedure |
auricular acupressure (aa) |
1 |
2019 |
| Other |
auricular points sticking |
1 |
2018 |
| Device |
auriculotherapy for analgesic use |
1 |
2017 |
| Other |
autohypnosis learning |
1 |
2018 |
| Procedure |
autologous-autologous tandem hematopoietic stem cell transplantation |
1 |
2005 |
| Biological |
autologous dendritic cell-adenovirus p53 vaccine |
1 |
2004 |
| Biological |
autologous dendritic cell vaccination |
1 |
2011 |
| Procedure |
autologous fat transplantation |
1 |
2014 |
| Procedure |
autologous hematopoietic stem cell transplantation |
1 |
2016 |
| Procedure |
autologous t cells |
1 |
2006 |
| Biological |
autologous tumor cell vaccine |
1 |
1999 |
| Other |
automated messaging |
1 |
2019 |
| Other |
autonomic nervous system monitoring |
1 |
2015 |
| Drug |
avandamet |
1 |
2009 |
| Drug |
avastin / mfolfox6 |
1 |
2012 |
| Drug |
avastin, docetaxel, carboplatin |
1 |
2010 |
| Drug |
avi-014 versus filgrastim |
1 |
2007 |
| Procedure |
axillar sentinel lymph node biopsy |
1 |
2010 |
| Procedure |
axillary clearance |
1 |
1999 |
| Procedure |
axillary dissection for breast carcinomas |
1 |
2010 |
| Procedure |
axillary lymph node biopsy |
1 |
2015 |
| Device |
axillary magseed |
1 |
2018 |
| Procedure |
axillary node dissection |
1 |
2013 |
| Radiation |
axillary radiation therapy |
1 |
2013 |
| Procedure |
axillary sentinel lymph node biopsy |
1 |
2012 |
| Procedure |
axillary treatment |
1 |
2015 |
| Drug |
az2281 |
1 |
2011 |
| Drug |
az2281 / carboplatin |
1 |
2011 |
| Drug |
az6244 |
1 |
2011 |
| Drug |
azacitidine |
1 |
2011 |
| Drug |
azacitidine (vidaza) |
1 |
2008 |
| Drug |
azd0530 |
1 |
2007 |
| Drug |
azd0530 (saracatinib) |
1 |
2010 |
| Drug |
azd1775 |
1 |
2016 |
| Drug |
azd2171 |
1 |
2007 |
| Drug |
azd4547 / anastrozole/letrozole |
1 |
2013 |
| Drug |
azd5363 when |
1 |
2012 |
| Drug |
azd5363 when/with weekly paclitaxel. |
1 |
2012 |
| Drug |
azd5363when |
1 |
2012 |
| Drug |
azd5363when/with weekly paclitaxel. |
1 |
2012 |
| Drug |
azd6244 |
1 |
2008 |
| Drug |
azd6738 160 mg od |
1 |
2017 |
| Drug |
azd6738 160 mg od / olaparib continuous 300 mg bd (28-day cycle). |
1 |
2017 |
| Drug |
azd8835 |
1 |
2014 |
| Drug |
azd8835 in combination with fulvestrant |
1 |
2014 |
| Drug |
azd9496 (reference) |
1 |
2016 |
| Drug |
azd9496 variant a |
1 |
2016 |
| Drug |
azd9496 variant b |
1 |
2016 |
| Drug |
azd9496 variant c |
1 |
2016 |
| Drug |
azd9496 variant d |
1 |
2016 |
| Drug |
azd9833 with palbociclib |
1 |
2018 |
| Device |
b-liteâ® light weight breast implant |
1 |
2018 |
| Drug |
b1: everolimus with nab-paclitaxel |
1 |
2020 |
| Drug |
b2: nab-paclitaxel |
1 |
2020 |
| Other |
background hormonal therapy |
1 |
2014 |
| Drug |
background treatment |
1 |
2011 |
| Other |
baduanjin exercise |
1 |
2017 |
| Drug |
balixafortide |
1 |
2018 |
| Device |
balloon brachytherapy |
1 |
2018 |
| Behavioral |
baseline fitness test |
1 |
2011 |
| Behavioral |
basic physical activity |
1 |
2016 |
| Behavioral |
basic public reporting |
1 |
2016 |
| Biological |
bat8001 for injection |
1 |
2019 |
| Device |
baxter isolex 3001 stem cell selection system |
1 |
1999 |
| Drug |
bay59-8862 (cytotoxic taxane) |
1 |
2002 |
| Drug |
bay86-9596 |
1 |
2010 |
| Other |
bc-predict |
1 |
2020 |
| Drug |
bcd-115 |
1 |
2017 |
| Behavioral |
bces 6 week program |
1 |
2016 |
| Biological |
bcg |
1 |
1999 |
| Behavioral |
bci assay results |
1 |
2014 |
| Other |
bcsms app |
1 |
2019 |
| Drug |
bdc-1001 |
1 |
2020 |
| Other |
beauty care |
1 |
2011 |
| Drug |
becatecarin |
1 |
2000 |
| Drug |
beclomethasone dipropionate |
1 |
2001 |
| Drug |
beep regimen |
1 |
2014 |
| Behavioral |
behavioral activation |
1 |
2010 |
| Behavioral |
behavioral activation/problem-solving (ba/ps) |
1 |
2010 |
| Behavioral |
behavioral dietary |
1 |
2006 |
| Behavioral |
behavioral dietary/exercise intervention |
1 |
2006 |
| Behavioral |
behavioral group counseling |
1 |
2012 |
| placebo |
behavioral placebo treatment |
1 |
2008 |
| Drug |
belladonna pills |
1 |
2018 |
| placebo |
belladonna placebo pills |
1 |
2018 |
| Drug |
bemcentinib; pembrolizumab |
1 |
2017 |
| Drug |
benadryl |
1 |
2011 |
| Drug |
benfin |
1 |
2001 |
| Drug |
berzosertib |
1 |
2019 |
| Behavioral |
beta-text text messaging intervention |
1 |
2019 |
| Drug |
betamethason 4 mg |
1 |
2017 |
| Drug |
bevacizumab-800cw |
1 |
2015 |
| Drug |
bevacizumab-irdye800cw |
1 |
2011 |
| Drug |
bevacizumab (drug), herceptin (drug) |
1 |
2004 |
| Drug |
bevacizumab / doxorubin hydrochloride liposme |
1 |
2007 |
| Drug |
bevacizumab 15 |
1 |
2005 |
| Drug |
bevacizumab 15/tac |
1 |
2005 |
| Drug |
bevacizumab 7.5 |
1 |
2005 |
| Drug |
bevacizumab 7.5/tac |
1 |
2005 |
| Drug |
bevacizumab maintenance therapy |
1 |
2006 |
| placebo |
bevacizumab placebo |
1 |
2010 |
| Drug |
bevacizumab, 10 mg |
1 |
2006 |
| Drug |
bevacizumab, 15 mg |
1 |
2006 |
| Drug |
bevacizumab, abraxane |
1 |
2007 |
| Biological |
bevacizumab, cyclophosphamide, capecitabine |
1 |
2010 |
| Other |
bevacizumab, docetaxel |
1 |
2011 |
| Drug |
bevacizumab, docetaxel, cisplatin |
1 |
2009 |
| Other |
bevacizumab, docetaxel/doxorubicin followed by surgery |
1 |
2011 |
| Drug |
bevacizumab, etoposide, cisplatin |
1 |
2010 |
| Biological |
bevacizumab, paclitaxel |
1 |
2010 |
| Biological |
bevacizumab/capecitabine |
1 |
2008 |
| Biological |
bevacizumab/paclitaxel |
1 |
2008 |
| Drug |
bevacizumab/trastuzumab maintenance therapy |
1 |
2006 |
| Drug |
bez235 / paclitaxel |
1 |
2011 |
| Drug |
bez235 / trastuzumab phase l/phase ll) |
1 |
2011 |
| Drug |
bgb-290 |
1 |
2018 |
| Drug |
bgt226 |
1 |
2008 |
| Drug |
bi 2536 |
1 |
2007 |
| Drug |
bibf |
1 |
2011 |
| Drug |
bibf / paclitaxel |
1 |
2011 |
| Drug |
bicalutamide 150 mg |
1 |
2017 |
| Drug |
biib021 |
1 |
2009 |
| Procedure |
bilateral mastectomy |
1 |
2015 |
| Procedure |
bio-field energy therapy |
1 |
2007 |
| Behavioral |
biobehavioral intervention |
1 |
2018 |
| Biological |
biological test |
1 |
2018 |
| Other |
biomarker study |
1 |
2017 |
| Other |
biomarkers |
1 |
2015 |
| Biological |
biomarkers blood, urine |
1 |
2018 |
| Biological |
biomarkers blood, urine/microbiota samples |
1 |
2018 |
| Procedure |
biopsy / radioactive seed placement |
1 |
2014 |
| Procedure |
biopsy of breast |
1 |
2017 |
| Procedure |
biopsy of target tumor |
1 |
2015 |
| Device |
bis |
1 |
2016 |
| Drug |
bisoprolol |
1 |
2014 |
| Drug |
bivatuzumab mertansine |
1 |
2014 |
| Drug |
bkm 120 |
1 |
2010 |
| placebo |
bkm120 placebo |
1 |
2013 |
| Drug |
bkm120/olaparib |
1 |
2012 |
| Dietary Supplement |
black cohosh |
1 |
2003 |
| Drug |
blis with anti-vegfr included therapy |
1 |
2019 |
| Biological |
blood-stage infection of p.vivax |
1 |
2018 |
| Other |
blood draws |
1 |
2010 |
| Procedure |
blood for detection of circulating tumor cells |
1 |
2016 |
| Other |
blood sample for genetic analysis (identification of germ line genetic factors that influence the risk of metastatic breast cancer) |
1 |
2011 |
| Genetic |
blood sample for genetic test |
1 |
2018 |
| Biological |
blood sample for hormonal measurement |
1 |
2018 |
| Procedure |
blood samples of 10 ml |
1 |
2014 |
| Other |
blood test sample |
1 |
2018 |
| Other |
blood test/ additional measurement |
1 |
2012 |
| Other |
blood/fecal collection |
1 |
2016 |
| Biological |
blood/tumor sample |
1 |
2011 |
| Device |
blossom |
1 |
2018 |
| Drug |
blue citrus |
1 |
2008 |
| Diagnostic Test |
blueprint |
1 |
2019 |
| Drug |
blz-100 |
1 |
2015 |
| Drug |
bmk120 |
1 |
2011 |
| Drug |
bms-247550 |
1 |
2000 |
| Drug |
bms-690514 |
1 |
2010 |
| Drug |
bms-754807 |
1 |
2008 |
| Drug |
bnp7787 |
1 |
2002 |
| Procedure |
body acupuncture |
1 |
2015 |
| Other |
body composition measurement |
1 |
2015 |
| Procedure |
bold mri scan |
1 |
2010 |
| Other |
bone marrow aspirate |
1 |
2016 |
| Procedure |
bone marrow aspiration /trephine biopsy |
1 |
2016 |
| Other |
bone mineral density |
1 |
2007 |
| Other |
bone pain education dvd |
1 |
2012 |
| Other |
bone scintigraphy |
1 |
2013 |
| Behavioral |
booklet |
1 |
2015 |
| Radiation |
boost irradiation |
1 |
2014 |
| Radiation |
boost to the tumour bed |
1 |
2013 |
| Other |
booties |
1 |
2014 |
| Drug |
bosutinib |
1 |
2019 |
| Drug |
boswellia |
1 |
2017 |
| Radiation |
brachytherapy apbi |
1 |
2015 |
| Procedure |
bracketing |
1 |
2018 |
| Other |
brain fitness program (bfp) |
1 |
2015 |
| Radiation |
brain radiotherapy |
1 |
2015 |
| Radiation |
brain radiotherapy/stereotactic radiosurgery |
1 |
2015 |
| Radiation |
brain sequential rt |
1 |
2014 |
| Genetic |
brca2 |
1 |
2015 |
| Other |
breast-q -reconstruction module (preoperative) version 2.0 satisfaction with breasts questionnaire |
1 |
2018 |
| Other |
breast-q questionnaire |
1 |
2017 |
| Behavioral |
breast-qâ© questionnaire |
1 |
2014 |
| Radiation |
breast brachytherapy with mammosite rts |
1 |
2010 |
| Radiation |
breast cancer |
1 |
2015 |
| Other |
breast cancer-related lymphedema measurements |
1 |
2019 |
| Behavioral |
breast cancer clinical trials education program |
1 |
2014 |
| Other |
breast cancer database |
1 |
2007 |
| Other |
breast cancer exercise intervention |
1 |
2018 |
| Behavioral |
breast cancer risk reduction household intervention |
1 |
2020 |
| Behavioral |
breast cancer risk reduction program |
1 |
2020 |
| Other |
breast cancer risk report |
1 |
2017 |
| Behavioral |
breast cancer screening compliance |
1 |
2005 |
| Behavioral |
breast cancer screening decision aid |
1 |
2013 |
| Behavioral |
breast cancer support group |
1 |
2005 |
| Procedure |
breast cancer surgery |
1 |
2016 |
| Procedure |
breast cancer surgery only - arm iii |
1 |
2006 |
| Behavioral |
breast cancer survivors |
1 |
2013 |
| Other |
breast cancer treatment decision aid for women 70 |
1 |
2016 |
| Other |
breast cancer treatment decision aid for women 70/ |
1 |
2016 |
| Procedure |
breast capsule biopsy |
1 |
2018 |
| Procedure |
breast conservative surgery |
1 |
2016 |
| Procedure |
breast conserving surgery |
1 |
2015 |
| Procedure |
breast conserving surgery with axillary lymph node dissection |
1 |
2005 |
| Procedure |
breast conserving surgery/mastectomy / snb/axillary dissection |
1 |
2015 |
| Procedure |
breast core biopsy |
1 |
2015 |
| Radiation |
breast ct scanning |
1 |
2012 |
| Procedure |
breast duct lavage |
1 |
2004 |
| Other |
breast health education |
1 |
2014 |
| Device |
breast imrt |
1 |
2005 |
| Device |
breast mri |
1 |
2014 |
| Diagnostic Test |
breast pet |
1 |
2016 |
| Radiation |
breast radiation |
1 |
2000 |
| Radiation |
breast radiation/regional radiation |
1 |
2000 |
| Procedure |
breast reconstruction |
1 |
2010 |
| Other |
breast reconstruction decision aid |
1 |
2019 |
| Procedure |
breast surgery / lymph node removal |
1 |
2013 |
| Procedure |
breast tomosynthesis |
1 |
2008 |
| Diagnostic Test |
breast ultrasound |
1 |
2017 |
| Other |
breastcare |
1 |
2013 |
| Behavioral |
breastq questionnaire- |
1 |
2010 |
| Other |
breathing exercise |
1 |
2020 |
| Behavioral |
brief behavioral therapy |
1 |
2013 |
| Behavioral |
brief preoperative smoking intervention |
1 |
2006 |
| Behavioral |
brief supportive-expressive group therapy |
1 |
2005 |
| Other |
bright blue-green light |
1 |
2017 |
| Other |
bright blue-green light using light visor cap |
1 |
2016 |
| Device |
bright white light |
1 |
2007 |
| Behavioral |
brim3 educational intervention |
1 |
2017 |
| Drug |
brn01 |
1 |
2010 |
| Other |
brochure |
1 |
2020 |
| Drug |
brostallicin |
1 |
2010 |
| Drug |
bryostatin 1 |
1 |
1999 |
| Drug |
bsi-201 |
1 |
2008 |
| Drug |
btp-114 |
1 |
2016 |
| Other |
bubble packaging for monthly prescription |
1 |
2012 |
| Device |
bubble: a new vr-ai way of treatment for hot flashes |
1 |
2020 |
| Behavioral |
buddy |
1 |
2017 |
| Drug |
budesonide |
1 |
2015 |
| Other |
buffy coat |
1 |
2016 |
| Drug |
buparlisib (bkm120) |
1 |
2014 |
| Drug |
bupivacaine injection |
1 |
2018 |
| Combination Product |
bupivacaine/triamcinolone |
1 |
2019 |
| Drug |
bupivicaine |
1 |
2007 |
| Drug |
bupropion |
1 |
2018 |
| Drug |
bupropion extended release (wellbutrin xl) |
1 |
2005 |
| Drug |
bupropion hydrochloride |
1 |
2017 |
| Drug |
bupropion hydrochloride controlled-release |
1 |
2019 |
| Drug |
byl719/olaparib |
1 |
2012 |
| Drug |
bzl101 |
1 |
2007 |
| Drug |
c1: pd-1 with nab-paclitaxel |
1 |
2020 |
| Drug |
c1: pd-1 with nab-paclitaxel/famitinib |
1 |
2020 |
| Drug |
c2: nab-paclitaxel |
1 |
2020 |
| Genetic |
c7r-gd2.cart cells |
1 |
2018 |
| Drug |
cabacitaxel |
1 |
2013 |
| Drug |
cabergoline |
1 |
2012 |
| Drug |
caelyx |
1 |
2005 |
| Drug |
caelyx (doxorubicin) treatment sequence ab |
1 |
2013 |
| Drug |
caelyx (doxorubicin) treatment sequence ba |
1 |
2013 |
| Drug |
caelyxâ® |
1 |
2018 |
| Drug |
caffeine |
1 |
2012 |
| Drug |
caffeine anhydrous 5% added to lipoderm cream base. |
1 |
2018 |
| Drug |
cal |
1 |
2003 |
| Other |
calcium diet |
1 |
2003 |
| Dietary Supplement |
calcium glucarate |
1 |
2006 |
| Dietary Supplement |
calcium salts |
1 |
2001 |
| Drug |
calcium/cholecalciferol |
1 |
2011 |
| Drug |
calendula weleda cream (weleda ag, sweden) contains extracts of marigold plant (calendula officinalis 10%), wool fat |
1 |
2012 |
| Drug |
calendula weleda cream (weleda ag, sweden) contains extracts of marigold plant (calendula officinalis 10%), wool fat/sesame oil |
1 |
2012 |
| Other |
calorie restricted diet |
1 |
2016 |
| Other |
calorie restricted diet/exercise |
1 |
2016 |
| Drug |
camrelizumab |
1 |
2020 |
| Drug |
camrelizumab in combination with nab-paclitaxel |
1 |
2019 |
| Drug |
camrelizumab in combination with nab-paclitaxel/famitinib |
1 |
2019 |
| Device |
canadvice |
1 |
2015 |
| Device |
canadvice/â® (smart phone app) |
1 |
2015 |
| Biological |
canakinumab |
1 |
2018 |
| Behavioral |
cancer-focused relationship enhancement |
1 |
2008 |
| Device |
cancer ablation |
1 |
2017 |
| Device |
cancer detection cartridge |
1 |
2019 |
| Device |
cancer vision goggles |
1 |
2016 |
| Behavioral |
cancer.net app |
1 |
2019 |
| Other |
cansort online tool |
1 |
2013 |
| Biological |
capecitabi:1000mg |
1 |
2019 |
| Biological |
capecitabin:1000mg |
1 |
2019 |
| Drug |
capecitabine - dose a |
1 |
2000 |
| Drug |
capecitabine - dose b |
1 |
2000 |
| Drug |
capecitabine (phase ii) |
1 |
2011 |
| Drug |
capecitabine (xelodaâ®) |
1 |
2004 |
| Combination Product |
capecitabine / bevacizumab/paclitaxel //- bevacizumab |
1 |
2018 |
| Combination Product |
capecitabine / vinorelbine |
1 |
2019 |
| Drug |
capecitabine in aduvant setting |
1 |
2005 |
| Drug |
capecitabine monotherapy |
1 |
2015 |
| Drug |
capecitabine oral product |
1 |
2020 |
| Drug |
capecitabine, lapatinib |
1 |
2008 |
| Drug |
capecitabine, nab-paclitaxel |
1 |
2010 |
| Drug |
capecitabine/aromatase inhibitor |
1 |
2019 |
| Drug |
capecitabine/oxaliplatin |
1 |
2005 |
| Drug |
capecitabine/pseudomonas aeruginosa combination |
1 |
2011 |
| Drug |
capmatinib |
1 |
2018 |
| Drug |
capsaicin |
1 |
2018 |
| Biological |
car-t cells recognizing epcam |
1 |
2016 |
| Drug |
carbo |
1 |
2013 |
| Drug |
carbo/cyclo |
1 |
2013 |
| Drug |
carbo/cyclo / atezolizumab |
1 |
2013 |
| Dietary Supplement |
carbohydrate |
1 |
2005 |
| Radiation |
carbon c 14 oxaliplatin |
1 |
2014 |
| Drug |
carboplatin / etoposide |
1 |
2016 |
| Drug |
carboplatin in dose dense regimen |
1 |
2005 |
| Drug |
carboplatin) versus ec followed by t (epirubicin |
1 |
2017 |
| Drug |
carboplatin, olaparib |
1 |
2015 |
| Drug |
carboplatin, thiotepa, |
1 |
2012 |
| Drug |
carboplatin, thiotepa,/cyclophosphamide |
1 |
2012 |
| Drug |
carboplatin. |
1 |
2018 |
| Drug |
carboplatin/ paclitaxel |
1 |
2009 |
| Drug |
carboplatin/paclitaxel |
1 |
2010 |
| Drug |
carboplatinum |
1 |
2020 |
| Drug |
carboxyamidotriazole |
1 |
2001 |
| Drug |
carbplatin, cyclophophamide, atezolizumab |
1 |
2016 |
| Other |
cardiac imaging |
1 |
2017 |
| Other |
cardiac imaging/circulating biomarkers |
1 |
2017 |
| Other |
cardiac magnetic resonance imaging (cmr) |
1 |
2015 |
| Other |
cardiopulmonary exercise test |
1 |
2015 |
| Other |
cardiopulmonary exercise test (cpet) |
1 |
2010 |
| Other |
care as usual |
1 |
2018 |
| Other |
care program |
1 |
2009 |
| Behavioral |
carevive cps |
1 |
2017 |
| Behavioral |
caringguidance after breast cancer diagnosis |
1 |
2018 |
| Device |
catheter |
1 |
2017 |
| Procedure |
cavity shaving |
1 |
2016 |
| Drug |
cblb612 |
1 |
2016 |
| Behavioral |
cbt |
1 |
2010 |
| Behavioral |
cbt intervention |
1 |
2015 |
| Drug |
cc-486 |
1 |
2014 |
| Behavioral |
ccc website |
1 |
2018 |
| Biological |
cd105 |
1 |
2014 |
| Biological |
cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine |
1 |
2014 |
| Biological |
cd3-muc1 bispecific antibody in treating breast cancer |
1 |
2018 |
| Biological |
cd34 |
1 |
2005 |
| Biological |
cd34/ derived dcs |
1 |
2005 |
| Biological |
cd80 breast cancer vaccine |
1 |
1999 |
| Biological |
cdca1<urlc10<kif20a<depdc1 |
1 |
2010 |
| Biological |
cdca1<urlc10<kif20a<depdc1/mphosph1 |
1 |
2010 |
| Biological |
cdh3 |
1 |
2014 |
| Drug |
cdk 4 |
1 |
2017 |
| Drug |
cdk 4/6 inhibitor |
1 |
2017 |
| Biological |
cdx-301 |
1 |
2019 |
| Biological |
cea rna-pulsed dc cancer vaccine |
1 |
2000 |
| Drug |
cef |
1 |
2008 |
| Drug |
cefazolin/clindamycin |
1 |
2018 |
| Diagnostic Test |
celcuity celx hsf |
1 |
2018 |
| Drug |
celecoxib / exemestane |
1 |
2002 |
| Drug |
celecoxib 400 mg |
1 |
2013 |
| Drug |
celecoxib 400 mg bid |
1 |
2006 |
| Drug |
celecoxib/chemotherapy |
1 |
2005 |
| Drug |
cemiplimab |
1 |
2009 |
| Drug |
cemiplimab/regn3767 |
1 |
2009 |
| Other |
centella cream |
1 |
2016 |
| Other |
center for epidemiological studies - depression |
1 |
2017 |
| Device |
ceprate sc |
1 |
1999 |
| Drug |
ceramide |
1 |
2001 |
| Device |
cesm |
1 |
2018 |
| Drug |
cetuximab, cisplatin |
1 |
2007 |
| Drug |
cfi-402257 |
1 |
2018 |
| Behavioral |
changing your habits brochure |
1 |
2013 |
| Other |
checklist, mychart, opennotes |
1 |
2017 |
| Drug |
chemo |
1 |
2000 |
| Behavioral |
chemo only |
1 |
2006 |
| Procedure |
chemokine modulation therapy |
1 |
2018 |
| Drug |
chemotherapeutic agent |
1 |
2019 |
| Drug |
chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) |
1 |
2017 |
| Drug |
chemotherapy (docetaxel, doxorubicin, cyclofosfamide, carboplatin, paclitaxel, gemcitabine) |
1 |
2012 |
| Drug |
chemotherapy (gemcitabine |
1 |
2018 |
| Drug |
chemotherapy (gemcitabine / carboplatin/eribulin) |
1 |
2018 |
| Drug |
chemotherapy adjuvant therapy |
1 |
2012 |
| Drug |
chemotherapy then hormonotherapy |
1 |
2012 |
| Drug |
chemotherapy/endocrine therapy (administered either concomitantly/sequentially) |
1 |
2017 |
| Drug |
chemotherapy/with trastuzumab |
1 |
2013 |
| Biological |
chemovax |
1 |
2014 |
| Behavioral |
chess |
1 |
2007 |
| Behavioral |
chess (comprehensive health enhancement support system) |
1 |
2007 |
| Radiation |
chest wall |
1 |
2015 |
| Radiation |
chestwall xrt |
1 |
2013 |
| Drug |
chidamide |
1 |
2015 |
| Biological |
chimeric antigen receptor t-cell therapy |
1 |
2018 |
| Drug |
chinese herbal medicine decoction |
1 |
2010 |
| Dietary Supplement |
chinese herbs |
1 |
2002 |
| Drug |
chlorhydrate de ropivacaine |
1 |
2006 |
| Drug |
cholecalciferol 2,000 iu |
1 |
2013 |
| Drug |
cholecalciferol 400 iu |
1 |
2013 |
| Drug |
chondroitin |
1 |
2008 |
| Drug |
chosen chemotherapy (capecitabine) |
1 |
2020 |
| Drug |
chosen chemotherapy (gemcitabine ) |
1 |
2020 |
| Drug |
chosen chemotherapy (vinorelbine ) |
1 |
2020 |
| Drug |
ci-1033 |
1 |
2003 |
| Drug |
ciclofosfamide |
1 |
2014 |
| Drug |
cilengitide |
1 |
2011 |
| Drug |
ciprofloxacin |
1 |
2007 |
| Other |
circulating biomarkers |
1 |
2017 |
| Other |
circulating tumor cell analysis |
1 |
2009 |
| Procedure |
circulating tumor cell blood draw |
1 |
2016 |
| Diagnostic Test |
circulating tumor cells evaluation |
1 |
2016 |
| Drug |
cirmtuzumab |
1 |
2016 |
| Drug |
cirmtuzumab / paclitaxel |
1 |
2016 |
| Drug |
cisplatin / 5-fluorouracil (5fu) |
1 |
2016 |
| Drug |
cisplatin combination |
1 |
2010 |
| Drug |
cisplatin/nab paclitaxel |
1 |
2017 |
| Device |
class 1 compression garment |
1 |
2006 |
| Drug |
clindamycin |
1 |
2018 |
| Behavioral |
clinical alerts |
1 |
2016 |
| Other |
clinical assessments |
1 |
2011 |
| Procedure |
clinical exam |
1 |
2009 |
| Other |
clinical hypnosis |
1 |
2018 |
| Behavioral |
clinical management |
1 |
2010 |
| Drug |
clino-san vaginal lubricant |
1 |
2008 |
| Device |
clipt patch |
1 |
2009 |
| Drug |
clodronate |
1 |
2001 |
| Drug |
clodronate disodium |
1 |
2005 |
| Drug |
clonidine |
1 |
2012 |
| Procedure |
closed suction drainage |
1 |
2010 |
| Biological |
clostridium novyi-nt |
1 |
2018 |
| Procedure |
cm assessment. |
1 |
2016 |
| Biological |
cmet rna car t cells |
1 |
2013 |
| Drug |
cmf |
1 |
2013 |
| Drug |
cmf chemotherapy |
1 |
2011 |
| Drug |
cmf(cyclophosphamide, methotrexate, fluorouracil) |
1 |
2005 |
| Drug |
cmf(cyclophosphamide, methotrexate, fluorouracil)/tamoxifen |
1 |
2005 |
| Drug |
cnf2024 |
1 |
2006 |
| Drug |
cnf2024 / trastuzumab |
1 |
2006 |
| Behavioral |
coaching |
1 |
2016 |
| Drug |
cocculineâ® |
1 |
2006 |
| Behavioral |
cogmed working memory training program |
1 |
2010 |
| Behavioral |
cognitive-behavioral group therapy |
1 |
2017 |
| Behavioral |
cognitive-behavioral group therapy/hypnosis |
1 |
2017 |
| Behavioral |
cognitive-behavioral stress management |
1 |
2016 |
| Behavioral |
cognitive-behavioral therapy |
1 |
2011 |
| Behavioral |
cognitive-behavioral therapy/hypnosis group |
1 |
2011 |
| Behavioral |
cognitive behavior therapy |
1 |
2017 |
| Behavioral |
cognitive behavioral mult-symptom management(cbt) |
1 |
2016 |
| Behavioral |
cognitive behavioral stress management |
1 |
2011 |
| Behavioral |
cognitive behavioral therapy cbt) for weight loss |
1 |
2008 |
| Behavioral |
cognitive behavioral therapy for insomnia (cbti) |
1 |
2008 |
| Behavioral |
cognitive behavioral training |
1 |
2014 |
| Behavioral |
cognitive existential therapy group 1 |
1 |
2016 |
| Behavioral |
cognitive rehabilitation |
1 |
2009 |
| Other |
cognitive restructuring |
1 |
2017 |
| Other |
cognitive stimulation |
1 |
2020 |
| Other |
cognitive stimulation sessions coupled with adapted physical activity sessions. |
1 |
2019 |
| Behavioral |
cognitive training intervention group |
1 |
2013 |
| Other |
cognitive, functional |
1 |
2014 |
| Other |
cognitive, functional/subjective assessments |
1 |
2014 |
| Device |
cohesive gel breast implant |
1 |
2012 |
| Drug |
cohort 1 adjuvant |
1 |
2008 |
| Drug |
cohort 1 neo-adjuvant |
1 |
2008 |
| Drug |
cohort 2 adjuvant |
1 |
2008 |
| Drug |
cohort 2 neo-adjuvant |
1 |
2008 |
| Drug |
cohort b |
1 |
2020 |
| Other |
coil testing |
1 |
2017 |
| Device |
coils in pet |
1 |
2019 |
| Device |
cold cap |
1 |
2018 |
| Other |
cold water test |
1 |
2015 |
| Drug |
colestipol |
1 |
2015 |
| Biological |
colloidal gold-bound tumor necrosis factor |
1 |
2007 |
| Drug |
com701 |
1 |
2018 |
| Drug |
com701 with opdivo (nivolumab). |
1 |
2018 |
| Biological |
combination |
1 |
2015 |
| Drug |
combination of docetaxel (dtx) |
1 |
2015 |
| Drug |
combination of docetaxel (dtx)/epirubicin (epi) |
1 |
2015 |
| Drug |
combination of ribociclib |
1 |
2016 |
| Drug |
combination of ribociclib / capecitabine |
1 |
2016 |
| Drug |
combination of trastuzumab |
1 |
2005 |
| Drug |
combination of trastuzumab/ps-341 |
1 |
2005 |
| Drug |
combination of veliparib |
1 |
2014 |
| Drug |
combination of veliparib / lapatinib |
1 |
2014 |
| Drug |
combination therapy (s81694 |
1 |
2017 |
| Drug |
combination therapy (s81694 / paclitaxel) phase i |
1 |
2017 |
| Drug |
combination therapy (s81694 / paclitaxel) phase ii |
1 |
2017 |
| Behavioral |
combined aerobic |
1 |
2016 |
| Behavioral |
combined aerobic/strength exercise training |
1 |
2016 |
| Behavioral |
combined exercise group |
1 |
2017 |
| Other |
combined exercise training |
1 |
2015 |
| Behavioral |
commercial weight loss program (cwlp) |
1 |
2012 |
| Behavioral |
commitment therapy (act) |
1 |
2020 |
| Other |
communication analysis |
1 |
2009 |
| Other |
communication intervention |
1 |
2015 |
| Other |
communication skills training |
1 |
2017 |
| Other |
communication tool |
1 |
2019 |
| Device |
comparator red light treatment |
1 |
2007 |
| Drug |
comparator: mk0752, notch inhibitor |
1 |
2005 |
| Drug |
comparator: mk0752, notch inhibitor - 1 day on, 6 off |
1 |
2005 |
| Drug |
comparator: mk0752, notch inhibitor - 3 days on, 4 off |
1 |
2005 |
| Drug |
comparator: mk0752, notch inhibitor - 3 days on, 4 off 350 mg |
1 |
2005 |
| Drug |
comparator: mk0752, notch inhibitor - 450 mg |
1 |
2005 |
| Drug |
comparator: ondansetron |
1 |
2004 |
| Drug |
comparator: ondansetron / duration of treatment: 3 days |
1 |
2004 |
| Behavioral |
comparison of evidential versus non-evidential education on women’s breast cancer prevention behaviors |
1 |
2011 |
| Other |
complete a health questionnaire |
1 |
2015 |
| Other |
complete decongestive therapy (cdt) |
1 |
2018 |
| Procedure |
complete level i-ii axillary lymphadenectomy |
1 |
2010 |
| Other |
completion of pro-ctcae items before consultation |
1 |
2016 |
| Other |
complex decongestive physiotherapy |
1 |
2020 |
| Other |
complex physical therapy |
1 |
2017 |
| Other |
complex physical therapy/pressotherapy |
1 |
2017 |
| Behavioral |
comprehensive health enhancement support system (chess.) |
1 |
2010 |
| Other |
compression therapy |
1 |
2015 |
| Device |
compression vest, thuasne |
1 |
2015 |
| Other |
compression/drainage therapy |
1 |
2017 |
| Other |
computer-assisted cognitive training |
1 |
2016 |
| Other |
computer-assisted intervention |
1 |
2014 |
| Behavioral |
computer-assisted rehabilitation |
1 |
2019 |
| Procedure |
computer decision board |
1 |
2005 |
| Behavioral |
computer program |
1 |
2007 |
| Device |
computerized tomography (ct) |
1 |
2014 |
| Drug |
concomitant cyclin-dependent kinase 4 |
1 |
2017 |
| Drug |
concomitant cyclin-dependent kinase 4/6 (cdk4/6) inhibitor/endocrine therapy |
1 |
2017 |
| Drug |
concurrent |
1 |
2011 |
| Radiation |
concurrent boost radiotherapy |
1 |
2011 |
| Radiation |
concurrent boost rt |
1 |
2009 |
| Procedure |
cone beam ct |
1 |
2009 |
| Behavioral |
conect |
1 |
2016 |
| Drug |
conjugated estrogens/bazedoxifene |
1 |
2016 |
| Drug |
conjugated linoleic acid (cla) |
1 |
2009 |
| Device |
connected device |
1 |
2018 |
| Behavioral |
connected wellness healthcoach software |
1 |
2015 |
| Other |
construction of a prognostic score (non-drug intervention types) |
1 |
2012 |
| Procedure |
consultation |
1 |
2018 |
| Radiation |
continuous bolus |
1 |
2013 |
| Device |
continuous low-irradiance photodynamic therapy (clipt) |
1 |
2016 |
| Procedure |
continuous serratus plane block |
1 |
2018 |
| Procedure |
contrast-enhanced magnetic resonance imaging |
1 |
2015 |
| Device |
contrast-enhanced mammogram |
1 |
2019 |
| Procedure |
contrast-enhanced ultrasound |
1 |
2005 |
| Device |
contrast-enhanced ultrasound (ceus) |
1 |
2014 |
| Other |
contrast agent |
1 |
2017 |
| Other |
contrast enhanced breast mri |
1 |
2011 |
| Device |
contrast enhanced dual energy (cedem) |
1 |
2015 |
| Diagnostic Test |
contrast microhalography (cem) |
1 |
2019 |
| Behavioral |
control group - observational |
1 |
2016 |
| Other |
control: standard of care |
1 |
2018 |
| Procedure |
controlled ovarian hyperstimulation (coh) |
1 |
2016 |
| Device |
contura catheter |
1 |
2009 |
| Procedure |
conventional axillary dissection |
1 |
2005 |
| Procedure |
conventional breast surgery |
1 |
2018 |
| Procedure |
conventional closure with drainage |
1 |
2014 |
| Procedure |
conventional diarthermy knife |
1 |
2009 |
| Procedure |
conventional excisional breast biopsy |
1 |
2015 |
| Radiation |
conventional fractionation radiotherapy |
1 |
2008 |
| Behavioral |
conventional hospital treatment |
1 |
2017 |
| Procedure |
conventional nipple sparing mastectomy |
1 |
2019 |
| Procedure |
conventional nipple sparing mastectomy (c-nsm) |
1 |
2019 |
| Radiation |
conventional plan |
1 |
2011 |
| Radiation |
conventional radiotherapy |
1 |
2019 |
| Radiation |
conventional surgery /rte |
1 |
2018 |
| Procedure |
conventional suture |
1 |
2019 |
| Other |
conventional therapy |
1 |
2020 |
| Radiation |
conventional whole breast radiation schedule |
1 |
2005 |
| Radiation |
conventionally fractionated whole breast irradiation |
1 |
2010 |
| Other |
conversational hypnosis |
1 |
2016 |
| Device |
cool-tip electrode for radiofrequency ablation |
1 |
2020 |
| Other |
cooling helmet |
1 |
2014 |
| Other |
coordifit |
1 |
2019 |
| Other |
coordinated e-follow-up. |
1 |
2017 |
| Other |
coordinated monitoring |
1 |
2020 |
| Behavioral |
coping class |
1 |
2012 |
| Behavioral |
coping with breast cancer web-based workbook |
1 |
2011 |
| Drug |
copper |
1 |
2020 |
| Dietary Supplement |
coq10 |
1 |
2004 |
| Dietary Supplement |
coq10/vitamin e |
1 |
2004 |
| Behavioral |
core |
1 |
2017 |
| Procedure |
core biopsy of lymph node |
1 |
2013 |
| Procedure |
core biopsy/cryoablation |
1 |
2018 |
| Device |
core needle biopsy |
1 |
2018 |
| Drug |
coreg crâ® |
1 |
2009 |
| Biological |
coriolus versicolor extract |
1 |
2008 |
| Procedure |
correlative |
1 |
2011 |
| Procedure |
correlative/special studies |
1 |
2011 |
| Drug |
corticosteroids |
1 |
2008 |
| Procedure |
cortisol tests |
1 |
2015 |
| Other |
cosmetic assessment |
1 |
2015 |
| Other |
cosmetics |
1 |
2018 |
| Other |
cost discussion |
1 |
2018 |
| Other |
counselling |
1 |
2020 |
| Behavioral |
countering cognitive impairment |
1 |
2015 |
| Behavioral |
couple’s cancer education |
1 |
2008 |
| Behavioral |
couples-based behavioral weight |
1 |
2015 |
| Behavioral |
couples-based behavioral weight/symptom management |
1 |
2015 |
| Behavioral |
couples mbsr |
1 |
2016 |
| Other |
courage with cancerâ„¢ (grace) |
1 |
2016 |
| Dietary Supplement |
cow’s milk |
1 |
2005 |
| Drug |
cp-724,714 |
1 |
2003 |
| Drug |
cpa 500mg |
1 |
2005 |
| Biological |
cpg oligodeoxynucleotide |
1 |
2008 |
| Drug |
cr011-vcmmae |
1 |
2008 |
| Drug |
cr1447 |
1 |
2014 |
| Drug |
cream |
1 |
2010 |
| Drug |
crizotinib |
1 |
2015 |
| Drug |
crizotinib oral capsule [xalkori] |
1 |
2018 |
| Device |
cryo-ablation |
1 |
2020 |
| Device |
cryo-assisted core needle biopsy |
1 |
2017 |
| Procedure |
cryosurgery , ire surgery ,surgery |
1 |
2017 |
| Behavioral |
csc |
1 |
2017 |
| Drug |
ct-2103 |
1 |
2005 |
| Drug |
ct-2103 (xyotax) |
1 |
2005 |
| Drug |
ct-p6 |
1 |
2010 |
| Procedure |
ct - 3 month follow-up |
1 |
2008 |
| Procedure |
ct - baseline |
1 |
2008 |
| Radiation |
ct (low-dose) |
1 |
2012 |
| Combination Product |
ct / ocoxin-viusid |
1 |
2018 |
| Combination Product |
ct / placebo |
1 |
2018 |
| Procedure |
ct scan - baseline |
1 |
2008 |
| Device |
ct scanner |
1 |
2015 |
| Biological |
cta |
1 |
2009 |
| Device |
cti |
1 |
2015 |
| Device |
cti/siemens biograph 40 pet/ct scanner |
1 |
2015 |
| Behavioral |
cts-bc-ch |
1 |
2018 |
| Other |
cucumber cream |
1 |
2016 |
| Behavioral |
culturally tailored genetic counseling |
1 |
2007 |
| Behavioral |
culturally tailored information |
1 |
2016 |
| Procedure |
curative surgery |
1 |
2017 |
| Drug |
curcumin-based gel |
1 |
2015 |
| Drug |
curcumin c3 complex |
1 |
2010 |
| Other |
current standard of care |
1 |
2019 |
| Radiation |
cyberknife for early stage breast cancer |
1 |
2015 |
| Drug |
cyclo |
1 |
2013 |
| Drug |
cyclophosphamide (c) |
1 |
2018 |
| Drug |
cyclophosphamide (c)] followed by paclitaxel (p) |
1 |
2007 |
| Drug |
cyclophosphamide (ctx) |
1 |
1999 |
| Drug |
cyclophosphamide (injection) |
1 |
2016 |
| Drug |
cyclophosphamide (post-operative) |
1 |
2011 |
| Drug |
cyclophosphamide (tablet) |
1 |
2016 |
| Drug |
cyclophosphamide (tac) |
1 |
2005 |
| Drug |
cyclophosphamide 600 mg |
1 |
2016 |
| Drug |
cyclophosphamide 600 mg/m2 iv |
1 |
2016 |
| Drug |
cyclophosphamide 600mg |
1 |
2018 |
| Drug |
cyclophosphamide 600mg/m^2 |
1 |
2018 |
| Drug |
cyclophosphamide combined |
1 |
2005 |
| Drug |
cyclophosphamide fluorouracil epirubicin docetaxel |
1 |
2011 |
| Drug |
cyclophosphamide followed by docetaxe |
1 |
2017 |
| Drug |
cyclophosphamide followed by docetaxe) |
1 |
2017 |
| Drug |
cyclophosphamide in combination with paclitaxel |
1 |
2008 |
| Drug |
cyclophosphamide sar439281 |
1 |
2016 |
| Drug |
cyclophosphamide sequential |
1 |
2005 |
| Drug |
cyclophosphamide(ac) treatment |
1 |
2018 |
| Drug |
cyclophosphamide, 4 cycles, followed by docetaxel |
1 |
2008 |
| Drug |
cyclophosphamide, doxorubicin, epirubicin, fluorouracil |
1 |
2016 |
| Drug |
cyclophosphamide, doxorubicin, epirubicin, fluorouracil/methotrexate (cdefm) |
1 |
2016 |
| Drug |
cyclophosphamide, epirubicin, paclitaxel |
1 |
2008 |
| Drug |
cyclophosphamide, methotrexate, |
1 |
2005 |
| Drug |
cyclophosphamide, methotrexate, 5 fu |
1 |
2010 |
| Drug |
cyclophosphamide, methotrexate, fluorouracil, peg-filgrastim |
1 |
2008 |
| Drug |
cyclophosphamide, methotrexate,/fluorouracil |
1 |
2005 |
| Drug |
cyclophosphamide/jx-594 |
1 |
2015 |
| Drug |
cyclophosphamide/jx-594 dose escalation |
1 |
2015 |
| Drug |
cyclosporins |
1 |
2009 |
| Genetic |
cyp2d6*10 gene test |
1 |
2017 |
| Device |
cyrcadia cbrâ„¢ device placement for abnormality screening |
1 |
2015 |
| Drug |
cytoxan-containing chemotherapy regimens |
1 |
2015 |
| Drug |
cytoxan (ac) |
1 |
2006 |
| Drug |
d-0502 |
1 |
2018 |
| Drug |
d1: vegfr |
1 |
2020 |
| Drug |
d1: vegfr/nab-paclitaxel |
1 |
2020 |
| Drug |
d2: nab-paclitaxel |
1 |
2020 |
| Drug |
dabrafenib |
1 |
2015 |
| Drug |
dabrafenib mesylate |
1 |
2015 |
| Drug |
dacarbazine |
1 |
2008 |
| Other |
daily fatigue |
1 |
2016 |
| Other |
daily fatigue/sleep log |
1 |
2016 |
| Drug |
dakin’s solution |
1 |
2014 |
| Drug |
dalotuzumab (mk0646) |
1 |
2008 |
| Drug |
dalteparin |
1 |
1999 |
| Other |
dance |
1 |
2017 |
| Drug |
dasatinib 100 mg |
1 |
2006 |
| Drug |
dasatinib/paclitaxel |
1 |
2009 |
| Behavioral |
day-time compression sleeve |
1 |
2012 |
| Drug |
day 8 |
1 |
2011 |
| Device |
dbt-tobi |
1 |
2018 |
| Radiation |
dbt/ffdm |
1 |
2010 |
| Diagnostic Test |
dbt/s2d |
1 |
2017 |
| Biological |
dc-cik |
1 |
2015 |
| Biological |
dc-cik immunotherapy |
1 |
2015 |
| Biological |
dc vaccine |
1 |
2009 |
| Biological |
dc1 vaccine |
1 |
2017 |
| Procedure |
dce-mri |
1 |
2013 |
| Procedure |
dce-mri/dwi |
1 |
2013 |
| Drug |
ddac-cp-olaparib |
1 |
2016 |
| Drug |
ddac-mini ctc |
1 |
2016 |
| Drug |
ddctx |
1 |
2020 |
| Drug |
ddepirubicin |
1 |
2020 |
| Drug |
debio 1347 |
1 |
2017 |
| Biological |
dec-205 |
1 |
2012 |
| Biological |
dec-205/ny-eso-1 fusion protein cdx-1401 |
1 |
2012 |
| Behavioral |
decad decision aid |
1 |
2017 |
| Other |
decision-aid |
1 |
2017 |
| Other |
decision aid for breast cancer screening |
1 |
2017 |
| Device |
decision aid group |
1 |
2014 |
| Other |
decision aids |
1 |
2017 |
| Other |
decision support workshop |
1 |
2013 |
| Other |
decongestive physiotherapy |
1 |
2018 |
| Other |
decongestive physiotherapy/taping |
1 |
2018 |
| Radiation |
decubitus |
1 |
2016 |
| Diagnostic Test |
dedicated axillary hybrid pet-mri |
1 |
2017 |
| Other |
dedicated/coordinated e-follow-up. |
1 |
2017 |
| Other |
dedicated/coordinated monitoring |
1 |
2020 |
| Other |
deep inspiration breath hold |
1 |
2017 |
| Other |
deep inspiration breath hold/free-breathing |
1 |
2017 |
| Radiation |
deep inspiratory breath-holding |
1 |
2018 |
| Drug |
defactinib |
1 |
2015 |
| Drug |
defactinib hydrochloride |
1 |
2015 |
| Drug |
defined green tea catechin extract |
1 |
2007 |
| Drug |
definity infusion |
1 |
2014 |
| Drug |
definity suspension for injection |
1 |
2020 |
| Drug |
degarelix |
1 |
2013 |
| Drug |
degarelix injection(s) |
1 |
2019 |
| Procedure |
delay procedure of siea flap. |
1 |
2010 |
| Procedure |
delayed-immediate breast reconstruction |
1 |
2007 |
| Procedure |
delayed-immediate reconstruction |
1 |
2018 |
| Procedure |
delayed acupuncture group |
1 |
2014 |
| Drug |
delayed metformin |
1 |
2014 |
| Procedure |
delayed reconstruction |
1 |
2018 |
| Other |
delayed yoga classes |
1 |
2007 |
| Other |
delivery of questionnaires |
1 |
2016 |
| Biological |
dendritic cell vaccine (dc1) |
1 |
2017 |
| Biological |
dendritic cells |
1 |
2018 |
| Drug |
denosumab 120 mg |
1 |
2018 |
| Drug |
denosumab 120 mg/1.7 ml subcutaneous solution [xgeva] |
1 |
2018 |
| Drug |
denosumab injection |
1 |
2017 |
| Procedure |
dense cranial electroacupuncture stimulation |
1 |
2015 |
| Biological |
derived dcs |
1 |
2005 |
| Procedure |
dermatologic complications management |
1 |
2015 |
| Drug |
desflurane |
1 |
2019 |
| Drug |
deslorelin |
1 |
2004 |
| Drug |
desmopressin |
1 |
2012 |
| Procedure |
detection of the tumor lesion |
1 |
2017 |
| Other |
determination of acceptance |
1 |
2016 |
| Other |
determination of acceptance///rejection of mastectomy |
1 |
2016 |
| Biological |
determination of esr1 mutations |
1 |
2015 |
| Biological |
detox-b adjuvant |
1 |
1999 |
| Device |
device: radiation: diffusing alpha radiation emitters therapy (dart) |
1 |
2019 |
| Procedure |
dexa scan |
1 |
2015 |
| Drug |
dexamethasone based mouthwash |
1 |
2014 |
| Drug |
dexamethasone physician choice |
1 |
2017 |
| Drug |
dexamethasone tapering dose |
1 |
2017 |
| Drug |
dexpantenol [bepantol] |
1 |
2008 |
| Biological |
dher2 |
1 |
2009 |
| Biological |
dher2 / as15 asci |
1 |
2009 |
| Drug |
dhes0815a |
1 |
2018 |
| Drug |
dhp107 |
1 |
2017 |
| Behavioral |
di |
1 |
2015 |
| Diagnostic Test |
diagnostic breast cancer scan |
1 |
2018 |
| Procedure |
diagnostic imaging: 18f-fdg pet |
1 |
2008 |
| Procedure |
diagnostic imaging: 18f-fdg pet/ct scan - baseline |
1 |
2008 |
| Procedure |
diagnostic imaging: 18f-fes pet |
1 |
2008 |
| Procedure |
diagnostic imaging: 18f-fes pet/ct - 3 month follow-up |
1 |
2008 |
| Procedure |
diagnostic imaging: 18f-fes pet/ct - baseline |
1 |
2008 |
| Other |
diagnostic intervention: positron emission tomography with 16-alpha-[18-fluoro]-17betaestradiol |
1 |
2011 |
| Other |
diaphragmatic breathing |
1 |
2017 |
| Other |
diaphragmatic breathing/relaxation |
1 |
2017 |
| Drug |
diclofenac |
1 |
2012 |
| Drug |
diclofenac epolamine patch |
1 |
2011 |
| Behavioral |
didactic session |
1 |
2016 |
| Behavioral |
diet intervention |
1 |
2009 |
| Other |
diet modification |
1 |
2019 |
| Behavioral |
diet, fat-restricted |
1 |
1999 |
| Other |
diet/exercise |
1 |
2014 |
| Behavioral |
diet/exercise intervention |
1 |
2009 |
| Behavioral |
dietary |
1 |
2017 |
| Behavioral |
dietary change |
1 |
2008 |
| Behavioral |
dietary counseling |
1 |
2020 |
| Other |
dietary fish (canned salmon, albacore) |
1 |
2011 |
| Behavioral |
dietary intervention group (control group) |
1 |
2019 |
| Dietary Supplement |
dietary soy |
1 |
2018 |
| Behavioral |
dietary supplements |
1 |
1999 |
| Behavioral |
dietary/physical activity intervention |
1 |
2017 |
| Behavioral |
dietetic advices |
1 |
2005 |
| Other |
different temperature-controlled breast prostheses |
1 |
2019 |
| Device |
diffuse optical spectroscopy imaging |
1 |
2007 |
| Procedure |
diffuse spectroscopy |
1 |
2005 |
| Procedure |
diffusion-weighted mr imaging |
1 |
2013 |
| Device |
diffusion-weighted nuclear magnetic resonance imaging (mri) |
1 |
2016 |
| Procedure |
diffusion tensor imaging |
1 |
2017 |
| Device |
diffusion weighted mri |
1 |
2016 |
| Device |
digital breast tomosynthesis (dbt) |
1 |
2017 |
| Radiation |
digital breast tomosynthesis/synthetic mammography |
1 |
2018 |
| Diagnostic Test |
digital foot candle datalogging light meter |
1 |
2017 |
| Diagnostic Test |
digital foot candle datalogging light meter (extech instrument, model sdl400) |
1 |
2016 |
| Procedure |
digital tomosynthesis mammography |
1 |
2017 |
| Device |
dignicap system |
1 |
2013 |
| Dietary Supplement |
diindolylmethane |
1 |
2011 |
| Dietary Supplement |
dim pills |
1 |
2015 |
| Other |
dim red light |
1 |
2017 |
| Other |
dim red light using light visor cap |
1 |
2016 |
| Drug |
dimethyl sulfoxide |
1 |
2018 |
| Drug |
dimethyldiguanide |
1 |
2012 |
| Behavioral |
discussion group |
1 |
2013 |
| Behavioral |
distance |
1 |
2009 |
| Behavioral |
distance supervised physical activity |
1 |
2016 |
| Dietary Supplement |
distilled water |
1 |
2011 |
| Device |
distress thermometer |
1 |
2010 |
| Drug |
dlbs1425 |
1 |
2011 |
| Drug |
dna intercalators |
1 |
2014 |
| Drug |
docetaxel - dose a |
1 |
2000 |
| Drug |
docetaxel - dose b |
1 |
2000 |
| Drug |
docetaxel (75 mg |
1 |
2011 |
| Drug |
docetaxel (75 mg/m2)/doxorubicin (50 mg/m2) |
1 |
2011 |
| Drug |
docetaxel (fec-t) |
1 |
2010 |
| Drug |
docetaxel (for 4 21-day cycles) after four 14-day cycles of doxorubicin |
1 |
2017 |
| Drug |
docetaxel (post-operative) |
1 |
2011 |
| Drug |
docetaxel (t) |
1 |
2006 |
| Drug |
docetaxel (t) / bevacizumab |
1 |
2006 |
| Drug |
docetaxel (taxotereâ®) |
1 |
2004 |
| Drug |
docetaxel , cisplatin , capecitabine |
1 |
2005 |
| Combination Product |
docetaxel / capecitabine |
1 |
2019 |
| Drug |
docetaxel / ciclofosfamide |
1 |
2014 |
| Drug |
docetaxel / cyclophosphamide |
1 |
2018 |
| Drug |
docetaxel / cyclophosphamide / pegfilgrastim |
1 |
2011 |
| Drug |
docetaxel / trastuzumab |
1 |
2007 |
| Drug |
docetaxel / trastuzumab / lapatinib |
1 |
2007 |
| Drug |
docetaxel / trastuzumab sc / pertuzumab |
1 |
2015 |
| Drug |
docetaxel 100 mg |
1 |
2016 |
| Drug |
docetaxel 100 mg/m2 iv/paclitaxel 80 mg/m2 iv |
1 |
2016 |
| Drug |
docetaxel 60mg |
1 |
2005 |
| Drug |
docetaxel 60mg/m2 every 21 days for 6 cycles |
1 |
2005 |
| Drug |
docetaxel 75mg |
1 |
2018 |
| Drug |
docetaxel chemotherapy |
1 |
2011 |
| Drug |
docetaxel combined |
1 |
2005 |
| Drug |
docetaxel cyclophosphamide |
1 |
2011 |
| Drug |
docetaxel every 3 week in combination with capecitabine |
1 |
2005 |
| Drug |
docetaxel followed by anthracycline |
1 |
2019 |
| Drug |
docetaxel followed by anthracycline/cyclophosphamide |
1 |
2019 |
| Drug |
docetaxel x 3 followed by fac x 3 |
1 |
2011 |
| Drug |
docetaxel, capecitabine |
1 |
2005 |
| Drug |
docetaxel, carboplatin |
1 |
2011 |
| Drug |
docetaxel, carboplatin, trastuzumab |
1 |
2011 |
| Drug |
docetaxel, carboplatin, trastuzumab (tch) |
1 |
2006 |
| Drug |
docetaxel, carboplatin, trastuzumab (tch) / bevacizumab |
1 |
2006 |
| Drug |
docetaxel, carboplatin, trastuzumab/lapatinib |
1 |
2011 |
| Drug |
docetaxel, carboplatin/trastuzumab |
1 |
2011 |
| Drug |
docetaxel, cyclophosphamide |
1 |
2008 |
| Drug |
docetaxel, doxorubicin |
1 |
2016 |
| Drug |
docetaxel, doxorubicin, |
1 |
2005 |
| Drug |
docetaxel, doxorubicin, cyclophosphamide (tac) |
1 |
2006 |
| Drug |
docetaxel, doxorubicin, cyclophosphamide (tac) / bevacizumab |
1 |
2006 |
| Drug |
docetaxel, epirubicin |
1 |
2013 |
| Drug |
docetaxel, epirubicin/cyclophosphamide |
1 |
2013 |
| Drug |
docetaxel, epirubicin/cyclophosphamide/endostar |
1 |
2013 |
| Drug |
docetaxel, trastuzumab |
1 |
2005 |
| Drug |
docetaxel,doxorubicin, cyclophosphamide |
1 |
2006 |
| Drug |
docetaxel/epirubicin |
1 |
2008 |
| Drug |
docetaxel/epirubicin/endostatin |
1 |
2008 |
| Drug |
docetaxel/ketoconazole |
1 |
2005 |
| Drug |
docetaxel/lapatinib |
1 |
2007 |
| Drug |
docetaxel: increase of the dose |
1 |
2012 |
| Dietary Supplement |
docosahexaenoic acid (dha) |
1 |
2019 |
| Drug |
donepezil hydrochloride |
1 |
2011 |
| Drug |
dose-dense doxorubicin/cyclophosphamide |
1 |
2016 |
| Drug |
dose-dense doxorubicin/cyclophosphamide / sunitinib |
1 |
2016 |
| Drug |
dose-dense doxorubicin/dose-dense epirubicin |
1 |
2018 |
| Drug |
dose-dense epirubicin |
1 |
2018 |
| Radiation |
dose-integrated accelerated ebrt in pn |
1 |
2015 |
| Radiation |
dose-integrated accelerated ebrt in pn/ breast cancer |
1 |
2015 |
| Radiation |
dose-integrated accelerated ebrt in pn0 breast cancer |
1 |
2015 |
| Drug |
dose dense ac-p |
1 |
2016 |
| Drug |
dose dense ac followed by t |
1 |
2011 |
| Drug |
dose dense ac followed by t / trastuzumab |
1 |
2011 |
| Drug |
dose dense ac followed by t / trastuzumab / pertuzumab |
1 |
2011 |
| Drug |
dose dense ac/fec100 followed by paclitaxel/docetaxel chemotherapy |
1 |
2011 |
| Drug |
dose dense with neulasta |
1 |
2005 |
| Device |
dose fractionation |
1 |
2018 |
| Procedure |
dosi |
1 |
2010 |
| Other |
dot imaging |
1 |
2013 |
| Drug |
dovitinib |
1 |
2010 |
| Drug |
doxil, paclitaxel, cyclophosphamide, avastin |
1 |
2008 |
| Drug |
doxil/caelyx (doxorubicin) treatment sequence ab |
1 |
2013 |
| Drug |
doxil/caelyx (doxorubicin) treatment sequence ba |
1 |
2013 |
| Drug |
doxorubicin (50 mg |
1 |
2011 |
| Drug |
doxorubicin (a) |
1 |
2018 |
| Drug |
doxorubicin / cyclophosphamide |
1 |
2009 |
| Drug |
doxorubicin 60mg |
1 |
2018 |
| Drug |
doxorubicin 60mg/m^2 |
1 |
2018 |
| Other |
doxorubicin followed by paclitaxel |
1 |
2004 |
| Other |
doxorubicin followed by surgery |
1 |
2011 |
| Drug |
doxorubicin hcl liposome |
1 |
2005 |
| Drug |
doxorubicin hydrochloride liposome injection |
1 |
2017 |
| Drug |
doxorubicin liposome |
1 |
2018 |
| Drug |
doxorubicin, cyclophosphamide |
1 |
2010 |
| Drug |
doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide |
1 |
2010 |
| Drug |
doxorubicin, cyclophosphamide, paclitaxel, trastuzumab |
1 |
2007 |
| Drug |
doxorubicin, docetaxel, cisplatin |
1 |
2007 |
| Drug |
doxorubicin, docetaxel, tamoxifen |
1 |
2007 |
| Drug |
doxorubicin, paclitaxel, cisplatin |
1 |
2012 |
| Drug |
doxorubicin. |
1 |
2018 |
| Drug |
doxorubicin/cyclophosphamide (ac) / bevacizumab |
1 |
2006 |
| Drug |
doxorubicin/cyclophosphamide(ac) treatment |
1 |
2018 |
| Drug |
doxorubicin/epirubicin |
1 |
2015 |
| Drug |
doxorubicine |
1 |
2005 |
| Drug |
doxorubicine / cyclophosphamide combined |
1 |
2005 |
| Drug |
doxorubicine / cyclophosphamide sequential |
1 |
2005 |
| Drug |
doxorubicine / docetaxel combined |
1 |
2005 |
| Drug |
doxorubicine / docetaxel sequential |
1 |
2005 |
| Drug |
doxorubin hydrochloride liposme |
1 |
2007 |
| Biological |
dpx-0907 consists of 7 tumor-specific hla-a2-restricted peptides, a universal t helper peptide, a polynucleotide adjuvant, a liposome |
1 |
2010 |
| Biological |
dpx-0907 consists of 7 tumor-specific hla-a2-restricted peptides, a universal t helper peptide, a polynucleotide adjuvant, a liposome/montanide isa51 vg |
1 |
2010 |
| Other |
drainage therapy |
1 |
2017 |
| Drug |
drug 1: ly3023414; drug 2: prexasertib |
1 |
2019 |
| Drug |
drug omission |
1 |
2020 |
| Drug |
drug: pegylated rhg-csf: 100âµg |
1 |
2012 |
| Drug |
drug: pegylated rhg-csf: 100âµg/kg |
1 |
2012 |
| Drug |
dtec→dtt |
1 |
2008 |
| Device |
dual-energy contrast-enhanced (dece) mammography |
1 |
2016 |
| Procedure |
dual-energy contrast-enhanced digital spectral mammography |
1 |
2017 |
| Radiation |
dual-time pet |
1 |
2012 |
| Radiation |
dual-time pet/ct (low-dose) |
1 |
2012 |
| Procedure |
dual energy contrast enhanced digital mammography (de cedm) |
1 |
2010 |
| Procedure |
dual energy x-ray absorptiometry (dexa) |
1 |
2006 |
| Procedure |
dual x-ray absorptiometry |
1 |
2009 |
| Procedure |
dual x-ray absorptiometry (dxa) |
1 |
2008 |
| Drug |
duavee |
1 |
2016 |
| Drug |
duavee 0.45mg-20mg tablet |
1 |
2020 |
| Drug |
duloxetine |
1 |
2009 |
| Drug |
duloxetine hydrochloride |
1 |
2012 |
| Drug |
durvalumab with tremelimumab |
1 |
2018 |
| Drug |
durvalumab/olaparib |
1 |
2009 |
| Biological |
durvalumib |
1 |
2019 |
| Procedure |
dwi |
1 |
2013 |
| Diagnostic Test |
dynamic contrast- enhanced (dce) mri |
1 |
2018 |
| Other |
e-based |
1 |
2019 |
| Other |
e-based/personalized breast reconstruction surgery decision aid |
1 |
2019 |
| Drug |
e-hdfl,ep,te,n-hdfl,np,t-hdfl,tp |
1 |
2008 |
| Other |
e-mail |
1 |
2019 |
| Other |
e-talkcare |
1 |
2018 |
| Drug |
e1: everolimus with nab-paclitaxel |
1 |
2020 |
| Drug |
e2: nab-paclitaxel |
1 |
2020 |
| Biological |
e39 peptide vaccine |
1 |
2013 |
| Biological |
e39 vaccine then j65 vaccine |
1 |
2013 |
| Drug |
e7070 |
1 |
2004 |
| Drug |
e7389 (eribulin mesylate) |
1 |
2014 |
| Procedure |
ear acupuncture |
1 |
2019 |
| Procedure |
early-drain removal |
1 |
2017 |
| Drug |
ec |
1 |
2016 |
| Drug |
ec regimen |
1 |
2015 |
| Drug |
ec to docetaxel |
1 |
2017 |
| Drug |
ec to docetaxel/paclitaxel |
1 |
2017 |
| Drug |
ec17 |
1 |
2013 |
| Other |
echocardiogram (echo) |
1 |
2015 |
| Biological |
edp1503 |
1 |
2018 |
| Other |
education control |
1 |
2018 |
| Behavioral |
education group |
1 |
2016 |
| Behavioral |
education intervention |
1 |
2006 |
| Other |
education materials |
1 |
2012 |
| Behavioral |
education/support |
1 |
2019 |
| Behavioral |
educational advises group |
1 |
2017 |
| Behavioral |
educational counseling intervention |
1 |
2005 |
| Behavioral |
educational materials/mail |
1 |
2015 |
| Behavioral |
educational materials/participant choice |
1 |
2015 |
| Behavioral |
educational video |
1 |
2019 |
| Other |
educational website |
1 |
2019 |
| Behavioral |
educational yoga program |
1 |
2019 |
| Drug |
efaproxiral |
1 |
2004 |
| Drug |
eflapegrastim |
1 |
2019 |
| Drug |
eg12014 |
1 |
2018 |
| Drug |
egcg |
1 |
2015 |
| Device |
elasto-gel cap |
1 |
2007 |
| Device |
elasto-gelâ„¢ |
1 |
2017 |
| Procedure |
electrical stimulation |
1 |
2015 |
| Procedure |
electroacupuncture (ea) |
1 |
2019 |
| Procedure |
electroacupuncture (ea)/auricular acupressure (aa) |
1 |
2019 |
| Procedure |
electroacupuncture therapy |
1 |
2016 |
| Procedure |
electrocautery |
1 |
2012 |
| Radiation |
electron beam therapy |
1 |
2016 |
| Other |
electron microscopy |
1 |
2007 |
| Radiation |
electronic brachytherapy |
1 |
2008 |
| Radiation |
electronic brachytherapy (axxent system) |
1 |
2009 |
| Drug |
eloxatin |
1 |
2007 |
| Procedure |
embryo freezing |
1 |
2016 |
| Behavioral |
emotional disclosure condition |
1 |
2018 |
| Behavioral |
empowerment |
1 |
2016 |
| Drug |
enalapril maleate |
1 |
2009 |
| Drug |
endocrine |
1 |
2007 |
| Drug |
endocrine-modulating drug therapy |
1 |
2009 |
| Other |
endocrine-therapy |
1 |
2019 |
| Drug |
endocrine monotherapy as per physician choice |
1 |
2019 |
| Drug |
endocrine therapy (administered either concomitantly |
1 |
2017 |
| Drug |
endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen) |
1 |
2017 |
| Drug |
endocrine therapy (non imp) |
1 |
2017 |
| Drug |
endocrine therapy 1 |
1 |
2018 |
| Drug |
endocrine therapy 2 |
1 |
2018 |
| Other |
endocrine therapy alone without radiotherapy |
1 |
2015 |
| Other |
endocrine therapy interruption |
1 |
2014 |
| Combination Product |
endocrine therapy/radiotherapy |
1 |
2019 |
| Drug |
endocrine therapy/with trastuzumab |
1 |
2013 |
| Procedure |
endoscopic assisted nipple sparing mastectomy |
1 |
2019 |
| Procedure |
endoscopic assisted nipple sparing mastectomy (e-nsm) |
1 |
2019 |
| Procedure |
endoscopic biopsy |
1 |
2004 |
| Drug |
endostatin |
1 |
2008 |
| Drug |
endotag-1 / paclitaxel |
1 |
2007 |
| Device |
endotracheal tube |
1 |
2008 |
| Drug |
endoxan |
1 |
2005 |
| Behavioral |
endurance training |
1 |
2005 |
| Procedure |
energy-based therapy |
1 |
2009 |
| Behavioral |
energy conservation work simplification education |
1 |
2019 |
| Behavioral |
engagement in physical activity |
1 |
2018 |
| Other |
enhanced geriatric follow-up |
1 |
2014 |
| Behavioral |
enhanced intervention |
1 |
2016 |
| Behavioral |
enhanced self-regulation condition |
1 |
2016 |
| Behavioral |
enhanced tailored |
1 |
2012 |
| Behavioral |
enhanced usual care |
1 |
2015 |
| Drug |
enmd-2076 |
1 |
2012 |
| Drug |
enobosarm |
1 |
2016 |
| Drug |
enteric-coated aspirin |
1 |
2016 |
| Drug |
entinostat (sndx-275) |
1 |
2009 |
| placebo |
entinostat(placebo) |
1 |
2017 |
| Behavioral |
envision the rhythms of life program |
1 |
2009 |
| Behavioral |
envision the rhythms of life program/distance |
1 |
2009 |
| Drug |
enzastaurin hydrochloride |
1 |
2006 |
| Biological |
eoc202 |
1 |
2018 |
| Other |
eoi |
1 |
2018 |
| Behavioral |
eortc qlq - br23, eq-5d-5l, eortc qlq-c30 |
1 |
2017 |
| Drug |
ep2006 |
1 |
2012 |
| Drug |
epacadostat 600 mg bid |
1 |
2017 |
| Other |
epainq questionnaire |
1 |
2018 |
| Drug |
epalrestat |
1 |
2017 |
| Other |
epclin genomic test |
1 |
2016 |
| Drug |
epi |
1 |
2016 |
| Drug |
epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile |
1 |
2005 |
| Drug |
epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile |
1 |
2005 |
| Drug |
epidoxorubicine, docetaxel, cyclophosphamide |
1 |
2005 |
| Drug |
epirubicin - cyclophosphamide |
1 |
2007 |
| Drug |
epirubicin - cyclophosphamide / docetaxel |
1 |
2007 |
| Drug |
epirubicin - cyclophosphamide / docetaxel / bevacizumab |
1 |
2007 |
| Drug |
epirubicin - cyclophosphamide / docetaxel / lapatinib |
1 |
2007 |
| Drug |
epirubicin - cyclophosphamide / docetaxel / trastuzumab |
1 |
2007 |
| Drug |
epirubicin (e) |
1 |
2018 |
| Drug |
epirubicin (epi) |
1 |
2015 |
| Drug |
epirubicin (post-operative) |
1 |
2011 |
| Drug |
epirubicin / ciclofosfamide / fluorouracil / paclitaxel |
1 |
2014 |
| Drug |
epirubicin / cisplatin / fluorouracil |
1 |
2014 |
| Drug |
epirubicin / cyclophosphamide in combination with paclitaxel/trastuzumab, followed by postoperative trastuzumab |
1 |
2008 |
| Drug |
epirubicin 90 mg |
1 |
2016 |
| Drug |
epirubicin 90 mg/m2 iv |
1 |
2016 |
| Drug |
epirubicin cyclophosphamide paclitaxel |
1 |
2011 |
| Drug |
epirubicin, carboplatin, docetaxel |
1 |
2007 |
| Drug |
epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin |
1 |
2019 |
| Drug |
epirubicin, cyclophosphamide, paclitaxel, |
1 |
2008 |
| Drug |
epirubicin, cyclophosphamide, paclitaxel, carboplatin |
1 |
2019 |
| Drug |
epirubicin, cyclophosphamide, paclitaxel, dabepoetin alfa |
1 |
2007 |
| Drug |
epirubicin, cyclophosphamide/docetaxel |
1 |
2008 |
| Drug |
epirubicin, paclitaxel, cyclophosphamide, methotrexate, 5 fu, darbepoetin alfa |
1 |
2007 |
| Drug |
epirubicin, paclitaxel, filgrastim |
1 |
2008 |
| Drug |
epirubicin/ctx/5-fu |
1 |
2015 |
| Other |
epirubicin/docetaxel sequential |
1 |
2007 |
| Drug |
epirubicin/pirarubicin |
1 |
2020 |
| Behavioral |
episodic future thinking |
1 |
2018 |
| Behavioral |
episodic recent thinking |
1 |
2018 |
| Dietary Supplement |
epo |
1 |
2018 |
| Drug |
epoetin alfa / packed rbc transfusion |
1 |
2006 |
| Drug |
epothilone d |
1 |
2006 |
| Other |
epworth sleepiness scale |
1 |
2016 |
| Biological |
er |
1 |
2013 |
| Biological |
er//her2-bc:dc vaccine/preop chemo |
1 |
2013 |
| Other |
eras pathway |
1 |
2020 |
| Drug |
erbitux |
1 |
2005 |
| Procedure |
erector spinae block |
1 |
2018 |
| Procedure |
erector spinae plane block |
1 |
2018 |
| Drug |
eribulin in combination |
1 |
2013 |
| Drug |
eribulin in combination w |
1 |
2012 |
| Drug |
eribulin in combination w/ cyclophosphamide |
1 |
2012 |
| Drug |
eribulin mesilate |
1 |
2015 |
| Drug |
eribulin mesylate administration as a 2 to 5 min iv infusion at on day 1 |
1 |
2011 |
| Drug |
eribulin mesylate administration as a 2 to 5 min iv infusion on day 1 |
1 |
2011 |
| Drug |
eribulin mesylate administration as a 2 to 5 min iv infusion on day 1/day 8 |
1 |
2011 |
| Drug |
eribulin) |
1 |
2018 |
| Drug |
eribulina |
1 |
2014 |
| Drug |
erlotinib hcl (osi-774) |
1 |
2005 |
| Drug |
eryaspase (l-asparaginase encapsulated in red blood cells) |
1 |
2018 |
| Drug |
esomeprazole |
1 |
2009 |
| Procedure |
esp block |
1 |
2019 |
| Drug |
essexâ® cream (schering-plough), aqueous cream without parabens |
1 |
2012 |
| Drug |
estramustine |
1 |
2016 |
| Drug |
estring |
1 |
2013 |
| Drug |
estrogen replacement therapy |
1 |
1999 |
| Drug |
estrogens |
1 |
1999 |
| Drug |
et743 |
1 |
2002 |
| Biological |
etbx-011 |
1 |
2017 |
| Biological |
etbx-021 |
1 |
2016 |
| Biological |
etbx-051 |
1 |
2017 |
| Biological |
etbx-061 |
1 |
2017 |
| Other |
eucerin |
1 |
2013 |
| Other |
european organization for research/treatment of cancer-quality of life questionnaire |
1 |
2016 |
| Other |
european organization for research/treatment of cancer-quality of life questionnaire (eortc qlq-c30) |
1 |
2017 |
| Other |
eurythmy therapy |
1 |
2019 |
| Behavioral |
eva-online |
1 |
2016 |
| Drug |
everolimus / letrozole |
1 |
2010 |
| Drug |
everolimus dose escalation |
1 |
2013 |
| Drug |
everolimus/exemestane |
1 |
2014 |
| Other |
evidence-based information |
1 |
2018 |
| Device |
evonail |
1 |
2016 |
| Drug |
evonailâ® solution |
1 |
2016 |
| Device |
exablate bbbd |
1 |
2018 |
| Drug |
exatecan mesylate |
1 |
2000 |
| Procedure |
excision of suspicious lymph nodes |
1 |
2019 |
| Procedure |
excision of tumor |
1 |
2014 |
| Procedure |
excision of tumor/mastectomy |
1 |
2014 |
| Drug |
exemestane (aromasinâ®) |
1 |
2005 |
| Drug |
exemestane / dasatinib |
1 |
2008 |
| Drug |
exemestane / placebo |
1 |
2008 |
| Drug |
exemestane followed by combination therapy |
1 |
2005 |
| Drug |
exemestane tablets |
1 |
2017 |
| Drug |
exemestane/gnrh analogue |
1 |
2012 |
| Drug |
exemestane/tamoxifen |
1 |
2013 |
| Other |
exercise / fruit/vegetable, low fat / calcium diet |
1 |
2003 |
| Other |
exercise after surgery |
1 |
2016 |
| Behavioral |
exercise dvd |
1 |
2012 |
| Device |
exercise guidebook |
1 |
2005 |
| Behavioral |
exercise only |
1 |
2015 |
| Behavioral |
exercise prescription |
1 |
2014 |
| Behavioral |
exercise program |
1 |
2012 |
| Behavioral |
exercise program low intensity |
1 |
2016 |
| Behavioral |
exercise program moderate intensity |
1 |
2016 |
| Other |
exercise regimen |
1 |
2015 |
| Behavioral |
exercise/adjustable compression wrap |
1 |
2016 |
| Behavioral |
exercise/compression garment |
1 |
2016 |
| Behavioral |
exercise/self-management |
1 |
2017 |
| Behavioral |
exercising block |
1 |
2010 |
| Other |
exergaming |
1 |
2014 |
| Drug |
exisulind |
1 |
2002 |
| Procedure |
expanded mckissock surgery |
1 |
2019 |
| Procedure |
expander prosthesis |
1 |
2014 |
| Behavioral |
experimental 1: exercise with 2 counseling types |
1 |
2009 |
| Procedure |
experimental 3d breast ultrasound imaging |
1 |
2009 |
| Drug |
experimental drug: aprepitant |
1 |
2017 |
| Drug |
experimental drug: dexamethasone |
1 |
2017 |
| Drug |
experimental drug: olanzapine |
1 |
2017 |
| Drug |
experimental drug: ondansetron |
1 |
2017 |
| Behavioral |
experimental individualized therapy |
1 |
2018 |
| Procedure |
experimental photoacoustic imaging |
1 |
2009 |
| Procedure |
experimental: led group |
1 |
2018 |
| Other |
experimental: training, phase 1 |
1 |
2019 |
| Other |
experimental: training, phase 2 |
1 |
2019 |
| Behavioral |
expressive writing |
1 |
2008 |
| Other |
extended follow up |
1 |
2011 |
| Radiation |
external beam boost |
1 |
2009 |
| Radiation |
external beam partial-breast irradiation |
1 |
2012 |
| Radiation |
external beam radiation |
1 |
2005 |
| Radiation |
external beam radiation therapy (ebrt) |
1 |
2011 |
| Radiation |
external fractionated radiotherapy |
1 |
2013 |
| Procedure |
f-18 fdg breast pet scan |
1 |
2017 |
| Diagnostic Test |
f-var3 pet |
1 |
2019 |
| Diagnostic Test |
f-var3 pet/ct |
1 |
2019 |
| Drug |
f18-ffnp |
1 |
2009 |
| Drug |
fac |
1 |
2016 |
| Drug |
fac x 3 followed by docetaxel x 3 |
1 |
2011 |
| Other |
facility access |
1 |
2016 |
| Behavioral |
facing forward |
1 |
2009 |
| Behavioral |
fact |
1 |
2015 |
| Behavioral |
fact-b |
1 |
2015 |
| Behavioral |
fact-b quality of life |
1 |
2012 |
| Behavioral |
fact-g questionnaire |
1 |
2017 |
| Behavioral |
fact/gog-ntx questionnaire |
1 |
2015 |
| Behavioral |
factsheet |
1 |
2015 |
| Drug |
famitinib malate |
1 |
2012 |
| Drug |
faslodex 500mg |
1 |
2012 |
| Drug |
faslodex dummy |
1 |
2012 |
| Drug |
fasn inhibitor tvb-2640 |
1 |
2017 |
| Dietary Supplement |
fasting-mimicking diet |
1 |
2020 |
| Other |
fasting mimicking diet |
1 |
2014 |
| Other |
fat reduction with increased fiber |
1 |
1999 |
| Other |
fat reduction without increased fiber |
1 |
1999 |
| Procedure |
fdg-pet/mr |
1 |
2014 |
| Device |
fdg pet |
1 |
2014 |
| Device |
fdg pet/ct |
1 |
2014 |
| Other |
fdht-pet scan |
1 |
2013 |
| Procedure |
fdht pet |
1 |
2015 |
| Drug |
fec-d |
1 |
2016 |
| Drug |
fec-doc adjuvant chemotherapy |
1 |
2014 |
| Drug |
fec-docgemzar adjuvant chemotherapy |
1 |
2014 |
| Drug |
fec-t |
1 |
2013 |
| Drug |
fec-t/pertuzumab |
1 |
2013 |
| Drug |
fec (fluorouracil, epirubicin, cyclophosphamide) |
1 |
2014 |
| Drug |
fec (fluorouracil, epirubicin, cyclophosphamide) / filgrastim / paclitaxel |
1 |
2014 |
| Drug |
fec chemotherapy |
1 |
2015 |
| Drug |
fec/te iodine |
1 |
2018 |
| Drug |
fec/te placebo |
1 |
2018 |
| Drug |
fec100 |
1 |
2014 |
| Drug |
fec100 followed by paclitaxel |
1 |
2011 |
| Drug |
fec3-d3 |
1 |
2013 |
| Drug |
fec75 |
1 |
2007 |
| Drug |
fec→t |
1 |
2008 |
| Other |
fecal collection |
1 |
2016 |
| Other |
feedback |
1 |
2012 |
| Behavioral |
feedback messages |
1 |
2018 |
| Drug |
ferric carboxymaltose |
1 |
2014 |
| Procedure |
fertility assessment |
1 |
2007 |
| Procedure |
fertility assessment/management |
1 |
2007 |
| Drug |
ferumoxtran-10 |
1 |
2005 |
| Drug |
ferumoxytol |
1 |
2012 |
| Other |
fes-pet scan |
1 |
2013 |
| Other |
fes-pet scan, |
1 |
2019 |
| Other |
fes-pet scan,/possibly one additional visit for an fdg-pet |
1 |
2019 |
| Diagnostic Test |
fes pet |
1 |
2018 |
| Diagnostic Test |
fes pet/ct |
1 |
2018 |
| Device |
ffdm alone |
1 |
2015 |
| Drug |
fgfr inhibitor azd4547 |
1 |
2015 |
| Drug |
filgrastim (eurofarma) |
1 |
2010 |
| Drug |
filgrastim (granulokine, amgen) |
1 |
2010 |
| Procedure |
fine-needle aspiration |
1 |
2009 |
| Procedure |
fine needle aspiration (fna) |
1 |
2013 |
| Procedure |
fine needle aspiration biopsy (fnab) |
1 |
2006 |
| Procedure |
fine needle aspiration/core biopsy of lymph node |
1 |
2013 |
| Drug |
fingolimod |
1 |
2019 |
| Drug |
fingolimod hydrochloride |
1 |
2019 |
| Dietary Supplement |
fish oil / epo |
1 |
2018 |
| Device |
fit bit device |
1 |
2015 |
| Behavioral |
fit2thrivemb app |
1 |
2019 |
| Device |
fitbit alta â®) |
1 |
2017 |
| Drug |
fixed-dose combination of capecitabine |
1 |
2016 |
| Drug |
fixed-dose combination of capecitabine/cyclophosphamide sar439281 |
1 |
2016 |
| Drug |
flac chemotherapy with gm-csf |
1 |
1999 |
| Drug |
flac with gm-csf |
1 |
1999 |
| Behavioral |
flexible support groups |
1 |
2016 |
| Device |
flexitouch |
1 |
2006 |
| Device |
flexitouch system |
1 |
2009 |
| Device |
flir thermacam p-65 |
1 |
2016 |
| Procedure |
flt pet |
1 |
2010 |
| Procedure |
flt pet/bold mri scan |
1 |
2010 |
| Drug |
flt3l |
1 |
2018 |
| Radiation |
fluciclovine |
1 |
2016 |
| Drug |
fludeoxyglucose (18f)-iba |
1 |
2010 |
| Drug |
fluocinonide cream |
1 |
2011 |
| Procedure |
fluorescence spectroscopy |
1 |
2005 |
| Procedure |
fluorescence spectroscopy/diffuse spectroscopy |
1 |
2005 |
| Drug |
fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (facbc) |
1 |
2013 |
| Radiation |
fluorine f 18-fluoroazomycin arabinoside |
1 |
2017 |
| Radiation |
fluorine f 18 fluorthanatrace |
1 |
2018 |
| Drug |
fluoro-l-thymidine-(18f) |
1 |
2005 |
| Other |
fluorophotometry |
1 |
2007 |
| Procedure |
fluoroscopic technique |
1 |
2017 |
| Other |
fluoroscopy-guided mld |
1 |
2015 |
| Drug |
fluorouracil epirubicin cyclophosphamide |
1 |
2010 |
| Drug |
fluorouracil epirubicin cyclophosphamide/docetaxel (fec-t) |
1 |
2010 |
| Drug |
fluorouracil, epirubicin, cyclophosphamide, docetaxel |
1 |
2016 |
| Drug |
fluoruracil |
1 |
2015 |
| Drug |
fluvastatin sodium |
1 |
2006 |
| Drug |
fluvestrant |
1 |
2019 |
| Drug |
fluvestrant / oral vinorelbine |
1 |
2019 |
| Procedure |
fna/core biopsy |
1 |
2013 |
| Radiation |
focal radiation therapy |
1 |
2019 |
| Procedure |
focused ultrasound |
1 |
2018 |
| Dietary Supplement |
folic acid |
1 |
2010 |
| Drug |
folinic acid) |
1 |
2016 |
| Other |
follow-up after neoadjuvant chemotherapy |
1 |
2017 |
| Behavioral |
follow-up strategy for breast cancer |
1 |
2005 |
| Behavioral |
football fitness |
1 |
2017 |
| Genetic |
foundationone cdx |
1 |
2019 |
| Behavioral |
four conversations |
1 |
2016 |
| Other |
foxp3 ratio |
1 |
2012 |
| Other |
fr-mask |
1 |
2019 |
| Radiation |
fraction |
1 |
2016 |
| Radiation |
fractionated stereotactic radiotherapy(fsrt) |
1 |
2019 |
| Other |
free breathing |
1 |
2016 |
| Drug |
free doxorubicin |
1 |
2008 |
| Drug |
free doxorubicin/cyclophosphamide, 4 cycles, followed by docetaxel/trastuzumab, 4 cycles |
1 |
2008 |
| Drug |
fresolimumab |
1 |
2011 |
| Procedure |
frozen glove |
1 |
2009 |
| Other |
fruit |
1 |
2003 |
| Diagnostic Test |
full field digital mammography |
1 |
2001 |
| Drug |
fulvestrant / placebo |
1 |
2008 |
| Drug |
fulvestrant / zactima |
1 |
2008 |
| Drug |
fulvestrant 50 mg |
1 |
2018 |
| Drug |
fulvestrant 50 mg/ml prefilled syringe [faslodex] |
1 |
2018 |
| Drug |
fulvestrant 500 mg |
1 |
2016 |
| Drug |
fulvestrant 500mg |
1 |
2018 |
| Drug |
fulvestrant 50mg solution for injection |
1 |
2017 |
| Drug |
fulvestrant injectable product |
1 |
2017 |
| Drug |
fulvestrant prefilled syringe |
1 |
2019 |
| Drug |
fulvestrant with enzalutamide |
1 |
2016 |
| Drug |
fulvestrant/tamoxifen/aromatase inhibitor |
1 |
2015 |
| Other |
function assessment of cancer therapy (fact) surveys |
1 |
2015 |
| Other |
functional compressive bandage |
1 |
2019 |
| Procedure |
functional magnetic resonance imaging |
1 |
2012 |
| Drug |
g-csf) |
1 |
1999 |
| Drug |
g1t38 |
1 |
2016 |
| Drug |
g1t48 |
1 |
2018 |
| Procedure |
ga with ett |
1 |
2019 |
| Drug |
gadofosveset contrast agent enhanced mri axilla |
1 |
2011 |
| Other |
gadolinium |
1 |
2015 |
| Radiation |
gadopentetate dimeglumine |
1 |
2002 |
| Drug |
gadoterate meglumine |
1 |
2016 |
| Drug |
gallium ga 68-labeled grpr antagonist bay86-7548 |
1 |
2019 |
| Radiation |
gallium ga 68-labeled psma-11 |
1 |
2019 |
| Radiation |
gallium ga 68 fapi-46 |
1 |
2019 |
| Drug |
galunisertib |
1 |
2016 |
| Drug |
gamma-secretase |
1 |
2010 |
| Drug |
gamma-secretase inhibitor ro4929097 |
1 |
2010 |
| Drug |
gamma-secretase/notch signalling pathway inhibitor ro4929097 |
1 |
2010 |
| Drug |
ganglioside-monosialic acid |
1 |
2015 |
| Dietary Supplement |
garlic |
1 |
2004 |
| Procedure |
gas |
1 |
2006 |
| Other |
gas chromatography / tandem mass spectometry |
1 |
2009 |
| Other |
gauntlet |
1 |
2017 |
| Drug |
gb221 |
1 |
2019 |
| Biological |
gb221,2 mg |
1 |
2019 |
| Biological |
gb221,2 mg/kg |
1 |
2019 |
| Biological |
gb221,6 mg |
1 |
2019 |
| Biological |
gb221,6 mg/kg |
1 |
2019 |
| Biological |
gb221,8mg |
1 |
2019 |
| Biological |
gb221,8mg/kg |
1 |
2019 |
| Biological |
gb221:2mg |
1 |
2019 |
| Biological |
gb221:2mg/kg/capecitabi:1000mg/kg |
1 |
2019 |
| Drug |
gcsf |
1 |
2017 |
| Drug |
gdc-0032 |
1 |
2013 |
| Drug |
gdc-0084 |
1 |
2018 |
| Drug |
gdc-0927 |
1 |
2014 |
| placebo |
gdc-0941 matching placebo |
1 |
2011 |
| placebo |
gdc-0980 matching placebo |
1 |
2011 |
| Drug |
gefitinib (iressaâ„¢, zd1839) |
1 |
2008 |
| Drug |
gefitinib/fulvestrant |
1 |
2005 |
| Drug |
gem |
1 |
2016 |
| Drug |
gemcitabine - 21 day cycle |
1 |
2018 |
| Drug |
gemcitabine - 28 day cycle |
1 |
2018 |
| Drug |
gemcitabine , paclitaxel |
1 |
2007 |
| Drug |
gemcitabine / carboplatin |
1 |
2016 |
| Drug |
gemcitabine 1000 mg |
1 |
2016 |
| Drug |
gemcitabine 1000 mg/mâ² |
1 |
2016 |
| Drug |
gemcitabine 1250 mg |
1 |
2016 |
| Drug |
gemcitabine 1250 mg/mâ² |
1 |
2016 |
| Drug |
gemcitabine, carboplatin |
1 |
2005 |
| Drug |
gemcitabine, cisplatin |
1 |
2015 |
| Drug |
gemcitabine, docetaxel |
1 |
2006 |
| Drug |
gemcitabine, epirubicin, paclitaxel |
1 |
2006 |
| Drug |
gemcitabine, paclitaxel |
1 |
2011 |
| Drug |
gemcitabine,carboplatin |
1 |
2015 |
| Drug |
gemcitabine/carboplatin/bsi-201 |
1 |
2008 |
| Drug |
gemcitabine/cisplatin |
1 |
2007 |
| Drug |
gemcitabine/vinorelbine |
1 |
2007 |
| Drug |
general anesthesia/opioids |
1 |
2007 |
| Other |
general education dvd |
1 |
2012 |
| Other |
genetic counseling |
1 |
2016 |
| Other |
genetic education |
1 |
1999 |
| Other |
genetic education/counseling |
1 |
1999 |
| Genetic |
genetic signature |
1 |
2017 |
| Drug |
genexol-pmâ® |
1 |
2009 |
| Drug |
genexolâ® |
1 |
2009 |
| Diagnostic Test |
genomic analysis |
1 |
2019 |
| Drug |
genomic driven chemotherapy |
1 |
2010 |
| Drug |
genomically directed monotherapy |
1 |
2014 |
| Behavioral |
gentle exercise |
1 |
2013 |
| Genetic |
germline genetic testing of brca1 |
1 |
2015 |
| Genetic |
germline genetic testing of brca1/brca2 |
1 |
2015 |
| Behavioral |
getting back on track |
1 |
2011 |
| Biological |
gi-4000 |
1 |
2017 |
| Biological |
gi-6207 |
1 |
2017 |
| Biological |
gi-6301 |
1 |
2017 |
| Device |
gilupi cellcollectorâ® |
1 |
2018 |
| Drug |
ginkgo biloba |
1 |
2002 |
| Drug |
ginseng compound |
1 |
2015 |
| Biological |
globo-h-gm2-lewis-y-muc1-32(aa)-stn(c)-tf(c)-tn(c)-klh conjugate vaccine |
1 |
2002 |
| Device |
globo h ihc assay |
1 |
2018 |
| Drug |
glse compound |
1 |
2015 |
| Drug |
glucosamine |
1 |
2008 |
| Dietary Supplement |
glucose |
1 |
2018 |
| Biological |
gm-csf (sargramostim) |
1 |
2007 |
| Biological |
gm2-klh vaccine |
1 |
1999 |
| Drug |
gmi-1359 |
1 |
2019 |
| Other |
gnrh a |
1 |
2019 |
| Drug |
gnrha |
1 |
2015 |
| Behavioral |
go! to sleep |
1 |
2015 |
| Behavioral |
goal-setting education, yoga |
1 |
2018 |
| Behavioral |
gog-ntx questionnaire |
1 |
2015 |
| Device |
goggle-based device with light-emitting diodes (led) |
1 |
2014 |
| Drug |
gonadotropin-releasing hormone agonist |
1 |
2014 |
| Drug |
goserelin (premenopausal women) |
1 |
2015 |
| Drug |
goserelin / aromatase inhibitor / palbociclib |
1 |
2015 |
| Drug |
goserelin 3.6 mg |
1 |
2018 |
| Drug |
goserelin acetate (zoladex) |
1 |
2008 |
| Drug |
goserelin/tam/ai |
1 |
2015 |
| Biological |
gp2 peptide / gm-csf vaccine |
1 |
2007 |
| Drug |
gp2 peptide / gm-csf vaccine/trastuzumab |
1 |
2017 |
| Drug |
granisetron hydrochloride |
1 |
2006 |
| Biological |
granulocyte-macrophage colony-stimulating factor |
1 |
2019 |
| Biological |
granulocyte colony stimulating factor: filgrastim |
1 |
2017 |
| Biological |
granulocyte colony stimulating factor: filgrastim/pegfilgastrim |
1 |
2017 |
| Dietary Supplement |
grape seed extract |
1 |
2007 |
| Device |
green indocianine |
1 |
2017 |
| Drug |
green tea extract supplement |
1 |
2009 |
| Drug |
grn1005 |
1 |
2011 |
| Drug |
grn163l |
1 |
2008 |
| Drug |
grn163l in combination with trastuzumab |
1 |
2010 |
| Behavioral |
group counseling |
1 |
2009 |
| Behavioral |
group phone counseling |
1 |
2011 |
| Other |
group rehabilitative treatment |
1 |
2019 |
| Behavioral |
group session |
1 |
2018 |
| Behavioral |
group sessions |
1 |
2014 |
| Behavioral |
group therapy intervention |
1 |
2007 |
| Other |
growing resiliency |
1 |
2016 |
| Other |
growing resiliency/courage with cancerâ„¢ (grace) |
1 |
2016 |
| Biological |
growth factor support |
1 |
2009 |
| Biological |
gsk biologicals’ 719125 |
1 |
2005 |
| Drug |
gsk1120212 |
1 |
2011 |
| Drug |
gsk525762 |
1 |
2016 |
| Biological |
gti-2040 |
1 |
2003 |
| Drug |
gtx-024 |
1 |
2015 |
| Drug |
gtx-024 9mg |
1 |
2012 |
| Drug |
guarana extract |
1 |
2009 |
| Behavioral |
guided lifestyle program intervention |
1 |
2020 |
| Drug |
guided relaxation |
1 |
2007 |
| Drug |
gw572016 (lapatinib) |
1 |
2004 |
| Drug |
h |
1 |
2016 |
| Drug |
h3b-6545 |
1 |
2017 |
| Behavioral |
habit development intervention |
1 |
2018 |
| Dietary Supplement |
half-strength tryptophan depletion (control) |
1 |
2005 |
| Behavioral |
hands-on-healing |
1 |
2007 |
| Biological |
hank for infusion |
1 |
2017 |
| Device |
harmonic |
1 |
2012 |
| Other |
hcg |
1 |
2019 |
| Drug |
hd201 |
1 |
2016 |
| Other |
health communication |
1 |
2020 |
| Other |
health education |
1 |
2017 |
| Behavioral |
health education control |
1 |
2014 |
| Behavioral |
health education intervention |
1 |
2018 |
| Other |
health education program |
1 |
2016 |
| Other |
health education series |
1 |
2018 |
| Behavioral |
health enhancement program |
1 |
2017 |
| Behavioral |
healthy eating control |
1 |
2007 |
| Other |
healthy living |
1 |
2012 |
| Behavioral |
healthy living coaching calls |
1 |
2019 |
| Other |
healthy living control |
1 |
2019 |
| Other |
healthy nutrition |
1 |
2011 |
| Behavioral |
healthy wife control group |
1 |
2011 |
| Other |
height, weight, bmi measure |
1 |
2015 |
| Procedure |
helical tomotherapy imrt |
1 |
2007 |
| Device |
hepilor |
1 |
2019 |
| Biological |
her-2-targeting car t cells infusion |
1 |
2015 |
| Biological |
her2-bc:dc vaccine |
1 |
2013 |
| Drug |
her2 bats |
1 |
2018 |
| Drug |
her2 bats with pembrolizumab |
1 |
2017 |
| Biological |
her2 dc1 vaccine |
1 |
2018 |
| Drug |
her2 directed therapy |
1 |
2015 |
| Drug |
herba scutellaria barbata |
1 |
2002 |
| Other |
herba scutellaria barbatae (hsb) |
1 |
2002 |
| Drug |
herceptin (her2-neu positive patients only) |
1 |
2005 |
| Drug |
herceptin (trastuzuamb) |
1 |
2014 |
| Biological |
herceptin (trastuzumab) |
1 |
2019 |
| Drug |
herceptin (post-operative) |
1 |
2011 |
| Drug |
herceptin iv [trastuzumab] |
1 |
2009 |
| Drug |
herceptin sc [trastuzumab] |
1 |
2009 |
| Biological |
herceptin,6 mg |
1 |
2019 |
| Biological |
herceptin,6 mg/kg |
1 |
2019 |
| Biological |
herceptin:2mg |
1 |
2019 |
| Biological |
herceptin:2mg/kg/capecitabin:1000mg/kg |
1 |
2019 |
| Drug |
herceptinâ„¢ (her) |
1 |
2000 |
| Drug |
herceptinâ„¢ (her) / chemo |
1 |
2000 |
| Drug |
herzuma |
1 |
2018 |
| Drug |
hf10 |
1 |
2009 |
| Procedure |
high-dose chemo with autologous bmt |
1 |
2007 |
| Procedure |
high-dose chemotherapy |
1 |
2007 |
| Drug |
high-dose methotrexate (8 gm |
1 |
2015 |
| Drug |
high-dose methotrexate (8 gm/m2; hd-mtx) |
1 |
2015 |
| Radiation |
high-dose rate brachytherapy |
1 |
2015 |
| Device |
high-intensity focused ultrasound (hifu) |
1 |
2017 |
| Device |
high-intensity focused ultrasound ablation |
1 |
2001 |
| Radiation |
high dose boost |
1 |
2005 |
| Procedure |
high dose chemo then auto hematopoietic cell transplant |
1 |
2005 |
| Biological |
high dose frî± vaccine |
1 |
2015 |
| Procedure |
high dose melphalan |
1 |
1999 |
| Procedure |
high dose melphalan/autologous bone marrow transplantation |
1 |
1999 |
| Other |
high fat diet |
1 |
2013 |
| Other |
high flow nasal cannula oxygen therapy |
1 |
2015 |
| Device |
high frequency percussive ventilation |
1 |
2016 |
| Device |
high instensity focused ultrasound |
1 |
2017 |
| Drug |
high level vitamin d |
1 |
2016 |
| Other |
high volume |
1 |
2011 |
| Other |
higher-load resistance training (hl) |
1 |
2018 |
| Other |
higher-volume resistance training (hv) |
1 |
2018 |
| Behavioral |
higher intensity physical activity intervention |
1 |
2018 |
| Radiation |
higher per daily radiation therapy |
1 |
2011 |
| Drug |
hiltonol |
1 |
2016 |
| Other |
hippotherapy |
1 |
2020 |
| Device |
histologic examination |
1 |
2012 |
| Biological |
hlx02 |
1 |
2017 |
| Drug |
hmn14 (labetuzumab) |
1 |
2002 |
| Other |
home-based adapted physical activity |
1 |
2016 |
| Other |
home-based upper-body rehabilitation with online support |
1 |
2016 |
| Other |
home exercise |
1 |
2015 |
| Other |
home safety guide |
1 |
2017 |
| Other |
home visit, health education |
1 |
2019 |
| Other |
homeopathy remedy |
1 |
2016 |
| Drug |
honey based (hb) syrup |
1 |
2020 |
| Drug |
hormone replacement therapy |
1 |
1999 |
| Other |
horne-ostberg morningness-eveningness questionnaire |
1 |
2016 |
| Procedure |
hot flashes attenuation |
1 |
2004 |
| Drug |
hsp-130 |
1 |
2016 |
| Biological |
hsv-tk |
1 |
2016 |
| Behavioral |
ht education) |
1 |
2019 |
| Biological |
htert/survivin multi-peptide vaccine |
1 |
2007 |
| Drug |
humanized anti-her2 antibody |
1 |
2011 |
| Biological |
humanized anti-her2 monoclonal antibody compound for injection .r&d code: b002. |
1 |
2020 |
| Biological |
humanized anti-pd-1 monoclonal antibody toripalimab |
1 |
2016 |
| Biological |
humnc2-car44 car t cells |
1 |
2019 |
| Biological |
humnc2-car44 car t cells @ rp2d |
1 |
2019 |
| Other |
hyalo-gyn |
1 |
2012 |
| Drug |
hydrocortisone |
1 |
2014 |
| Drug |
hydrogen peroxide |
1 |
2016 |
| Drug |
hydroxytyrosol |
1 |
2014 |
| Behavioral |
hygiene |
1 |
2005 |
| Behavioral |
hygiene/dietetic advices |
1 |
2005 |
| Drug |
hylacare |
1 |
2013 |
| Drug |
hyperpolarized pyruvate (13c) injection |
1 |
2017 |
| Behavioral |
hypnosedation |
1 |
2017 |
| Behavioral |
hypnosis group |
1 |
2011 |
| Behavioral |
hypnosis intervention |
1 |
2015 |
| Radiation |
hypo fractionated whole breast radiotherapy |
1 |
2018 |
| Radiation |
hypofractionated irradiation |
1 |
2010 |
| Radiation |
hypofractionated partial breast irradiation |
1 |
2017 |
| Radiation |
hypofractionated simultaneous integrated boost radiotherapy |
1 |
2017 |
| Radiation |
hypofractionated whole breast irradiation |
1 |
2010 |
| Radiation |
hypofractionated whole breast radiation schedule |
1 |
2005 |
| Radiation |
hypofractionation radiotherapy |
1 |
2008 |
| Radiation |
hypofractionation with sib |
1 |
2015 |
| Radiation |
hypofractionation with simultaneous integrated boost |
1 |
2013 |
| Biological |
î³î´ t cell |
1 |
2015 |
| Other |
î³î´ t cells/ surgery |
1 |
2017 |
| Drug |
ibandronat |
1 |
2005 |
| Drug |
ibandronate |
1 |
2005 |
| Drug |
ibandronate sodium |
1 |
2005 |
| Drug |
ibandronate, capecitabine |
1 |
2005 |
| Drug |
ibandronic acid |
1 |
2015 |
| Drug |
ibrutinib |
1 |
2015 |
| Drug |
ibrutinib 420 mg |
1 |
2017 |
| Drug |
ibrutinib 560 mg |
1 |
2017 |
| Drug |
ibrutinib 840 mg |
1 |
2017 |
| Drug |
ibuprofen tab 400 mg |
1 |
2015 |
| Drug |
ic-green kit |
1 |
2017 |
| Combination Product |
ic2000 |
1 |
2017 |
| Combination Product |
ic2000/spy-phi |
1 |
2017 |
| Other |
icarebreast |
1 |
2019 |
| Other |
icbn preservation surgery |
1 |
2018 |
| Drug |
icotinib |
1 |
2015 |
| Drug |
idasanutlin |
1 |
2018 |
| Procedure |
ideal |
1 |
2007 |
| Device |
ifabond (tm) |
1 |
2012 |
| Drug |
ig-001 |
1 |
2014 |
| Other |
igcdg |
1 |
2017 |
| Other |
igrt for prone partial breast irradiation (pbi) |
1 |
2014 |
| Dietary Supplement |
ih636 grape seed proanthocyanidin extract |
1 |
2005 |
| Drug |
il-2 |
1 |
2010 |
| Drug |
il-3 |
1 |
1999 |
| Radiation |
imaging investigations (with radiation) |
1 |
2009 |
| Device |
imaging with s-flare imaging system |
1 |
2010 |
| Drug |
imatinib/vinorelbine |
1 |
2006 |
| Biological |
imc-18f1 |
1 |
2010 |
| Biological |
imc-a12 (cixutumumab) |
1 |
2008 |
| Drug |
imetelstat sodium |
1 |
2010 |
| Behavioral |
imetx intervention |
1 |
2017 |
| Drug |
imexon |
1 |
2006 |
| Drug |
imipramine |
1 |
2017 |
| Procedure |
immediate acupuncture group |
1 |
2014 |
| Procedure |
immediate breast reconstruction |
1 |
2017 |
| Drug |
immu-132 |
1 |
2012 |
| Drug |
immune-attractant |
1 |
2016 |
| Other |
immunohistochemical detection of lymphocytes t cd8 |
1 |
2012 |
| Other |
immunohistochemical detection of lymphocytes t cd8//foxp3 ratio |
1 |
2012 |
| Device |
immunopulse |
1 |
2018 |
| Device |
immunostimulating interstitial laser thermotherapy |
1 |
2016 |
| Biological |
immunotherapeutic sb719125 (primary) |
1 |
2003 |
| Biological |
imp321 |
1 |
2006 |
| Biological |
imp321 (eftilagimod alpha) |
1 |
2015 |
| Procedure |
implantation of dermal matrix substitute |
1 |
2009 |
| Device |
implanted port for chemo administration (x-port isp) |
1 |
2013 |
| Biological |
imprime pgg |
1 |
2016 |
| Behavioral |
improving ai adherence in older breast cancer survivors (rejoin) |
1 |
2019 |
| Behavioral |
improving cognition with group intervention |
1 |
2012 |
| Behavioral |
improving the delivery of effective care to minorities |
1 |
2005 |
| Behavioral |
improvisational comedy |
1 |
2016 |
| Procedure |
in vitro-treated bone marrow transplantation |
1 |
1999 |
| Other |
in2005e |
1 |
2015 |
| Biological |
incmga00012 |
1 |
2017 |
| Behavioral |
increased physical activity |
1 |
2015 |
| Behavioral |
independent tailored intervention |
1 |
2008 |
| Radiation |
indium in 111 monoclonal antibody bre-3 |
1 |
2001 |
| Behavioral |
individual mbsr |
1 |
2016 |
| Behavioral |
individual sleep promotion plan |
1 |
2007 |
| Other |
individualised rehabilitation |
1 |
2018 |
| Other |
individualized complementary medicine treatment |
1 |
2011 |
| Behavioral |
individualized exercise program |
1 |
2011 |
| Other |
individualized food-based intervention |
1 |
2018 |
| Behavioral |
individualized integrative medicine intervention |
1 |
2016 |
| Behavioral |
individualized interventions |
1 |
2017 |
| Behavioral |
individualized manualized health education intervention |
1 |
2016 |
| Other |
individualized usual care |
1 |
2011 |
| Behavioral |
individualized, tailored follow-up program |
1 |
2016 |
| Behavioral |
individually tailored nurse navigation |
1 |
2017 |
| Drug |
indocyanine green solution |
1 |
2015 |
| Drug |
indocynanine green |
1 |
2014 |
| Drug |
indole-3-carbinol |
1 |
2002 |
| Drug |
indomethacin |
1 |
2016 |
| Drug |
indoximod |
1 |
2013 |
| Drug |
induction chemotherapy |
1 |
2011 |
| Other |
induction therapy |
1 |
2013 |
| Procedure |
infiltration with ropivacaine solution |
1 |
2011 |
| Biological |
influenza vaccine |
1 |
2019 |
| Other |
information |
1 |
2015 |
| Other |
information booklet |
1 |
2018 |
| Behavioral |
information only |
1 |
2005 |
| Behavioral |
information services (irx) |
1 |
2006 |
| Behavioral |
informed breast cancer surgical treatment |
1 |
2007 |
| Drug |
infracyanine |
1 |
2016 |
| Genetic |
ingn 201 |
1 |
2006 |
| Biological |
inhalation of essential oils |
1 |
2018 |
| Drug |
iniparib (sar2405550 -bsi-201) |
1 |
2010 |
| Drug |
iniparib / irinotecan |
1 |
2010 |
| Drug |
inj. progesterone |
1 |
2012 |
| Biological |
injections subcutaneously talazoparib |
1 |
2018 |
| Procedure |
insertion of a single drain |
1 |
2014 |
| Procedure |
insertion of double drains |
1 |
2014 |
| Other |
insomnia severity index (isi) |
1 |
2015 |
| Behavioral |
integrative medicine intervention |
1 |
2018 |
| Behavioral |
integrative mind-body-medicine group program |
1 |
2019 |
| Device |
intelligent breast exam, ibe |
1 |
2015 |
| Radiation |
intensity modulated radiation therapy |
1 |
2011 |
| Radiation |
intensity modulated radiotherapy |
1 |
2010 |
| Radiation |
intensity modulated radiotherapy (imrt) for breast cancer |
1 |
2010 |
| Other |
intensive cardiovascular monitoring |
1 |
2018 |
| Behavioral |
intensive group |
1 |
2010 |
| Behavioral |
interactive internet-based website |
1 |
2012 |
| Behavioral |
interactive voice response (ivr) reminders |
1 |
2014 |
| Biological |
interferon-alpha-2b |
1 |
2017 |
| Biological |
interferon-gamma (ifn-î³) |
1 |
2017 |
| Biological |
interferon inoculation |
1 |
2017 |
| Drug |
interleukin-1 |
1 |
1999 |
| Biological |
interleukin-4 pe38kdel cytotoxin |
1 |
2002 |
| Drug |
interleukin 7 |
1 |
2011 |
| Radiation |
internal mammary nodal irradiation |
1 |
2020 |
| Procedure |
internal mammary sentinel lymph node biopsy |
1 |
2012 |
| Behavioral |
internet-based cognitive behavioral therapy. |
1 |
2014 |
| Behavioral |
internet-delivered mindfulness-based cognitive therapy |
1 |
2017 |
| Radiation |
interstitial implant brachytherapy |
1 |
2009 |
| Procedure |
interstitial radiation therapy |
1 |
2017 |
| Other |
intervention-specific carevive questionnaire |
1 |
2019 |
| Other |
intervention arm |
1 |
2011 |
| Other |
intervention. exercise |
1 |
2014 |
| Procedure |
interventional therapy |
1 |
2015 |
| Other |
interventions are self controlled by the patient via a mp3 player |
1 |
2018 |
| Other |
interventions are self controlled by the patient via a mp3 player/noise reduction headphones. |
1 |
2018 |
| Other |
interview |
1 |
2019 |
| Behavioral |
interviews |
1 |
2015 |
| Behavioral |
intimacy enhancement |
1 |
2019 |
| Behavioral |
intimacy enhancing intervention |
1 |
2016 |
| Procedure |
intra-operative magnetic resonance imaging (mri) |
1 |
2015 |
| Device |
intra-operative mri |
1 |
2014 |
| Radiation |
intra-operative radiation therapy (iort) |
1 |
2013 |
| Radiation |
intra-operative radiation to tumor bed |
1 |
2009 |
| Radiation |
intra-operative radiotherapy (iort) |
1 |
2005 |
| Radiation |
intra operative radiation therapy (iort) |
1 |
2008 |
| Radiation |
intra operative radiotherapy |
1 |
2015 |
| Device |
intrabeam |
1 |
2009 |
| Device |
intrabeam (carl zeiss, oberkochen, germany) |
1 |
2015 |
| Radiation |
intracavitary accelerated partial breast irradiation |
1 |
2008 |
| Radiation |
intracavitary brachytherapy |
1 |
2005 |
| Drug |
intraductal arm |
1 |
2006 |
| Radiation |
intraoperative electron radiotherapy |
1 |
2013 |
| Procedure |
intraoperative modified pec block |
1 |
2019 |
| Radiation |
intraoperative radiation therapy (iort) |
1 |
2016 |
| Radiation |
intraoperative radiotherapy (iort) |
1 |
2014 |
| Drug |
intrathecal methotrexate |
1 |
2010 |
| Drug |
intravenous arm |
1 |
2006 |
| Drug |
intravenous pca only |
1 |
2015 |
| Device |
intrinsic subtyping of primary breast cancer |
1 |
2018 |
| Drug |
investigational cancer drug |
1 |
2003 |
| Device |
investigational imaging device |
1 |
2017 |
| Device |
investigational software |
1 |
2019 |
| Device |
investigational software/coils in pet/mr scan |
1 |
2019 |
| Drug |
investigator’s choice of anti-cancer treatment (except immunotherapy) |
1 |
2018 |
| Drug |
investigator’s choice of treatment |
1 |
2011 |
| Other |
invitation for breast screening |
1 |
2010 |
| Drug |
iodine |
1 |
2018 |
| Radiation |
iodine i 124 iododeoxyuridine |
1 |
2005 |
| Device |
iort with ct-guided hdr brachytherapy |
1 |
2015 |
| Drug |
ipaq |
1 |
2007 |
| Radiation |
ipas |
1 |
2012 |
| Device |
ipbs |
1 |
2013 |
| Procedure |
ir imaging |
1 |
2019 |
| Drug |
irinotecan / carboplatin |
1 |
2005 |
| Drug |
irinotecan / carboplatin / erbitux |
1 |
2005 |
| Drug |
irinotecan/capecitabine |
1 |
2007 |
| Drug |
irofulven |
1 |
1999 |
| Drug |
irosustat |
1 |
2013 |
| Drug |
irosustat (bn83495) |
1 |
2013 |
| Biological |
isb 1302 250 ng |
1 |
2019 |
| Biological |
isb 1302 250 ng/kg |
1 |
2019 |
| Biological |
isb 1302 325 ng |
1 |
2019 |
| Biological |
isb 1302 325 ng/kg |
1 |
2019 |
| Biological |
isb 1302 325 ng/kg-d1;425 ng/kg -d8,d15,d22 |
1 |
2019 |
| Biological |
isb 1302 325 ng/kg-d1;550 ng/kg -d8,d15,d22 |
1 |
2019 |
| Biological |
isb 1302 325ng |
1 |
2019 |
| Biological |
isb 1302 325ng/kg d1;550 ng/kg d8;900 ng/kg d15,22 |
1 |
2019 |
| Biological |
isb 1302 325ng/kgd1;550 ng/kg d8;700 ng/kgd15,22 |
1 |
2019 |
| Biological |
isb 1302 at the mtd and |
1 |
2019 |
| Biological |
isb 1302 at the mtd and/or rp2d dose |
1 |
2019 |
| Biological |
isb 1302 escalating doses,1200 ng |
1 |
2019 |
| Biological |
isb 1302 escalating doses,1200 ng/kg d15,22 |
1 |
2019 |
| Behavioral |
ishare |
1 |
2020 |
| Biological |
isis 3521 |
1 |
1999 |
| Drug |
isis 5132 |
1 |
1999 |
| Drug |
isoflurane |
1 |
2007 |
| Drug |
isoflurane, sevoflurane |
1 |
2019 |
| Drug |
isoflurane, sevoflurane/desflurane |
1 |
2019 |
| Drug |
isotope |
1 |
2014 |
| Drug |
ispinesib |
1 |
2004 |
| Procedure |
issue of information booklet |
1 |
2005 |
| Biological |
it-pil12-ep |
1 |
2015 |
| Other |
it system |
1 |
2007 |
| Drug |
itraconazole |
1 |
2008 |
| Drug |
iv |
1 |
2013 |
| Drug |
iv analgesia |
1 |
2017 |
| Drug |
iv bisphosphonates |
1 |
2004 |
| Dietary Supplement |
iv glutamine |
1 |
2008 |
| Drug |
iv lbh589 |
1 |
2008 |
| Drug |
iv/oral n-acetylcysteine |
1 |
2013 |
| Biological |
ivac_m_uid |
1 |
2014 |
| Biological |
ivac_w_bre1_uid |
1 |
2014 |
| Biological |
ivac_w_bre1_uid/ivac_m_uid |
1 |
2014 |
| Drug |
ixabepilone (ixempra) |
1 |
2008 |
| Drug |
ixabepilone / cetuximab |
1 |
2008 |
| Drug |
ixabepilone, 16 mg |
1 |
2006 |
| Drug |
ixabepilone, 16 mg/m^2 / bevacizumab, 10 mg/kg |
1 |
2006 |
| Drug |
ixabepilone, 40 mg |
1 |
2006 |
| Drug |
ixabepilone, 40 mg/m^2 / bevacizumab, 15 mg/kg |
1 |
2006 |
| Drug |
ixazomib |
1 |
2016 |
| Biological |
j65 vaccine then e39 vaccine |
1 |
2013 |
| Behavioral |
joint loosening yoga |
1 |
2019 |
| Drug |
js001 |
1 |
2019 |
| Drug |
jx-594 |
1 |
2015 |
| Drug |
jx-594 dose escalation |
1 |
2015 |
| Drug |
ketamine/bupivacaine injection |
1 |
2018 |
| Drug |
ketamine/placebo |
1 |
2006 |
| Drug |
ketorolac 30 mg iv |
1 |
2013 |
| Biological |
keyhole limpet hemocyanin |
1 |
1999 |
| Biological |
kg-d1;425 ng |
1 |
2019 |
| Biological |
kg-d1;550 ng |
1 |
2019 |
| Biological |
kg -d8,d15,d22 |
1 |
2019 |
| Drug |
kg (her2 low expression) |
1 |
2017 |
| Drug |
kg (her2 positive) |
1 |
2017 |
| Drug |
kg cpg 7909 |
1 |
2002 |
| Biological |
kg d1;550 ng |
1 |
2019 |
| Biological |
kg d15,22 |
1 |
2019 |
| Biological |
kg d8;700 ng |
1 |
2019 |
| Biological |
kg d8;900 ng |
1 |
2019 |
| Drug |
kg iv (her2 positive patients only) |
1 |
2016 |
| Drug |
kg iv saturation, then 6 mg |
1 |
2016 |
| Drug |
kg, capecitabine |
1 |
2008 |
| Drug |
kg, paclitaxel |
1 |
2008 |
| Biological |
kgd1;550 ng |
1 |
2019 |
| Biological |
kgd15,22 |
1 |
2019 |
| Drug |
khk2375 |
1 |
2015 |
| Device |
kibur microdevice |
1 |
2015 |
| Behavioral |
kim-chi |
1 |
2011 |
| Other |
kinesiotherapy |
1 |
2016 |
| Other |
kinesiotherapy protocol |
1 |
2019 |
| Behavioral |
kirtan kriya meditation |
1 |
2018 |
| Drug |
kn026 combination |
1 |
2019 |
| Drug |
kn026 monotherapy |
1 |
2019 |
| Biological |
kn046 |
1 |
2019 |
| Biological |
ks24.22 cells |
1 |
2010 |
| Drug |
ku-0059436 (azd2281) (parp inhibitor) |
1 |
2007 |
| Drug |
l-carnitine 500mg oral tablet |
1 |
2020 |
| Drug |
l-nmma |
1 |
2016 |
| Biological |
la tnbc: dc vaccine |
1 |
2013 |
| Biological |
la tnbc: dc vaccine/preop chemo |
1 |
2013 |
| Other |
laboratory assay |
1 |
2005 |
| Other |
laboratory biomarker |
1 |
2017 |
| Biological |
laboratory blood samples |
1 |
2015 |
| Other |
laboratory testing |
1 |
2009 |
| Drug |
lactate-containing vaginal lubricant |
1 |
2009 |
| Drug |
lactic acid-based topical cream |
1 |
2006 |
| Drug |
laniquidar |
1 |
2002 |
| Procedure |
laparoscopic surgery |
1 |
1999 |
| placebo |
lapatinib-placebo |
1 |
2006 |
| Drug |
lapatinib (gw572016) 1000 mg |
1 |
2006 |
| Drug |
lapatinib (gw572016) 1500 mg |
1 |
2006 |
| Drug |
lapatinib (gw572016) oral tablets |
1 |
2006 |
| Drug |
lapatinib (gw572016, tykerb) |
1 |
2010 |
| Drug |
lapatinib / capecitabine |
1 |
2010 |
| Drug |
lapatinib / capecitabine (phase ii) |
1 |
2011 |
| Drug |
lapatinib in combination with an anti-cancer agent |
1 |
2008 |
| Drug |
lapatinib in combination with an anti-cancer agent as specified by parent protocol |
1 |
2008 |
| Drug |
lapatinib in combination with capecitabine |
1 |
2007 |
| Drug |
lapatinib in combination with weekly paclitaxel |
1 |
2010 |
| Drug |
lapatinib in tandem with capecitabine |
1 |
2016 |
| Drug |
lapatinib oral tablets |
1 |
2006 |
| Drug |
lapatinib, docetaxel, trastuzumab |
1 |
2005 |
| Drug |
lapatinib/capecitabine |
1 |
2017 |
| Drug |
lapatinib/capecitabine/vinorelbine |
1 |
2015 |
| Drug |
lapatinib/esomeprazole |
1 |
2009 |
| Drug |
lapatinib/herceptin |
1 |
2017 |
| Drug |
lapatinib/nab-paclitaxel |
1 |
2008 |
| Drug |
lapatinib/oral vinorelbine |
1 |
2009 |
| Drug |
lapatinib/temozolomide |
1 |
2008 |
| Drug |
larotaxel |
1 |
2006 |
| Drug |
larotaxel (rpr109881, xrp9881) |
1 |
2004 |
| Drug |
larotrectinib |
1 |
2015 |
| Drug |
larotrectinib sulfate |
1 |
2015 |
| Procedure |
laser alone |
1 |
2009 |
| Procedure |
laser/mld combined |
1 |
2009 |
| Drug |
lasofoxifene |
1 |
2018 |
| Drug |
lbh589 |
1 |
2008 |
| Drug |
lcl161 |
1 |
2012 |
| Drug |
lcz696 |
1 |
2018 |
| Behavioral |
lean book |
1 |
2016 |
| Behavioral |
lean book/videos |
1 |
2016 |
| Other |
learning workshops |
1 |
2018 |
| Procedure |
least acupuncture stimulation |
1 |
2015 |
| Drug |
lee-011 |
1 |
2015 |
| Drug |
leflunomide |
1 |
2018 |
| Drug |
lenvatinib |
1 |
2017 |
| Drug |
lep-etu |
1 |
2010 |
| Behavioral |
less intensive |
1 |
2010 |
| Drug |
letrozole - concomitant |
1 |
2005 |
| Drug |
letrozole - sequential |
1 |
2005 |
| Drug |
letrozole ,goserelin |
1 |
2007 |
| Drug |
letrozole / temsirolimus (cci-779) |
1 |
2003 |
| Drug |
letrozole 2.5 mg |
1 |
2015 |
| Drug |
letrozole 2.5mg tab |
1 |
2020 |
| Procedure |
letrozole as adjuvant therapy |
1 |
2007 |
| Drug |
letrozole in combination with bevacizumab |
1 |
2005 |
| Drug |
letrozole, lapatinib |
1 |
2011 |
| Drug |
letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel |
1 |
2016 |
| Drug |
letrozole/anastrozole tablets |
1 |
2019 |
| Drug |
letrozole/anastrozole/fulvestrant |
1 |
2018 |
| Drug |
letrozole/atorvastatin |
1 |
2016 |
| Drug |
letrozole/low-dose metronomic capecitabine |
1 |
2018 |
| Drug |
letrozole/prometrium |
1 |
2018 |
| Drug |
letrozole; avastin |
1 |
2007 |
| Biological |
leucostim 5âµg |
1 |
2017 |
| Biological |
leucostim 5âµg/kg/day |
1 |
2017 |
| Drug |
leucovorin (calcium folinate |
1 |
2016 |
| Biological |
leukineâ® (sargramostim, gm-csf) |
1 |
2011 |
| Biological |
leukineâ® (sargramostim, gm-csf)/water for injection |
1 |
2011 |
| Drug |
leuplin |
1 |
2018 |
| Drug |
leuplin/zoladex |
1 |
2018 |
| Drug |
leuporelin acetate |
1 |
2017 |
| Drug |
life information rehabilitation therapy |
1 |
2017 |
| Behavioral |
lifestyle- supportive care |
1 |
2017 |
| Other |
light touch |
1 |
2020 |
| Behavioral |
lighter intensity physical activity intervention |
1 |
2018 |
| Device |
lightpathâ® imaging system. |
1 |
2016 |
| Behavioral |
lii |
1 |
2015 |
| Other |
limit heart dose |
1 |
2016 |
| Dietary Supplement |
limonene |
1 |
2010 |
| Other |
limonene containing massage oil |
1 |
2011 |
| Behavioral |
linear aerobic training |
1 |
2010 |
| Behavioral |
linguistically |
1 |
2016 |
| Behavioral |
linguistically/culturally tailored information |
1 |
2016 |
| Other |
lipoderm cream base |
1 |
2018 |
| Drug |
liposomal-doxorubicin |
1 |
2010 |
| Drug |
liposomal-doxorubicin/cyclophosphamide |
1 |
2010 |
| Drug |
liposomal annamycin |
1 |
2001 |
| Drug |
liposomal pegylated doxorubicine |
1 |
2007 |
| Procedure |
liposuction |
1 |
2009 |
| Diagnostic Test |
liquid biopsy |
1 |
2019 |
| Drug |
lisinopril |
1 |
2009 |
| Drug |
lithium carbonate |
1 |
2006 |
| Device |
lmaâ® |
1 |
2008 |
| Radiation |
lni 15 fractions |
1 |
2017 |
| Radiation |
lni 5 fractions |
1 |
2017 |
| Other |
local-distal points association |
1 |
2017 |
| Procedure |
local anesthetic |
1 |
2010 |
| Other |
local distribution points association |
1 |
2017 |
| Procedure |
localization |
1 |
2017 |
| Procedure |
loco-regional anaesthesia |
1 |
2017 |
| Other |
loft therapy |
1 |
2015 |
| Drug |
lomustine |
1 |
2018 |
| Drug |
lonaprisan (zk 230211, bay86-5044) |
1 |
2007 |
| Other |
long intervention protocol |
1 |
2017 |
| Drug |
loratadine |
1 |
2012 |
| Procedure |
louis-3d imaging procedure |
1 |
2012 |
| Dietary Supplement |
lovaza-omega 3 fatty acid capsules |
1 |
2011 |
| Drug |
lovaza 4gm |
1 |
2008 |
| Dietary Supplement |
lovaza 4gm oral |
1 |
2008 |
| Drug |
lovaza 4gm/raloxifene 30mg |
1 |
2008 |
| Drug |
lovazaâ® |
1 |
2013 |
| Drug |
low-dose metronomic capecitabine |
1 |
2018 |
| Behavioral |
low-fat diet |
1 |
2005 |
| Procedure |
low-intensity bodywork therapy |
1 |
2002 |
| Radiation |
low-let cobalt-60 gamma ray therapy |
1 |
1999 |
| Device |
low-level laser |
1 |
2015 |
| Device |
low-power microwave breast imaging system |
1 |
2018 |
| Behavioral |
low carbohydrate diet / exercise |
1 |
2012 |
| Drug |
low dose cyclophosphamide |
1 |
2017 |
| Biological |
low dose frî± vaccine |
1 |
2015 |
| Behavioral |
low fat diet/exercise |
1 |
2012 |
| Other |
low fat high n3 diet |
1 |
2013 |
| Other |
low glycemic index mediterranean diet |
1 |
2016 |
| Behavioral |
low intensity exercise training 1 |
1 |
2016 |
| Behavioral |
low intensity exercise training 2 |
1 |
2016 |
| Device |
low level laser |
1 |
2011 |
| Device |
low level laser therapy |
1 |
2011 |
| Other |
lower-load resistance training (ll) |
1 |
2018 |
| Drug |
ls301 |
1 |
2016 |
| Device |
lsg |
1 |
2012 |
| Drug |
lsz102 |
1 |
2016 |
| Drug |
ltld |
1 |
2018 |
| Drug |
ltx-315 |
1 |
2013 |
| Drug |
ltx-315 / ipilimumab |
1 |
2013 |
| Drug |
ltx-315 / pembrolizumab |
1 |
2013 |
| Drug |
ltx-315 consecutive lesions |
1 |
2013 |
| Drug |
lucitanib |
1 |
2014 |
| Device |
lum 2.6 imaging device |
1 |
2015 |
| Combination Product |
lum imaging system |
1 |
2017 |
| Drug |
lum015 |
1 |
2015 |
| Procedure |
lumpectomy without sentinel node biopsy |
1 |
2015 |
| Procedure |
lumpectomy, axillary block dissection, breast conserving surgery |
1 |
2011 |
| Procedure |
lumpectomy/mastectomy with sentinel node/axillary node dissection |
1 |
2013 |
| Drug |
lumretuzumab |
1 |
2013 |
| Drug |
lupin’s pegfilgrastim |
1 |
2018 |
| Drug |
lurbinectedin (pm01183) |
1 |
2014 |
| Other |
luvena |
1 |
2012 |
| Procedure |
lvef 3 month |
1 |
2016 |
| Procedure |
lvef 4 month |
1 |
2016 |
| Drug |
lx-039 tablets |
1 |
2019 |
| Drug |
ly2523355 |
1 |
2011 |
| Drug |
ly2606368 |
1 |
2014 |
| Drug |
ly2835219 |
1 |
2014 |
| Drug |
ly2880070 |
1 |
2015 |
| Drug |
ly3023414 |
1 |
2014 |
| Drug |
ly3295668 |
1 |
2017 |
| Drug |
ly3295668 erbumine |
1 |
2019 |
| Drug |
ly3484356 |
1 |
2019 |
| Drug |
ly353381 |
1 |
2002 |
| Drug |
ly573636-sodium |
1 |
2009 |
| Procedure |
lymph node removal |
1 |
2013 |
| Procedure |
lymphatic massage (decongestive lymphatic therapy) (arm 1) |
1 |
2005 |
| Procedure |
lymphovenous bypass |
1 |
2019 |
| Drug |
lynparza |
1 |
2019 |
| Procedure |
m |
1 |
2011 |
| Drug |
m2 alternately q21 days for 6 cycles |
1 |
2005 |
| Drug |
m2 days 1 |
1 |
2012 |
| Drug |
m2 days 1, 8 |
1 |
2012 |
| Drug |
m2 every 21 days for 6 cycles |
1 |
2005 |
| Drug |
m2 iv |
1 |
2016 |
| Drug |
m2 weekly |
1 |
2011 |
| Drug |
m2) q21 days x 6 cycles |
1 |
2005 |
| Drug |
m2; hd-mtx) |
1 |
2015 |
| Drug |
mâ² |
1 |
2016 |
| Biological |
mab her 2 (herceptin) |
1 |
2006 |
| Device |
macrodyne livmd plate |
1 |
2018 |
| Drug |
mag-tn3 |
1 |
2015 |
| Drug |
mag-tn3 / as15 |
1 |
2015 |
| Drug |
mage-12 peptide vaccine |
1 |
2007 |
| Drug |
magnesium oxide |
1 |
2011 |
| Drug |
magnesium sulfate |
1 |
2020 |
| Procedure |
magnetic resonance imaging (mri) |
1 |
2018 |
| Procedure |
magnetic resonance spectroscopy |
1 |
2008 |
| Device |
magseed marker |
1 |
2018 |
| Behavioral |
mail |
1 |
2015 |
| Behavioral |
mail-based |
1 |
2007 |
| Behavioral |
mainly exercise induced weight loss |
1 |
2012 |
| Drug |
maintenance erlotinib |
1 |
2009 |
| Drug |
maitake mushroom extract compound |
1 |
2015 |
| Behavioral |
male spouse transition toolkit |
1 |
2014 |
| Device |
mamma board |
1 |
2005 |
| Device |
mammatyperâ„¢ |
1 |
2014 |
| Other |
mammography (cesm) |
1 |
2012 |
| Other |
mammography (cesm)/mri |
1 |
2012 |
| Diagnostic Test |
mammography outside official screening |
1 |
2019 |
| Radiation |
mammography/tomosynthesis imaging |
1 |
2008 |
| Procedure |
mammoplasty |
1 |
2019 |
| Radiation |
mammosite |
1 |
2005 |
| Radiation |
mammosite brachytherapy radiation |
1 |
2008 |
| Device |
mammosite ml |
1 |
2011 |
| Radiation |
mammosite/other single-entry intracavitary device |
1 |
2005 |
| Drug |
mango juice |
1 |
2009 |
| Other |
manual therapy protocol |
1 |
2019 |
| Other |
manual therapy, kinesiotherapy |
1 |
2010 |
| Behavioral |
manualized group intervention |
1 |
2013 |
| Procedure |
mapping |
1 |
2019 |
| Procedure |
margin ablation |
1 |
2007 |
| Drug |
marimastat |
1 |
1999 |
| Procedure |
marking |
1 |
2010 |
| Other |
mass spectrometer analysis of tissue sample |
1 |
2015 |
| Procedure |
massage |
1 |
2012 |
| Procedure |
massage therapy |
1 |
2014 |
| Procedure |
massage/with meditation |
1 |
2012 |
| Procedure |
mastectomy with sentinel node |
1 |
2013 |
| Other |
matrix-assisted laser desorption ionization mass spectrometry |
1 |
2008 |
| Drug |
maximum tolerated dose (mtd) of leronlimab |
1 |
2019 |
| Other |
mbsr |
1 |
2012 |
| Behavioral |
mbsr 6 weeks program |
1 |
2010 |
| Behavioral |
mbsr(bc) 6 week program |
1 |
2016 |
| Drug |
mcla-128 |
1 |
2017 |
| Drug |
mdm2 |
1 |
2018 |
| Biological |
mdm2-polyepitope plasmid dna vaccine |
1 |
2014 |
| Drug |
mdm2/mdmx inhibitor alrn-6924 |
1 |
2018 |
| Drug |
mdmx inhibitor alrn-6924 |
1 |
2018 |
| Drug |
mdx-010 |
1 |
2004 |
| Drug |
me-344 |
1 |
2016 |
| Drug |
medi-573 |
1 |
2011 |
| Biological |
medi6469 |
1 |
2013 |
| Drug |
medi9447 |
1 |
2018 |
| Behavioral |
medical consultation for a standardized geriatric evaluation |
1 |
2017 |
| Device |
medical device |
1 |
2017 |
| Other |
medication monitoring control |
1 |
2019 |
| Other |
medication taken to manage the symptom burden of cipn |
1 |
2014 |
| Other |
meditation |
1 |
2019 |
| Behavioral |
meditation-based stress reduction program |
1 |
2018 |
| Procedure |
meditation therapy |
1 |
2017 |
| Other |
mediterranean diet, physical exercise |
1 |
2019 |
| Other |
mediterranean diet, physical exercise/mindfulness workshops |
1 |
2019 |
| Drug |
medroxyprogesterone progesterone acetate (mpa) |
1 |
2007 |
| Drug |
medroxyprogesterone with cyclophosphamide |
1 |
2007 |
| Drug |
medroxyprogesterone with cyclophosphamide / methotrexate |
1 |
2007 |
| Drug |
megestrol acetate 160 mg |
1 |
2017 |
| Drug |
megestrol acetate 160mg tablet |
1 |
2017 |
| Drug |
megestrol acetate 20mg |
1 |
2000 |
| Drug |
megestrol acetate 20mg/day |
1 |
2000 |
| Drug |
megestrol acetate 40 mg/day |
1 |
2000 |
| placebo |
megestrol acetate placebo 20 mg |
1 |
2000 |
| Drug |
megestrol acetate placebo 20 mg/day |
1 |
2000 |
| placebo |
megestrol acetate placebo 40 mg |
1 |
2000 |
| Drug |
megestrol acetate placebo 40 mg/day |
1 |
2000 |
| Drug |
melatonin 3 mg |
1 |
2013 |
| Drug |
memantine hydrochloride |
1 |
2012 |
| Other |
memory intervention |
1 |
2012 |
| Behavioral |
memory training |
1 |
2011 |
| Drug |
men1611 |
1 |
2018 |
| Behavioral |
menopausal health resources |
1 |
2018 |
| Drug |
menopause symptom checklist |
1 |
2009 |
| Device |
mepitel filmâ® |
1 |
2019 |
| Drug |
merck 3475 pembrolizumab |
1 |
2016 |
| Drug |
mes with anti-vegfr included therapy |
1 |
2019 |
| Device |
meso biomatrix device |
1 |
2013 |
| Biological |
mesothelin-targeted t cells |
1 |
2016 |
| Behavioral |
message |
1 |
2016 |
| Device |
metal wire |
1 |
2016 |
| Procedure |
metastasectomy for the metastatic sites |
1 |
2020 |
| Procedure |
metastasis biopsy |
1 |
2018 |
| Procedure |
metastatic lesion biopsy |
1 |
2014 |
| Drug |
metformin / myocet / cyclophosphamide |
1 |
2013 |
| Drug |
metformin hydrochloride 850 mg tablets |
1 |
2019 |
| Drug |
metformin xr |
1 |
2014 |
| Drug |
metformin/chemotherapy |
1 |
2019 |
| Drug |
methotrexate (cdefm) |
1 |
2016 |
| Drug |
methylene blue (1%) |
1 |
2006 |
| Drug |
metoprolol |
1 |
2011 |
| Drug |
metronomic chemotherapy |
1 |
2012 |
| Behavioral |
mf-wlp |
1 |
2015 |
| Drug |
mfolfox6 |
1 |
2012 |
| Biological |
mgah22 |
1 |
2010 |
| Behavioral |
mhealth intervention |
1 |
2015 |
| Other |
mick assay |
1 |
2005 |
| Device |
micopure ultrasound |
1 |
2017 |
| Procedure |
micro ablative radiofrequency |
1 |
2019 |
| Device |
microablative fractional co2 laser therapy |
1 |
2018 |
| Other |
microbiology |
1 |
2016 |
| Biological |
microbiota samples |
1 |
2018 |
| Drug |
midazolam premedication |
1 |
2013 |
| Drug |
mifepristone/eribulin in combination |
1 |
2013 |
| Dietary Supplement |
milk |
1 |
2007 |
| Behavioral |
mind-body exercises |
1 |
2018 |
| Behavioral |
mind body medicine day care clinic |
1 |
2016 |
| Behavioral |
mindful awareness practices (maps) |
1 |
2012 |
| Behavioral |
mindful eating intervention |
1 |
2019 |
| Behavioral |
mindful movement program |
1 |
2015 |
| Other |
mindfulness-based cognitive therapy |
1 |
2012 |
| Behavioral |
mindfulness-based relationship enhancement (mbre) |
1 |
2015 |
| Behavioral |
mindfulness-based therapy |
1 |
2017 |
| Behavioral |
mindfulness based cognitive therapy |
1 |
2015 |
| Behavioral |
mindfulness based stress reduction |
1 |
2018 |
| Behavioral |
mindfulness based stress reduction (mbsr) |
1 |
2009 |
| Behavioral |
mindfulness based swinging effect intervention |
1 |
2019 |
| Behavioral |
mindfulness session |
1 |
2018 |
| Other |
mindfulness workshops |
1 |
2019 |
| Behavioral |
mindfulness/self-compassion focussed exercises during walking training |
1 |
2019 |
| Device |
mini-flare imaging system |
1 |
2011 |
| Procedure |
minimally-invasive biopsy |
1 |
2017 |
| Drug |
miracle mouthwash |
1 |
2014 |
| Drug |
miracle mouthwash/hydrocortisone |
1 |
2014 |
| Procedure |
mit |
1 |
2018 |
| Drug |
mitoxantrone hydrochloride liposome injection |
1 |
2015 |
| Other |
mittens |
1 |
2014 |
| Other |
mittens/booties |
1 |
2014 |
| Drug |
mk-0752 |
1 |
2008 |
| Drug |
mk-0752, docetaxel, pegfilgrastim |
1 |
2008 |
| Drug |
mk-2206 with |
1 |
2009 |
| Drug |
mk-2206 with/without trastuzumab |
1 |
2009 |
| Drug |
mkc-1 |
1 |
2006 |
| Drug |
ml prefilled syringe [faslodex] |
1 |
2018 |
| Drug |
ml, 35 ml |
1 |
2017 |
| Procedure |
mld combined |
1 |
2009 |
| Drug |
mm-111 / herceptin |
1 |
2010 |
| Drug |
mm-398 |
1 |
2012 |
| Procedure |
moderate-intensity |
1 |
2002 |
| Behavioral |
moderate-intensity aerobic exercise intervention |
1 |
2016 |
| Behavioral |
moderate-intensity exercise |
1 |
2006 |
| Procedure |
moderate-intensity/low-intensity bodywork therapy |
1 |
2002 |
| Behavioral |
moderate physical activity |
1 |
2016 |
| Other |
moderate volume |
1 |
2011 |
| Behavioral |
moderated support |
1 |
2006 |
| Other |
modern educational program |
1 |
2017 |
| Procedure |
modified radical mastectomy/breast-conserving surgery |
1 |
2011 |
| Procedure |
modified radical mastectomy/breast conserving surgery with axillary lymph node dissection |
1 |
2005 |
| Biological |
modified vaccinia virus ankara vaccine expressing p53 |
1 |
2015 |
| Drug |
modradoc006 |
1 |
2019 |
| Drug |
modradoc006/r |
1 |
2019 |
| Genetic |
molecular alteration |
1 |
2011 |
| Procedure |
molecular breast imaging (mbi) |
1 |
2014 |
| Procedure |
molecular imaging |
1 |
2013 |
| Device |
molli localization |
1 |
2018 |
| Drug |
mometasone furoate |
1 |
2007 |
| Other |
mometasone furoate 0.1% |
1 |
2013 |
| Other |
mono-chemotherapy |
1 |
2019 |
| Drug |
monoclonal antibody 3a1 |
1 |
1999 |
| Drug |
monoclonal antibody 95-5-49 |
1 |
1999 |
| Drug |
monoclonal antibody 95-6-22 |
1 |
1999 |
| Biological |
monoclonal antibody cal |
1 |
2003 |
| Biological |
monoclonal antibody huhmfg1 |
1 |
2004 |
| Drug |
monosialotetrahexosyl ganglioside (gm1) |
1 |
2020 |
| Drug |
montanide isa-51 |
1 |
2007 |
| Biological |
montanide isa 51 vg |
1 |
2011 |
| Biological |
montanide isa51 vg |
1 |
2010 |
| Other |
montreal cognitive assessment (moca) |
1 |
2017 |
| Drug |
morphine |
1 |
2017 |
| Drug |
motexafin gadolinium injection |
1 |
2004 |
| Behavioral |
motivational intervention group |
1 |
2017 |
| Behavioral |
motivational interviewing intervention |
1 |
2013 |
| Behavioral |
moving on abc plus |
1 |
2018 |
| Other |
moxibustion |
1 |
2009 |
| Drug |
moxifloxacin hydrochloride 400mg tablet |
1 |
2018 |
| Drug |
mpdl3280a |
1 |
2015 |
| Biological |
mphosph1 |
1 |
2010 |
| Radiation |
mr-guided single dose preoperative pbi |
1 |
2019 |
| Procedure |
mr-hifu induced hyperthermia |
1 |
2018 |
| Device |
mr scan |
1 |
2019 |
| Device |
mri-tobi |
1 |
2018 |
| Procedure |
mri biopsy |
1 |
2017 |
| Diagnostic Test |
mri screening |
1 |
2019 |
| Device |
mri, digital mammography, ultrasound |
1 |
2006 |
| Device |
mri, digital mammography, ultrasound/positron emission tomography (pet) |
1 |
2006 |
| Procedure |
mri/mrs |
1 |
2002 |
| Procedure |
mriâ±biopsy |
1 |
2010 |
| Drug |
msb0010718c |
1 |
2016 |
| Drug |
mtc-dox for injection |
1 |
2002 |
| Drug |
mtor inhibitor with nab-paclitaxel |
1 |
2019 |
| Biological |
muc1 |
1 |
1999 |
| Biological |
muc1-klh vaccine |
1 |
1999 |
| Biological |
muc1-klh vaccine/qs21 |
1 |
1999 |
| Biological |
muc1 peptide-poly-iclc adjuvant vaccine |
1 |
2009 |
| Drug |
mucoadhesive oral wound rinse |
1 |
2013 |
| Radiation |
multi-beam imrt |
1 |
2014 |
| Radiation |
multi-beam intensity-modulated radiation therapy |
1 |
2010 |
| Biological |
multi-epitope her2 peptide vaccine h2nvac |
1 |
2019 |
| Diagnostic Test |
multi-parametric mri |
1 |
2019 |
| Behavioral |
multifaceted educational intervention |
1 |
2006 |
| Drug |
multimodal analgesia |
1 |
2020 |
| Other |
multimodal physiotherapy |
1 |
2016 |
| Radiation |
multiple beams utilizing either intensity-modulated |
1 |
2010 |
| Radiation |
multiple beams utilizing either intensity-modulated/3d-conformal techniques |
1 |
2010 |
| Procedure |
multiple injection paravertebral blocks |
1 |
2016 |
| Device |
multispectral imager |
1 |
2018 |
| Procedure |
musculoskeletal complications management |
1 |
2006 |
| Procedure |
musculoskeletal complications management/prevention |
1 |
2006 |
| Behavioral |
music |
1 |
2018 |
| Other |
music listening |
1 |
2018 |
| Behavioral |
music listening program |
1 |
2018 |
| Behavioral |
music method |
1 |
2019 |
| Device |
must device |
1 |
2019 |
| Biological |
mutant p53 peptide pulsed dendritic cell vaccine |
1 |
2001 |
| Genetic |
mutation analysis |
1 |
2010 |
| Biological |
mv |
1 |
2015 |
| Drug |
mycograb, docetaxel |
1 |
2005 |
| Drug |
mycophenolate mofetil |
1 |
2006 |
| Drug |
myelo001 |
1 |
2016 |
| Behavioral |
myhealth |
1 |
2016 |
| Biological |
myl- 1401o |
1 |
2015 |
| Biological |
myl-1401h |
1 |
2015 |
| Drug |
myocet (non-pegylated liposomal doxorubicin (npld)) |
1 |
2010 |
| Drug |
myocet / cyclophosphamide |
1 |
2013 |
| Drug |
myocetâ® |
1 |
2008 |
| Drug |
myocetâ®/cyclophosphamide/trastuzumab, 4 cycles, followed by docetaxel/trastuzumab, 4 cycles |
1 |
2008 |
| Other |
myofascial massage |
1 |
2020 |
| Biological |
n-803 |
1 |
2017 |
| Drug |
nab-paclitaxel (abraxane) |
1 |
2008 |
| Drug |
nab-paclitaxel (paclitaxel-albumin) |
1 |
2016 |
| Drug |
nab-paclitaxel (paclitaxel-albumin) / carboplatin |
1 |
2016 |
| Drug |
nab-paclitaxel (paclitaxel-albumin) / gemcitabine |
1 |
2016 |
| Drug |
nab-paclitaxel / capecitabine |
1 |
2019 |
| Drug |
nab-paclitaxel / epirubicin |
1 |
2019 |
| Drug |
nab-paclitaxel 100 mg |
1 |
2012 |
| Drug |
nab-paclitaxel 100 mg/m2 days 1, 8/15 |
1 |
2012 |
| Drug |
nab-paclitaxel 150 mg |
1 |
2012 |
| Drug |
nab-paclitaxel 150 mg/m2 days 1, 8/15 |
1 |
2012 |
| Drug |
nab-paclitaxel 150 mg/m2 days 1/15 |
1 |
2012 |
| Drug |
nab-paclitaxel followed by anthracycline |
1 |
2019 |
| Drug |
nab-paclitaxel followed by anthracycline/cyclophosphamide |
1 |
2019 |
| Drug |
nab paclitaxel. |
1 |
2018 |
| Drug |
nac |
1 |
2017 |
| Device |
naf pet |
1 |
2014 |
| Device |
naf pet/ct |
1 |
2014 |
| Device |
naf pet/mri |
1 |
2014 |
| Drug |
naltrexone/bupropion |
1 |
2018 |
| Other |
nanoemulsion |
1 |
2019 |
| Device |
nanoknife ledc system |
1 |
2015 |
| Drug |
nanoparticle albumin-bound paclitaxel |
1 |
2018 |
| Drug |
nanoparticle albumin-bound paclitaxel (np) |
1 |
2018 |
| Drug |
nanoparticle albumin-bound rapamycin |
1 |
2016 |
| Drug |
nanoparticle albumin bound paclitaxel followed by fec |
1 |
2005 |
| Drug |
nanosomal docetaxel lipid suspension (100 mg |
1 |
2018 |
| Drug |
nanosomal docetaxel lipid suspension (100 mg/m2) |
1 |
2018 |
| Drug |
nanosomal docetaxel lipid suspension (75 mg |
1 |
2018 |
| Drug |
nanosomal docetaxel lipid suspension (75 mg/m2) |
1 |
2018 |
| Drug |
naproxen |
1 |
2012 |
| Behavioral |
narrative visualization |
1 |
2018 |
| Biological |
natural killer cells |
1 |
2010 |
| Drug |
navelbine (oraly) |
1 |
2007 |
| Drug |
nefopam |
1 |
2015 |
| Procedure |
negative pressure wound therapy |
1 |
2019 |
| Drug |
nelipepimut-s |
1 |
2015 |
| Drug |
nelipepimut-s/gm-csf vaccine |
1 |
2015 |
| Biological |
neo-antigen pulsed dendritic cell |
1 |
2019 |
| Drug |
neoadjuvant (f)ec-paclitaxel chemotherapy |
1 |
2018 |
| Drug |
neoadjuvant chemotherapy |
1 |
2017 |
| Drug |
neoadjuvant chemotherapy with docetaxel |
1 |
2012 |
| Drug |
neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone) |
1 |
2015 |
| Drug |
neoadjuvant docetaxel / cyclophosphamide |
1 |
2015 |
| Drug |
neoadjuvant docetaxel / cyclophosphamide / trastuzumab / pertuzumab |
1 |
2015 |
| Drug |
neoadjuvant docetaxel / trastuzumab / pertuzumab |
1 |
2015 |
| Drug |
neoadjuvant docetaxel/cyclophosphamide |
1 |
2012 |
| Drug |
neoadjuvant endocrine therapy |
1 |
2015 |
| Drug |
neoadjuvant endocrine therapy / palbociclib (if lack of response to endocrine therapy alone) |
1 |
2015 |
| Drug |
neoadjuvant letrozole (postmenopausal women) |
1 |
2015 |
| Drug |
neoadjuvant olaparib |
1 |
2015 |
| Radiation |
neoadjuvant radiotherapy |
1 |
2018 |
| Drug |
neoadjuvant tamoxifen |
1 |
2015 |
| Drug |
neoadjuvant tamoxifen / goserelin (premenopausal women) |
1 |
2015 |
| Biological |
neoantigen dna vaccine |
1 |
2017 |
| Drug |
neostigmine |
1 |
2016 |
| Drug |
nepa |
1 |
2017 |
| Biological |
nerofe is a first in class derivative of a human hormon-peptide(tcapf), with cancer suppressive properties. |
1 |
2018 |
| Other |
nerve mobilization |
1 |
2015 |
| Drug |
netupitant |
1 |
2017 |
| Drug |
netupitant/palonosetron hydrochloride |
1 |
2017 |
| Biological |
neu |
1 |
2006 |
| Biological |
neu dc vaccine |
1 |
2012 |
| Biological |
neu transduced dendritic cells |
1 |
2005 |
| Biological |
neu, cea, |
1 |
2009 |
| Drug |
neulastaâ® (pegfilgrastim) |
1 |
2012 |
| Drug |
neulastim |
1 |
2017 |
| Drug |
neupogen |
1 |
2016 |
| Biological |
neupogen 5âµg |
1 |
2017 |
| Biological |
neupogen 5âµg/kg/day |
1 |
2017 |
| Behavioral |
neurocognitive tests |
1 |
2015 |
| Other |
neurodynamic techniques |
1 |
2017 |
| placebo |
neurofeedback training (placebo |
1 |
2009 |
| Behavioral |
neurofeedback training (placebo / sham) |
1 |
2009 |
| Drug |
neuromuscular taping |
1 |
2015 |
| Behavioral |
neuropathic pain scale (nps) questionnaire |
1 |
2015 |
| Other |
neuropsychological, psycho-pathological |
1 |
2018 |
| Other |
neuropsychological, psycho-pathological/quality of life assessments |
1 |
2018 |
| Biological |
neuvaxâ„¢ vaccine |
1 |
2011 |
| Procedure |
new software sequences, fiesta |
1 |
2007 |
| Procedure |
new software sequences, fiesta/vibrant-de/ideal |
1 |
2007 |
| Behavioral |
newsletter |
1 |
2011 |
| Behavioral |
newsletter about physical activity |
1 |
2013 |
| Behavioral |
newsletter about physical activity/breast cancer survivors |
1 |
2013 |
| Drug |
nexavar (sorafenib) |
1 |
2007 |
| Diagnostic Test |
next-generation sequencing (ngs) |
1 |
2017 |
| Diagnostic Test |
next generation sequencing (ngs) detection |
1 |
2018 |
| Behavioral |
nhanes food questionnaire |
1 |
2017 |
| Other |
nhs breast screening programme |
1 |
2020 |
| Drug |
nicotine |
1 |
1999 |
| Behavioral |
night-time compression system garment |
1 |
2012 |
| Drug |
nilotinib |
1 |
2019 |
| Drug |
nilotinib hydrochloride monohydrate |
1 |
2019 |
| Drug |
nimesulide |
1 |
2011 |
| Procedure |
nipple-sparing mastectomy |
1 |
2010 |
| Device |
nipple reconstruction |
1 |
2010 |
| Other |
nir |
1 |
2014 |
| Device |
nir imaging system |
1 |
2008 |
| Device |
nir imaging with flare |
1 |
2011 |
| Device |
nir imaging with flare/mini-flare imaging system |
1 |
2011 |
| Other |
nir/us diagnostic group |
1 |
2014 |
| Other |
nir/us neoadjuvant chemotherapy group |
1 |
2014 |
| Other |
nir/us process validation group |
1 |
2014 |
| Drug |
nir178 |
1 |
2018 |
| Drug |
nivolumab 360mg |
1 |
2018 |
| placebo |
nivolumab placebo |
1 |
2019 |
| Drug |
nk012/carboplatin |
1 |
2010 |
| Drug |
nk105 |
1 |
2012 |
| Procedure |
no axillary surgery versus slnb |
1 |
2015 |
| Drug |
no bevacizumab |
1 |
2010 |
| Radiation |
no bolus |
1 |
2013 |
| Other |
no hormone |
1 |
2019 |
| Radiation |
no internal mammary nodal irradiation |
1 |
2020 |
| Other |
no limited movement after surgery |
1 |
2018 |
| Other |
no loco-regional treatment |
1 |
2005 |
| Behavioral |
no meditation |
1 |
2007 |
| Other |
no mobile community |
1 |
2018 |
| Other |
no name |
1 |
2008 |
| Other |
no radiation |
1 |
2018 |
| Procedure |
no shave margins |
1 |
2011 |
| Behavioral |
no walking exercise |
1 |
2015 |
| Radiation |
nodal irradiation |
1 |
2017 |
| Radiation |
nodal radiation therapy |
1 |
2013 |
| Other |
noise reduction headphones. |
1 |
2018 |
| Drug |
nolvadex (tamoxifen) |
1 |
2005 |
| placebo |
nolvadex placebo |
1 |
2008 |
| Dietary Supplement |
non-estrogenic pollen extract pcc-100 |
1 |
2018 |
| Other |
non-invasive positive pressure ventilation (nippv) |
1 |
2015 |
| Drug |
non-steroidal aromatase inhibitor |
1 |
2017 |
| Drug |
non-steroidal aromatase inhibitor therapy |
1 |
2007 |
| Behavioral |
non-tailored booklet on exercise |
1 |
2012 |
| Behavioral |
non-tailored booklet on exercise/diet |
1 |
2012 |
| Procedure |
non drains will be placed during operation |
1 |
2010 |
| Other |
non invasive venous ultrasound |
1 |
2011 |
| Behavioral |
non navigated latinas |
1 |
2014 |
| Drug |
non pegylated liposomal doxorubicin |
1 |
2006 |
| Drug |
non pegylated liposomal doxorubicin/docetaxel |
1 |
2006 |
| Procedure |
non surgical periodontal treatment |
1 |
2017 |
| Device |
nonlinear microscopy imaging of excised surgical margins |
1 |
2016 |
| Drug |
norethindrone acetate |
1 |
1999 |
| Drug |
normal level vitamin d |
1 |
2016 |
| Drug |
normale saline solution |
1 |
2016 |
| Radiation |
normofractionated |
1 |
2016 |
| Drug |
notch signalling pathway inhibitor ro4929097 |
1 |
2010 |
| Drug |
nov 002 |
1 |
2007 |
| Drug |
npld |
1 |
2011 |
| Drug |
nsai: letrozole |
1 |
2018 |
| Drug |
nsai: letrozole/anastrazole |
1 |
2018 |
| Device |
nuclear breast imaging using mbi gamma camera |
1 |
2010 |
| Behavioral |
nueva vida intervention |
1 |
2014 |
| Behavioral |
nuevo amancer-ii stress management program |
1 |
2016 |
| Behavioral |
nurse-led care |
1 |
2014 |
| Behavioral |
nurse amie |
1 |
2017 |
| Other |
nurse education |
1 |
2009 |
| Other |
nurse education/care program |
1 |
2009 |
| Other |
nutrition counseling |
1 |
2020 |
| Behavioral |
nutrition education |
1 |
2014 |
| Behavioral |
nutrition education intervention |
1 |
2006 |
| Other |
nutrition intervention |
1 |
2019 |
| Other |
nutrition physical activity text message |
1 |
2016 |
| Behavioral |
nutritional |
1 |
2018 |
| Behavioral |
nutritional counseling |
1 |
2011 |
| Procedure |
nutritional support |
1 |
2002 |
| Behavioral |
nutritional/goal-setting education, yoga |
1 |
2018 |
| Drug |
nvb |
1 |
2016 |
| Drug |
nx |
1 |
2007 |
| Biological |
ny-eso-1 fusion protein cdx-1401 |
1 |
2012 |
| Drug |
obi-821 |
1 |
2014 |
| Drug |
obi-833 |
1 |
2014 |
| Drug |
obi-833/obi-821 |
1 |
2014 |
| Biological |
oblimersen sodium |
1 |
1999 |
| Other |
observation/standard therapy |
1 |
2014 |
| Drug |
obt076, a cd205-directed antibody-drug conjugate |
1 |
2019 |
| Behavioral |
occupational therapy |
1 |
2018 |
| Behavioral |
occupational therapy informed yoga |
1 |
2018 |
| Combination Product |
ocoxin-viusid |
1 |
2018 |
| Biological |
ocpm immunotherapeutic vaccine |
1 |
2008 |
| Drug |
octreotide acetate |
1 |
1999 |
| Drug |
octreotide pamoate |
1 |
1999 |
| Drug |
odanacatib |
1 |
2006 |
| placebo |
odanacatib matching placebo |
1 |
2006 |
| Drug |
odm-209 |
1 |
2019 |
| Other |
offer of health-care assisted disclosure by sending direct letters to at-risk relatives |
1 |
2019 |
| Drug |
ofs |
1 |
2015 |
| Drug |
ofs / anastrozole |
1 |
2015 |
| Drug |
ofs / exemestane |
1 |
2015 |
| Other |
ohmd app |
1 |
2019 |
| placebo |
olanzapine placebo |
1 |
2016 |
| Drug |
olaparib [lynparzaâ®] |
1 |
2019 |
| Drug |
olaparib [lynparzaâ®]/trastuzumab [herceptinâ®] |
1 |
2019 |
| Drug |
olaparib 200 mg bd (21-day cycle). |
1 |
2017 |
| Drug |
olaparib continuous (28-day cycle) 300 mg bd. |
1 |
2017 |
| Drug |
olaparib continuous 300 mg bd (28-day cycle). |
1 |
2017 |
| Drug |
olaparib oral product |
1 |
2017 |
| Drug |
olaparib oral product in combination with durvalumab |
1 |
2017 |
| Dietary Supplement |
omega-3 fatty acid supplement |
1 |
2011 |
| Dietary Supplement |
omega-3 ffa |
1 |
2016 |
| Dietary Supplement |
omega-3 supplementation |
1 |
2017 |
| Dietary Supplement |
omega 3 fatty acids |
1 |
2014 |
| Procedure |
omission of axillary dissection |
1 |
2019 |
| Radiation |
omission of radiation |
1 |
2018 |
| Radiation |
omission of radiation therapy |
1 |
2016 |
| Drug |
onalespib lactate |
1 |
2015 |
| Drug |
onartuzumab |
1 |
2010 |
| placebo |
onartuzumab placebo |
1 |
2010 |
| Drug |
onc201 |
1 |
2018 |
| Radiation |
once-weekly breast irradiation |
1 |
2013 |
| Radiation |
once daily apbi |
1 |
2018 |
| Other |
onco geriatric evaluation |
1 |
2016 |
| Device |
oncodoc logiciel |
1 |
2008 |
| Procedure |
oncologic breast surgery |
1 |
2016 |
| Behavioral |
oncology care |
1 |
2016 |
| Biological |
oncolytic measles virus encoding thyroidal sodium iodide symporter |
1 |
2013 |
| Procedure |
oncoplastic approach excisional breast biopsy |
1 |
2015 |
| Other |
oncoplastic free rom |
1 |
2015 |
| Other |
oncoplastic limited rom |
1 |
2015 |
| Device |
oncotype dx breast cancer test |
1 |
2010 |
| Diagnostic Test |
oncotype dx breast recurrence score |
1 |
2018 |
| Genetic |
oncotypedx test |
1 |
2011 |
| Drug |
ondansetron 4 mg |
1 |
2017 |
| Drug |
ondansetron hydrochloride |
1 |
2006 |
| Other |
one-on-one interview |
1 |
2015 |
| Behavioral |
online gym |
1 |
2017 |
| Behavioral |
online health management program |
1 |
2015 |
| Other |
online mindfulness training |
1 |
2016 |
| Behavioral |
online support decision tool |
1 |
2018 |
| Other |
online symptom management |
1 |
2016 |
| Dietary Supplement |
ons post-op |
1 |
2020 |
| Dietary Supplement |
ons post-op 3 months |
1 |
2020 |
| Dietary Supplement |
ons pre-op |
1 |
2020 |
| Dietary Supplement |
ons pre-op / ons post-op |
1 |
2020 |
| Dietary Supplement |
ons pre-op / ons post-op / ons post-op 3 months |
1 |
2020 |
| Biological |
ont-10, varlilumab combination |
1 |
2014 |
| Biological |
ontak |
1 |
2007 |
| Procedure |
oocyte |
1 |
2016 |
| Procedure |
oocyte/embryo freezing |
1 |
2016 |
| Drug |
opc |
1 |
2017 |
| Drug |
open label phase with conventional 10mg everolimus dosing week 4-24 |
1 |
2015 |
| Device |
operative gamma camera |
1 |
2006 |
| Procedure |
opioid-free general anesthesia |
1 |
2019 |
| Drug |
opioids |
1 |
2007 |
| Other |
opportunistic breast cancer screening |
1 |
2015 |
| Biological |
opt-821(30 î¼g |
1 |
2012 |
| Biological |
opt-822 |
1 |
2012 |
| Biological |
opt-822/opt-821(30 î¼g/100 î¼g) |
1 |
2012 |
| Other |
optibra study |
1 |
2019 |
| Device |
optical imaging |
1 |
2008 |
| Device |
optical tomography using near infrared diffused light assisted with ultrasound |
1 |
2016 |
| Device |
optiflow |
1 |
2019 |
| Device |
optiflow/ventilator |
1 |
2019 |
| Other |
option grid |
1 |
2017 |
| Other |
optional acupuncture |
1 |
2019 |
| Procedure |
optional biopsy |
1 |
2014 |
| Procedure |
optional research biopsy |
1 |
2016 |
| Device |
optonuclear probe |
1 |
2016 |
| Drug |
or dexamethasone) |
1 |
2015 |
| Biological |
or rp2d dose |
1 |
2019 |
| Drug |
oral capsule of q-122 |
1 |
2019 |
| Drug |
oral capsules talazoparib |
1 |
2018 |
| Drug |
oral etoposide |
1 |
2017 |
| placebo |
oral lactose placebo |
1 |
2012 |
| Drug |
oral lbh589 |
1 |
2008 |
| Procedure |
oral management |
1 |
2015 |
| Drug |
oral n-acetylcysteine |
1 |
2013 |
| Drug |
oral paclitaxel |
1 |
2017 |
| Drug |
orteronel |
1 |
2013 |
| Drug |
osimertinib |
1 |
2015 |
| Procedure |
osteopathic technique |
1 |
2016 |
| Other |
osteopathy sessions |
1 |
2015 |
| Radiation |
other single-entry intracavitary device |
1 |
2005 |
| Drug |
ots167po |
1 |
2016 |
| Device |
outcomes4me mobile app |
1 |
2020 |
| Other |
ovarian function suppression |
1 |
2017 |
| Other |
ovarian function suppression/ablation |
1 |
2017 |
| Other |
ovarian ultrasound scan |
1 |
2018 |
| Drug |
oxaliplatin / 5-fluorouracil (5fu) / leucovorin (calcium folinate/folinic acid) |
1 |
2016 |
| Drug |
oxidative phosphorylation inhibitor iacs-010759 |
1 |
2017 |
| Drug |
oxybutynin chloride |
1 |
2016 |
| Biological |
p10s-padre with montanideâ„¢ isa 51 vg |
1 |
2016 |
| Biological |
p53 peptide vaccine |
1 |
2001 |
| Other |
pa intervention |
1 |
2017 |
| Drug |
pac-cb |
1 |
2017 |
| Drug |
packed rbc transfusion |
1 |
2006 |
| Drug |
paclitaxel (ptx) |
1 |
2019 |
| Drug |
paclitaxel (taxol) |
1 |
2008 |
| Drug |
paclitaxel (x) |
1 |
2018 |
| Drug |
paclitaxel / atezolizumab |
1 |
2013 |
| Drug |
paclitaxel / everolimus (rad001) |
1 |
2007 |
| Combination Product |
paclitaxel / gemcitabine |
1 |
2019 |
| Drug |
paclitaxel / pazopanib |
1 |
2009 |
| Drug |
paclitaxel 80 mg/m2 |
1 |
2012 |
| Drug |
paclitaxel 80 mg/m2 weekly |
1 |
2011 |
| Drug |
paclitaxel 80mg |
1 |
2018 |
| Drug |
paclitaxel 80mg/m^2 |
1 |
2018 |
| Drug |
paclitaxel 80mg/m^2/docetaxel 75mg/m^2 |
1 |
2018 |
| Drug |
paclitaxel albumin nanoparticle for injectable suspension |
1 |
2005 |
| Drug |
paclitaxel cisplatin |
1 |
2010 |
| Other |
paclitaxel followed by doxorubicin |
1 |
2004 |
| Drug |
paclitaxel only |
1 |
2017 |
| Drug |
paclitaxel poliglumex |
1 |
2005 |
| Drug |
paclitaxel protein-bound particles for injectable suspension (albumin-bound) |
1 |
2005 |
| Drug |
paclitaxel weekly in combination with capecitabine |
1 |
2005 |
| Drug |
paclitaxel(with carbo) |
1 |
2020 |
| Drug |
paclitaxel) |
1 |
2007 |
| Drug |
paclitaxel) phase i |
1 |
2017 |
| Drug |
paclitaxel) phase ii |
1 |
2017 |
| Drug |
paclitaxel, 90 mg |
1 |
2006 |
| Drug |
paclitaxel, 90 mg/m^2 / bevacizumab, 10 mg/kg |
1 |
2006 |
| Drug |
paclitaxel, bevacizumab, liposomal doxorubicin, capecitabine |
1 |
2010 |
| Drug |
paclitaxel, carboplatin |
1 |
2010 |
| Drug |
paclitaxel, carboplatinum, doxorubicin, endoxan, capecitabine |
1 |
2013 |
| Drug |
paclitaxel, cisplatin |
1 |
2017 |
| Drug |
paclitaxel, gemcitabine, lapatinib |
1 |
2010 |
| Drug |
paclitaxel, trastuzumab |
1 |
2008 |
| Drug |
paclitaxel, trastuzumab/carboplatin |
1 |
2008 |
| Drug |
paclitaxel,gemcitabine,sunitinib |
1 |
2010 |
| Drug |
paclitaxel. |
1 |
2018 |
| Drug |
paclitaxel/anthracycline |
1 |
2009 |
| Drug |
paclitaxel/carboplatin |
1 |
2016 |
| Drug |
paclitaxel/epirubicin |
1 |
2015 |
| Drug |
paclitaxel/gemcitabine/trastuzumab |
1 |
2007 |
| Drug |
paclitaxel/reparixin |
1 |
2013 |
| Drug |
paclitaxel/sorafenib |
1 |
2011 |
| Drug |
paclitaxel/trastuzumab |
1 |
2011 |
| Drug |
paclitaxel/with carboplatin followed by epirubicin/cyclophosphamide |
1 |
2019 |
| Behavioral |
padi |
1 |
2015 |
| Behavioral |
pai |
1 |
2015 |
| Behavioral |
pain assessment |
1 |
2015 |
| Procedure |
pain therapy |
1 |
1999 |
| Drug |
palbociclib (if lack of response to endocrine therapy alone) |
1 |
2015 |
| Drug |
palbociclib / chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen) |
1 |
2017 |
| Drug |
palbociclib / letrozole |
1 |
2019 |
| Drug |
palbociclib / letrozole/fulvestrant |
1 |
2016 |
| Drug |
palbociclib / taselisib / pictilisib |
1 |
2015 |
| Drug |
palbociclib 75mg |
1 |
2018 |
| Drug |
palbociclib pd-0332991 |
1 |
2013 |
| Drug |
palifosfamide |
1 |
2012 |
| Behavioral |
palliative |
1 |
2016 |
| Radiation |
palliative radiation therapy |
1 |
2010 |
| Radiation |
palliative radiotherapy |
1 |
2017 |
| Procedure |
palliative surgery |
1 |
2010 |
| Other |
palliative treatment |
1 |
2019 |
| Behavioral |
palliative/oncology care |
1 |
2016 |
| Drug |
palonosetron |
1 |
2018 |
| Drug |
pamidronate disodium |
1 |
2000 |
| Drug |
pamiparib |
1 |
2017 |
| Drug |
panagen |
1 |
2014 |
| Biological |
panvac-f |
1 |
2005 |
| Biological |
panvac-v |
1 |
2005 |
| Procedure |
paper decision board |
1 |
2005 |
| Other |
paper drug diary |
1 |
2019 |
| Device |
papillon |
1 |
2017 |
| Device |
papillon /tm |
1 |
2017 |
| Other |
paracetamol (drug analgesic class1) |
1 |
2019 |
| Drug |
paracetamol 1,5 g |
1 |
2017 |
| Drug |
paraplatinâ® |
1 |
2014 |
| Procedure |
paravertebral blocks |
1 |
2019 |
| Other |
paravertebral group |
1 |
2017 |
| Drug |
paricalcitol |
1 |
2008 |
| Drug |
parp inhibitor 2x-121 |
1 |
2018 |
| Drug |
parp inhibitor included therapy |
1 |
2019 |
| Drug |
part a: azd8186 monotherapy |
1 |
2013 |
| Drug |
part b: azd8186 monotherapy |
1 |
2013 |
| Drug |
part c1: abiraterone acetate combination with azd8186 |
1 |
2013 |
| Drug |
part c2: abiraterone acetate combination with azd8186 |
1 |
2013 |
| Drug |
part d1: azd2014 combination with azd8186 |
1 |
2013 |
| Drug |
part d2 azd2014 combination with azd8186 |
1 |
2013 |
| Radiation |
partial breast irradiation (pbi) |
1 |
2006 |
| Radiation |
partial breast irradiation prior to surgery |
1 |
2019 |
| Radiation |
partial breast irradiation using 32 gy |
1 |
2008 |
| Radiation |
partial breast irradiation using 32 gy / 8 fractions |
1 |
2008 |
| Radiation |
partial breast irradiation using 36 gy |
1 |
2008 |
| Radiation |
partial breast irradiation using 36 gy / 9 fractions |
1 |
2008 |
| Radiation |
partial breast irradiation using 40 gy |
1 |
2008 |
| Radiation |
partial breast irradiation using 40 gy /10 fractions |
1 |
2008 |
| Procedure |
partial mastectomy/additional shave margin |
1 |
2016 |
| Procedure |
partial submuscular coverage |
1 |
2014 |
| Behavioral |
participant choice |
1 |
2015 |
| Procedure |
participants receive slnb as well as non slns resection |
1 |
2019 |
| Behavioral |
partner-assisted coping skills training |
1 |
2016 |
| Behavioral |
partner-assisted tailored intervention |
1 |
2008 |
| Drug |
pasireotide |
1 |
2011 |
| Drug |
patent blue v dye |
1 |
2003 |
| Behavioral |
patient-participation aid |
1 |
2013 |
| Other |
patient-reported outcomes measurement information system (promis)-depression |
1 |
2017 |
| Other |
patient-reported outcomes measurement information system (promis)-physical function |
1 |
2017 |
| Device |
patient activated controlled expansion device |
1 |
2009 |
| Behavioral |
patient assistance |
1 |
2005 |
| Behavioral |
patient decision aid |
1 |
2018 |
| Behavioral |
patient navigated latinas |
1 |
2014 |
| Other |
patient navigation |
1 |
2008 |
| Behavioral |
patient navigator matched with subject |
1 |
2012 |
| Behavioral |
patient preference in treatment decision making |
1 |
2017 |
| Other |
patient questionaires |
1 |
2014 |
| Behavioral |
patient reported outcome (pro) |
1 |
2018 |
| Behavioral |
patient reported outcomes |
1 |
2020 |
| Other |
patient to receive standard care without acupuncture |
1 |
2007 |
| Other |
patient to receive standard care without acupuncture/sham acupuncture. |
1 |
2007 |
| Procedure |
patients receive slnb |
1 |
2016 |
| Other |
patients with invasive breast cancer will receive: |
1 |
2018 |
| Other |
patientslikeme (plm) |
1 |
2015 |
| Drug |
patritumab |
1 |
2009 |
| Drug |
patritumab/trastuzumab |
1 |
2009 |
| Device |
paxman scalp cooler |
1 |
2019 |
| Drug |
pazopanib (gw786034) |
1 |
2008 |
| Drug |
pazopanib (gw786034) 400 mg |
1 |
2006 |
| Drug |
pazopanib (gw786034) 800 mg |
1 |
2006 |
| Drug |
pazopanib hydrochloride |
1 |
2007 |
| Drug |
pazopanib monotherapy |
1 |
2009 |
| Drug |
pazopanib/capecitabine |
1 |
2011 |
| Radiation |
pbi radiotherapy 6 gy |
1 |
2014 |
| Radiation |
pbi radiotherapy 8 gy |
1 |
2014 |
| Other |
pbi with concurrent chemotherapy |
1 |
2013 |
| Radiation |
pbi with sequential chemotherapy |
1 |
2013 |
| Behavioral |
pco plus |
1 |
2016 |
| Drug |
pd-0332991 (palbociclib) |
1 |
2016 |
| Drug |
pd-0332991/t-dm1 |
1 |
2013 |
| Drug |
pd 0332991 |
1 |
2008 |
| Drug |
pdr001 |
1 |
2017 |
| Procedure |
pecs |
1 |
2019 |
| Drug |
pecs-1 |
1 |
2019 |
| Procedure |
pecs ii block |
1 |
2017 |
| Procedure |
pecsii |
1 |
2019 |
| Procedure |
pecsii/paravertebral blocks |
1 |
2019 |
| Behavioral |
pedometer intervention |
1 |
2013 |
| Behavioral |
peer-led |
1 |
2006 |
| Behavioral |
peer support program |
1 |
2011 |
| Drug |
pegcyte |
1 |
2017 |
| Biological |
pegfilgastrim |
1 |
2017 |
| Drug |
pegylated irinotecan |
1 |
2014 |
| Drug |
pegylated liposomal doxorubicin (pld) |
1 |
2018 |
| Drug |
pegylated liposomal doxorubicin (sch 200746) |
1 |
2005 |
| Drug |
pegylated liposomal doxorubicin/docetaxel |
1 |
2017 |
| Drug |
pegylated lyposomal doxorubicin |
1 |
2008 |
| Drug |
pegylated rhg-csf 100î¼g |
1 |
2014 |
| Drug |
pegylated rhg-csf 100î¼g/kg |
1 |
2014 |
| Drug |
pegylated rhg-csf: 6mg |
1 |
2012 |
| Drug |
pegylated rhg-csf:150 î¼g |
1 |
2014 |
| Drug |
pegylated rhg-csf:150 î¼g/kg |
1 |
2014 |
| Biological |
pelareorep |
1 |
2019 |
| Procedure |
pelvic ultrasound |
1 |
2018 |
| Procedure |
pem breast biopsy |
1 |
2009 |
| Drug |
pembrolizumab - 4 cycle |
1 |
2009 |
| Drug |
pembrolizumab - 8 cycle |
1 |
2009 |
| Drug |
pembrolizumab (200mg iv for 30 minutes |
1 |
2019 |
| Biological |
pembrolizumab (k) |
1 |
2018 |
| Drug |
pembrolizumab (keytruda) |
1 |
2010 |
| Drug |
pembrolizumab 100 mg in 4 ml injection |
1 |
2017 |
| Drug |
pembrolizumab combination |
1 |
2018 |
| Drug |
pembrolizumab injection |
1 |
2018 |
| Drug |
pembrolizumab/ exemestane/ leuprolide |
1 |
2016 |
| Drug |
pemetrexed disodium |
1 |
2000 |
| Device |
penguin cold caps |
1 |
2017 |
| Drug |
pentoxifylline |
1 |
2001 |
| Drug |
pepcid |
1 |
2015 |
| Drug |
peptide natriurã©tique de type b |
1 |
2012 |
| Procedure |
percutaneous removal |
1 |
2007 |
| Procedure |
percutaneous removal/margin ablation |
1 |
2007 |
| Drug |
perflutren protein-type a microspheres injectable suspension |
1 |
2014 |
| Drug |
perifosine |
1 |
2003 |
| Drug |
perillyl alcohol |
1 |
1999 |
| Drug |
perioperative chemotherapy |
1 |
2006 |
| Biological |
peripheral blood lymphocyte therapy |
1 |
1999 |
| Procedure |
peripheral blood progenitor cell |
1 |
1999 |
| Genetic |
peripheral blood progenitor cells carrying mdr1 |
1 |
1999 |
| Other |
peritumoral adipose tissue sample |
1 |
2018 |
| Drug |
perjeta |
1 |
2017 |
| Drug |
perjeta injectable product |
1 |
2017 |
| Radiation |
permanent breast seeds implant |
1 |
2010 |
| Device |
peroperative scintillating probe |
1 |
2006 |
| Other |
personalized breast reconstruction surgery decision aid |
1 |
2019 |
| Behavioral |
personalized health care service |
1 |
2017 |
| Biological |
personalized polyepitope dna vaccine |
1 |
2015 |
| Biological |
personalized synthetic long peptide vaccine (poly iclc) |
1 |
2015 |
| Behavioral |
personalized web intervention arm |
1 |
2017 |
| Behavioral |
personally-valued |
1 |
2013 |
| placebo |
pertuzumab-placebo |
1 |
2010 |
| Drug |
pertuzumab / trastuzumab |
1 |
2012 |
| Drug |
pertuzumab / trastuzumab / metronomic chemotherapy |
1 |
2012 |
| Drug |
pertuzumab 420 mg |
1 |
2009 |
| Drug |
pertuzumab 840 mg iv saturation, then 420 mg iv (selected her2 positive patients only) |
1 |
2016 |
| Drug |
pertuzumab 840mg |
1 |
2018 |
| Drug |
pertuzumab 840mg/420mg |
1 |
2018 |
| Drug |
pertuzumab in combination with trastuzumab |
1 |
2011 |
| Drug |
pertuzumab in combination with trastuzumab/paclitaxel |
1 |
2011 |
| Drug |
pertuzumab/trastuzumab |
1 |
2009 |
| Drug |
pertuzumab/trastuzumab fdc sc |
1 |
2018 |
| Procedure |
pet (positron emission tomography) |
1 |
2005 |
| Diagnostic Test |
pet ct |
1 |
2020 |
| Radiation |
pet imaging with cu-64 labeled trastuzumab |
1 |
2008 |
| Other |
pet with fdg |
1 |
2016 |
| Device |
pet/ct |
1 |
2015 |
| Radiation |
pet/ct imaging |
1 |
2013 |
| Device |
pet/ct scan |
1 |
2014 |
| Drug |
pf-01367338) |
1 |
2008 |
| Drug |
pf-06804103 |
1 |
2017 |
| Drug |
pf-06873600 |
1 |
2018 |
| Biological |
pf-06936308 |
1 |
2018 |
| Drug |
pf-06952229 |
1 |
2018 |
| Drug |
pf-3512676 |
1 |
2002 |
| Behavioral |
pharmacist’s behavioral intervention |
1 |
2016 |
| Other |
pharmacodynamic study |
1 |
2017 |
| Other |
pharmacogenomic study |
1 |
2015 |
| Other |
pharmacological studies |
1 |
2013 |
| Drug |
phase ll) |
1 |
2011 |
| Drug |
phenelzine sulfate |
1 |
2018 |
| Drug |
phenergan |
1 |
2015 |
| Device |
philips sonalleve mr-hifu breast tumor therapy system |
1 |
2015 |
| Device |
philips sonalleveâ® mr-hifu breast therapy system |
1 |
2018 |
| Behavioral |
phone |
1 |
2016 |
| Other |
phone-based system |
1 |
2010 |
| Behavioral |
phone call |
1 |
2014 |
| Other |
phone questionnaires |
1 |
2015 |
| Biological |
phosphate-buffered saline (pbs) |
1 |
2018 |
| Biological |
phosphate buffer saline (pbs) |
1 |
2012 |
| Procedure |
photoacoustic imaging |
1 |
2019 |
| Device |
photobiomodulation |
1 |
2019 |
| Device |
photobiomodulation therapy (pbmt) |
1 |
2019 |
| Radiation |
photon beam radiation therapy |
1 |
2017 |
| Behavioral |
physical activity coaching calls |
1 |
2019 |
| Behavioral |
physical activity/dietary change |
1 |
2008 |
| Other |
physical exercise program |
1 |
2019 |
| Other |
physical performance testing |
1 |
2018 |
| Procedure |
physical therapya |
1 |
2013 |
| Procedure |
physical therapyb |
1 |
2013 |
| Drug |
physician’s-choice |
1 |
2013 |
| Drug |
physician’s choice chemotherapy |
1 |
2013 |
| Behavioral |
physio,pain,psychotherapy;social,nutrit.counselling&sports |
1 |
2005 |
| Dietary Supplement |
phytomedâ„¢ |
1 |
2013 |
| Drug |
pi3k-beta inhibitor gsk2636771 |
1 |
2015 |
| Drug |
pi3kbeta inhibitor azd8186 |
1 |
2017 |
| Other |
picture option grid |
1 |
2017 |
| Other |
pilates |
1 |
2017 |
| Drug |
pilocarpine hydrochloride |
1 |
2006 |
| Drug |
pipac with abraxane |
1 |
2017 |
| Other |
pittsburgh sleep quality index |
1 |
2016 |
| Drug |
pixantrone dimaleate |
1 |
2010 |
| placebo |
placebo (for enzalutamide) |
1 |
2013 |
| placebo |
placebo (melatonin) |
1 |
2013 |
| placebo |
placebo (p) |
1 |
2018 |
| placebo |
placebo (vitamin d) |
1 |
2013 |
| placebo |
placebo 15 |
1 |
2005 |
| Drug |
placebo 15/tac |
1 |
2005 |
| placebo |
placebo 7.5 |
1 |
2005 |
| Drug |
placebo 7.5/docetaxel, doxorubicin,/cyclophosphamide (tac) |
1 |
2005 |
| placebo |
placebo administered with either exemestane |
1 |
2008 |
| placebo |
placebo auriculotherapy |
1 |
2017 |
| placebo |
placebo control |
1 |
2019 |
| placebo |
placebo dlbs1425 |
1 |
2011 |
| placebo |
placebo excipient |
1 |
2016 |
| placebo |
placebo for abt-869 |
1 |
2008 |
| placebo |
placebo for atezolizumab |
1 |
2019 |
| placebo |
placebo for ipatasertib |
1 |
2019 |
| placebo |
placebo formulation |
1 |
2020 |
| placebo |
placebo gel |
1 |
2009 |
| placebo |
placebo mld |
1 |
2015 |
| placebo |
placebo pill |
1 |
2015 |
| placebo |
placebo pills of radium bromatum |
1 |
2018 |
| placebo |
placebo sessions |
1 |
2012 |
| placebo |
placebo tab |
1 |
2015 |
| placebo |
placebo tablets |
1 |
2019 |
| placebo |
placebo text message |
1 |
2016 |
| placebo |
placebo to bevacizumab |
1 |
2006 |
| placebo |
placebo treatment |
1 |
2019 |
| placebo |
placebo vaginal lubricant |
1 |
2009 |
| placebo |
placebo, trastuzumab, docetaxel |
1 |
2019 |
| Drug |
placebo/celecoxib 400 mg/cholecalciferol 400 iu/cholecalciferol 2,000 iu |
1 |
2013 |
| Dietary Supplement |
placebo/soy protein |
1 |
2010 |
| Other |
placebo/tamoxifen |
1 |
2010 |
| Dietary Supplement |
placebo/vitamin e |
1 |
2004 |
| Other |
plasma |
1 |
2016 |
| Other |
plasma soluble tnf receptor pulldown |
1 |
2019 |
| Other |
plasma soluble tnf receptor pulldown / chemotherapy |
1 |
2019 |
| Other |
plasma/buffy coat |
1 |
2016 |
| Device |
plasmablade 3.0s |
1 |
2018 |
| Procedure |
plastic surgery |
1 |
2016 |
| Combination Product |
platelet rich plasma |
1 |
2018 |
| Drug |
platinum based chemotherapies |
1 |
2014 |
| Drug |
pld |
1 |
2019 |
| Drug |
pld, cyclophosphamide, trastuzumab, paclitaxel |
1 |
2007 |
| Other |
pliates method treatment |
1 |
2019 |
| Drug |
pm01183 |
1 |
2012 |
| Drug |
pmd-026 |
1 |
2019 |
| Behavioral |
pn |
1 |
2014 |
| Behavioral |
pn usual |
1 |
2014 |
| Behavioral |
pn/ |
1 |
2014 |
| Biological |
pngvl3-hicd vaccine |
1 |
2007 |
| Other |
point of service delivery model |
1 |
2019 |
| Drug |
pol6326 |
1 |
2013 |
| Behavioral |
polyamine-free diet |
1 |
2006 |
| Genetic |
polygenic risk score |
1 |
2015 |
| Genetic |
polymorphism analysis |
1 |
2006 |
| Dietary Supplement |
polyphenol |
1 |
2018 |
| Drug |
polyphenon e |
1 |
2008 |
| Diagnostic Test |
polysomnography (easy ambulatory 2 cadwell, kennewick, wa) |
1 |
2016 |
| Diagnostic Test |
polysomnography (psg) |
1 |
2017 |
| Device |
port |
1 |
2015 |
| Device |
position device |
1 |
2013 |
| Behavioral |
positive online psychotherapy |
1 |
2016 |
| Behavioral |
positive psychotherapy |
1 |
2016 |
| Device |
positron emission mammography (pem) |
1 |
2010 |
| Procedure |
positron emission mammography (pem) when available |
1 |
2013 |
| Device |
positron emission tomography pet |
1 |
2016 |
| Device |
positron emission tomography pet/ct |
1 |
2016 |
| Diagnostic Test |
positron emission tomography/computed tomography |
1 |
2013 |
| Device |
positron emission tomography/x-ray computed tomography |
1 |
2016 |
| Other |
possibly one additional visit for an fdg-pet |
1 |
2019 |
| Drug |
post-operative adjuvant therapy |
1 |
2008 |
| Procedure |
post-treatment volume margin resection |
1 |
2018 |
| Radiation |
post mastectomy radiation therapy |
1 |
2016 |
| Device |
post mastectomy ultrasound |
1 |
2015 |
| Procedure |
post procedure mammogram |
1 |
2007 |
| Drug |
post radiotherapy commencement of anastrozole |
1 |
2009 |
| Procedure |
post therapy surgery |
1 |
2017 |
| Procedure |
postoperative analgesia |
1 |
2019 |
| Radiation |
postoperative radiotherapy breast |
1 |
2015 |
| Radiation |
postoperative radiotherapy breast/chest wall / regional lymph nodes |
1 |
2015 |
| Behavioral |
power-remote |
1 |
2013 |
| Drug |
poziotinib hydrochloride |
1 |
2019 |
| Drug |
pqr309 |
1 |
2015 |
| Drug |
pralatrexate injection |
1 |
2010 |
| Biological |
prame |
1 |
2007 |
| Drug |
prasterone |
1 |
2011 |
| Behavioral |
prayer |
1 |
2007 |
| Behavioral |
pre-consultation educational group intervention |
1 |
2016 |
| Drug |
pre-medication: decadron |
1 |
2015 |
| Drug |
pre-medication: zofran |
1 |
2015 |
| Drug |
pre-radiotherapy commencement of anastrozole |
1 |
2009 |
| Procedure |
pre-treatment volume margin resection |
1 |
2018 |
| Drug |
pre operativetrastuzumab |
1 |
2007 |
| Drug |
pre treatment recurrence score:18-25 letrozole |
1 |
2019 |
| Drug |
pre treatment recurrence score:18-25 letrozole / palbociclib |
1 |
2019 |
| Drug |
pre treatment recurrence score:26-100 letrozole |
1 |
2019 |
| Drug |
pre treatment recurrence score:26-100 letrozole / palbociclib |
1 |
2019 |
| Behavioral |
precam |
1 |
2020 |
| Behavioral |
prehabilitation education |
1 |
2018 |
| Drug |
premedication |
1 |
2013 |
| Dietary Supplement |
preop |
1 |
2019 |
| Biological |
preop chemo |
1 |
2013 |
| Drug |
preoperative chemotherapy |
1 |
2020 |
| Drug |
preoperative dose intense chemotherapy (flac |
1 |
1999 |
| Drug |
preoperative dose intense chemotherapy (flac/g-csf) |
1 |
1999 |
| Procedure |
preoperative sentinel lymph node identification |
1 |
2010 |
| Procedure |
preoperative sentinel lymph node identification/marking |
1 |
2010 |
| Other |
pressotherapy |
1 |
2017 |
| Procedure |
prevention |
1 |
2006 |
| Other |
preventive intervention |
1 |
2016 |
| Procedure |
primary surgery |
1 |
2007 |
| Behavioral |
print-based education |
1 |
2016 |
| Procedure |
pro onc assay |
1 |
2010 |
| Procedure |
pro onc assay/treatment |
1 |
2010 |
| Other |
pro sub-study |
1 |
2015 |
| Other |
proactive telephone toxicity management |
1 |
2015 |
| Dietary Supplement |
probiotic |
1 |
2017 |
| Dietary Supplement |
probiotics |
1 |
2012 |
| Behavioral |
problem-solving (ba |
1 |
2010 |
| Behavioral |
problem solving intervention |
1 |
2019 |
| Drug |
prochlorperazine |
1 |
2017 |
| Drug |
progestins |
1 |
1999 |
| Other |
progressive relaxation exercises |
1 |
2019 |
| Behavioral |
progressive stretching |
1 |
2010 |
| Behavioral |
progressive stretching group |
1 |
2011 |
| Behavioral |
project connect online |
1 |
2016 |
| Drug |
promensil |
1 |
2018 |
| Drug |
promestriene |
1 |
2019 |
| Drug |
prometrium |
1 |
2018 |
| Behavioral |
prompt-sheet |
1 |
2011 |
| Behavioral |
prompts to report adherence |
1 |
2018 |
| Behavioral |
prompts to report adherence/symptoms via study app |
1 |
2018 |
| Behavioral |
prompts to report symptoms via study app |
1 |
2016 |
| Behavioral |
prone positioning |
1 |
2009 |
| Device |
prone radiotherapy |
1 |
2017 |
| Other |
prone to supine mri |
1 |
2018 |
| Behavioral |
prone/supine position |
1 |
2009 |
| Radiation |
prophylactic cranial irradiation |
1 |
2009 |
| Drug |
prophylactic loperamide |
1 |
2016 |
| Radiation |
prophylactic nipple-areolar complex rt |
1 |
2010 |
| Radiation |
prophylactic radiation to the contralateral breast |
1 |
2007 |
| Drug |
propofol group |
1 |
2015 |
| Drug |
propranolol |
1 |
2013 |
| Drug |
propranolol hydrochloride |
1 |
2013 |
| Device |
prosigna |
1 |
2016 |
| Behavioral |
prosocial online support group |
1 |
2011 |
| Behavioral |
prospect |
1 |
2015 |
| Behavioral |
prospective surveillance group |
1 |
2016 |
| Genetic |
proteomic profiling |
1 |
2008 |
| Radiation |
proton |
1 |
2015 |
| Radiation |
proton accelerated partial breast irradiation |
1 |
2019 |
| Radiation |
proton apbi |
1 |
2015 |
| Radiation |
proton beam radiotherapy |
1 |
2011 |
| Radiation |
proton radiation |
1 |
2011 |
| Radiation |
proton radiation therapy |
1 |
2007 |
| Radiation |
proton therapy |
1 |
2013 |
| Device |
provide a saliva sample for genetic testing |
1 |
2015 |
| Drug |
proxalutamide |
1 |
2019 |
| Behavioral |
ps) |
1 |
2010 |
| Drug |
pseudomonas aeruginosa combination |
1 |
2011 |
| Biological |
psma |
1 |
2007 |
| Biological |
psma/prame |
1 |
2007 |
| Behavioral |
psycho-education |
1 |
2018 |
| Behavioral |
psychoeducation |
1 |
2019 |
| Behavioral |
psychoeducation group |
1 |
2015 |
| Behavioral |
psychoeducative |
1 |
2006 |
| Procedure |
psychologic distress |
1 |
2006 |
| Behavioral |
psychological intervention |
1 |
2011 |
| Behavioral |
psychosexual intervention |
1 |
2013 |
| Behavioral |
psychosocial intervention |
1 |
2014 |
| Behavioral |
psychosocial intervention for couples |
1 |
2009 |
| Behavioral |
psychosocial rehabilitation course |
1 |
2010 |
| Behavioral |
psychosocial support |
1 |
2010 |
| Drug |
ptc |
1 |
2013 |
| Drug |
ptc-pz |
1 |
2019 |
| Drug |
ptc/pertuzumab |
1 |
2013 |
| Drug |
ptc299 |
1 |
2007 |
| Drug |
pth followed by dose dense ac of fec |
1 |
2011 |
| Drug |
ptk7-adc |
1 |
2017 |
| Drug |
ptk787 |
1 |
2005 |
| Drug |
pu-h71 |
1 |
2017 |
| Biological |
pumvc3-igfbp2-her2-igf1r plasmid dna vaccine |
1 |
2016 |
| Behavioral |
purpose project |
1 |
2017 |
| Drug |
pv-10 (rose bengal disodium 10%) |
1 |
2005 |
| Drug |
pvb protocol |
1 |
2019 |
| Biological |
pvsripo |
1 |
2018 |
| Drug |
pwcb |
1 |
2016 |
| Drug |
pwo |
1 |
2016 |
| Drug |
pyrotinib maleate |
1 |
2020 |
| Drug |
pyrotinib maleate tablets |
1 |
2019 |
| Drug |
pyrotinib maleate/letrozole |
1 |
2020 |
| Drug |
pyrotinib with capecitabine |
1 |
2019 |
| Drug |
pyrotinib, trastuzumab, docetaxel |
1 |
2019 |
| Drug |
pyrotinib/capecitabine |
1 |
2017 |
| Drug |
pyrotinib/fulvestrant |
1 |
2019 |
| Drug |
pyrotinib/trastuzumab/docetaxel/carboplatin |
1 |
2018 |
| Drug |
pyrotinib/vinorelbine |
1 |
2019 |
| Drug |
pyrotinib/with fulvestrant |
1 |
2019 |
| Drug |
qbx258 |
1 |
2015 |
| Other |
qigong mind-body exercise |
1 |
2016 |
| Other |
qst |
1 |
2015 |
| Procedure |
quadrantectomy |
1 |
2009 |
| Procedure |
quadrantectomy / sentinel node biopsy |
1 |
2009 |
| Procedure |
quadrantectomy/axillary dissection |
1 |
2009 |
| Other |
quality of life assessments |
1 |
2018 |
| Other |
quality of life in metastatic bc |
1 |
2018 |
| Behavioral |
quality of life pathway |
1 |
2020 |
| Behavioral |
quantitative genetic counseling |
1 |
2020 |
| Drug |
quantum dots coated with veldoreotide |
1 |
2019 |
| Behavioral |
questionnaire t1 to fill |
1 |
2016 |
| Behavioral |
questionnaire t2 to fill |
1 |
2016 |
| Behavioral |
questionnaire t3 to fill |
1 |
2016 |
| Behavioral |
questionnaire t4 to fill |
1 |
2016 |
| Behavioral |
questionnaire t5 to fill |
1 |
2016 |
| Procedure |
quilting |
1 |
2019 |
| Procedure |
quilting suture without drainage |
1 |
2014 |
| Drug |
r |
1 |
2019 |
| Behavioral |
r-cbsm |
1 |
2019 |
| Drug |
ra-223 dichloride |
1 |
2015 |
| Drug |
rad001 / bez235 |
1 |
2011 |
| Drug |
rad001, letrozole 2.5mg |
1 |
2005 |
| Drug |
rad140 |
1 |
2017 |
| Drug |
rad1901 |
1 |
2016 |
| Radiation |
radiation as adjuvant therapy for breast cancer |
1 |
2016 |
| Radiation |
radiation therapy brain metastasis in breast cancer |
1 |
2013 |
| Radiation |
radiation therapy with concurrent paclitaxel |
1 |
2008 |
| Radiation |
radical radiotherapy |
1 |
2019 |
| Procedure |
radical resection |
1 |
2019 |
| Procedure |
radio guided occult lesion localisation |
1 |
2007 |
| Device |
radioactive iodine seed |
1 |
2016 |
| Procedure |
radioactive seed placement |
1 |
2014 |
| Procedure |
radiofrequency |
1 |
2005 |
| Procedure |
radiofrequency-guided localization |
1 |
2017 |
| Procedure |
radioguided seed localization for nonpalpable breast cancers |
1 |
2005 |
| Device |
radioisotope |
1 |
2013 |
| Other |
radiological criteria |
1 |
2011 |
| Other |
radiology |
1 |
2007 |
| Other |
radiology/mri scan |
1 |
2007 |
| Radiation |
radiomics on mri |
1 |
2019 |
| Radiation |
radiosurgery |
1 |
2009 |
| Radiation |
radiotherapy - arm a |
1 |
2018 |
| Radiation |
radiotherapy - arm b |
1 |
2018 |
| Radiation |
radiotherapy by prone |
1 |
2016 |
| Radiation |
radiotherapy by prone/decubitus |
1 |
2016 |
| Drug |
radium-223 chloride (bay88-8223) |
1 |
2010 |
| Drug |
radium bromatum |
1 |
2018 |
| Drug |
radium bromatum pills |
1 |
2018 |
| Drug |
radium bromatum/apis mellifica/belladonna pills |
1 |
2018 |
| Drug |
radium bromatum/apis mellifica/belladonna placebo pills |
1 |
2018 |
| Radiation |
radium ra 223 dichloride |
1 |
2019 |
| Drug |
raloxifene 30 mg oral tablet |
1 |
2008 |
| Drug |
raloxifene 30mg |
1 |
2008 |
| Drug |
raloxifene 60 mg oral tablet |
1 |
2008 |
| Drug |
raloxifene followed by combination therapy |
1 |
2005 |
| Drug |
ramipril |
1 |
2014 |
| Biological |
ramucirumab |
1 |
2010 |
| Biological |
ramucirumab dp |
1 |
2010 |
| Drug |
ranitidine |
1 |
2011 |
| Biological |
ras peptide cancer vaccine |
1 |
2001 |
| Procedure |
rate of remission |
1 |
2006 |
| Drug |
ravuconazole |
1 |
2003 |
| Drug |
rc48-adc |
1 |
2018 |
| Drug |
rc48-adc 1.5 mg |
1 |
2017 |
| Drug |
rc48-adc 1.5 mg/kg (her2 positive) |
1 |
2017 |
| Drug |
rc48-adc 2.0 mg |
1 |
2017 |
| Drug |
rc48-adc 2.0 mg/kg (her2 low expression) |
1 |
2017 |
| Drug |
rc48-adc 2.0 mg/kg (her2 positive) |
1 |
2017 |
| Drug |
rc48-adc 2.5 mg |
1 |
2017 |
| Drug |
rc48-adc 2.5 mg/kg (her2 positive) |
1 |
2017 |
| Behavioral |
re-patterning sitting time group |
1 |
2015 |
| Behavioral |
reach |
1 |
2016 |
| Behavioral |
reach plus |
1 |
2016 |
| Behavioral |
reach/message |
1 |
2016 |
| Behavioral |
reach/phone |
1 |
2016 |
| Drug |
rebastinib |
1 |
2016 |
| Other |
receive mobile app-based education |
1 |
2020 |
| Behavioral |
recent physical activity questionnaire |
1 |
2017 |
| Biological |
recombinant anti-her2 humanized monoclonal antibody conjugate for injection.r&d code: b003. |
1 |
2019 |
| Biological |
recombinant flt3 ligand |
1 |
2000 |
| Biological |
recombinant fowlpox gm-csf vaccine adjuvant |
1 |
2002 |
| Drug |
recombinant human erythropoietin |
1 |
2005 |
| Biological |
recombinant human thrombopoietin |
1 |
2000 |
| Biological |
recombinant interferon alfa |
1 |
1999 |
| Biological |
recombinant interleukin-11 |
1 |
1999 |
| Biological |
recombinant interleukin-3 |
1 |
2000 |
| Biological |
recombinant vaccinia-cea(6d)-tricom vaccine |
1 |
2003 |
| Procedure |
reconstruction with adm. |
1 |
2014 |
| Procedure |
reconstruction with implant |
1 |
2014 |
| Procedure |
reconstructive surgery |
1 |
2016 |
| Other |
rectal swab |
1 |
2019 |
| Diagnostic Test |
rectal thermistor 400 series |
1 |
2017 |
| Behavioral |
reduced energy diet |
1 |
2017 |
| Drug |
reduced glutathione |
1 |
2005 |
| Behavioral |
reduced sedentary time intervention (rsti) |
1 |
2016 |
| Behavioral |
reducing sitting time group |
1 |
2015 |
| Drug |
ref-08-038 |
1 |
2017 |
| Drug |
reference1613 |
1 |
2017 |
| Other |
reflexology |
1 |
2012 |
| Other |
reflexology sessions |
1 |
2012 |
| Drug |
regional analgesia |
1 |
2007 |
| Drug |
regional analgesia/propofol |
1 |
2007 |
| Radiation |
regional lymph nodes |
1 |
2015 |
| Radiation |
regional nodal irradiation |
1 |
2020 |
| Radiation |
regional nodal xrt |
1 |
2013 |
| Radiation |
regional radiation |
1 |
2000 |
| Drug |
regn3767 |
1 |
2009 |
| Other |
rehabilitation after breast cancer surgery |
1 |
2019 |
| Behavioral |
rehabilitation programme “getting better together” |
1 |
2009 |
| Other |
rehabilitation protocol |
1 |
2019 |
| Other |
rejection of mastectomy |
1 |
2016 |
| Behavioral |
relaxation acupressure |
1 |
2011 |
| Behavioral |
relaxation only |
1 |
2018 |
| Other |
relaxation program |
1 |
2010 |
| Behavioral |
relieving joint pain |
1 |
2019 |
| Behavioral |
relieving joint pain/improving ai adherence in older breast cancer survivors (rejoin) |
1 |
2019 |
| Drug |
remifemin |
1 |
2017 |
| Combination Product |
remifentanil-propofol mixture |
1 |
2019 |
| Drug |
remifentanil 50 microg |
1 |
2017 |
| Drug |
remifentanil 50 microg/ml |
1 |
2017 |
| Procedure |
removal of tumor |
1 |
2010 |
| Procedure |
removal of tumor/tissue |
1 |
2010 |
| Procedure |
remove tumor only |
1 |
2010 |
| Drug |
reolysin |
1 |
2012 |
| Procedure |
repetitive transcranial magnetic stimulation |
1 |
2018 |
| Drug |
replens |
1 |
2013 |
| Other |
report symptoms via web |
1 |
2010 |
| Other |
report symptoms via web/phone-based system |
1 |
2010 |
| Other |
reproductive health survivorship care plan (scpr) |
1 |
2016 |
| Procedure |
research blood draw |
1 |
2016 |
| Genetic |
research blood for germline dna |
1 |
2016 |
| Procedure |
research bone marrow (optional) |
1 |
2016 |
| Diagnostic Test |
research scan for gradient-echo spectroscopic imaging (gsi) |
1 |
2018 |
| Procedure |
research tumor biopsy |
1 |
2016 |
| Other |
resistance |
1 |
2015 |
| Behavioral |
resistance exercise training |
1 |
2005 |
| Behavioral |
resistance training - fixed schedule |
1 |
2016 |
| Behavioral |
resistance training - flexible schedule |
1 |
2016 |
| Other |
resistance/aerobic training |
1 |
2015 |
| Behavioral |
resistive training |
1 |
2016 |
| Drug |
retinoid 9cuab30 |
1 |
2016 |
| Behavioral |
rex condition first |
1 |
2020 |
| Genetic |
rexin-g |
1 |
2007 |
| Device |
rfid |
1 |
2018 |
| Device |
rfid localization |
1 |
2018 |
| Device |
rfid/wire localization |
1 |
2018 |
| Other |
rgct |
1 |
2008 |
| Drug |
rhenium sulfure |
1 |
2006 |
| Drug |
rhg-csf |
1 |
2016 |
| Drug |
rhg-csf 5 î¼g |
1 |
2014 |
| Drug |
rhg-csf 5 î¼g/kg/day |
1 |
2014 |
| Drug |
rhg-csf 5ug |
1 |
2012 |
| Drug |
rhg-csf 5ug/kg/day |
1 |
2012 |
| Drug |
rhomboid intercostal |
1 |
2020 |
| Other |
rhomboid intercostal block |
1 |
2020 |
| Drug |
rhomboid intercostal/subserratus plane block with local anesthetic |
1 |
2020 |
| Drug |
rhsa |
1 |
2017 |
| Drug |
rhsa/gcsf |
1 |
2017 |
| Drug |
rhumab vegf (bevacizumab) |
1 |
2005 |
| Drug |
rhus toxicodendron 9 ch |
1 |
2019 |
| Drug |
rhus toxicodendron 9 ch / ruta graveolens 5 ch (homeopathic granules) |
1 |
2019 |
| Drug |
ribociclib 200mg oral tablet |
1 |
2019 |
| Combination Product |
ribociclib/aromatase inhibitor/fulvestrant |
1 |
2018 |
| Drug |
ribociclib/letrozole |
1 |
2017 |
| Radiation |
riop-intrabeamâ® system |
1 |
2018 |
| Procedure |
risas |
1 |
2016 |
| Other |
risk based screening |
1 |
2018 |
| Drug |
ritonavir |
1 |
2009 |
| Drug |
rituximab |
1 |
1999 |
| Device |
robotic assisted nipple sparing mastectomy |
1 |
2019 |
| Device |
robotic assisted nipple sparing mastectomy (r-nsm) |
1 |
2019 |
| Procedure |
roll |
1 |
2013 |
| Drug |
ropivacaine 5 mg |
1 |
2017 |
| Drug |
ropivacaine 5 mg/ml, 35 ml |
1 |
2017 |
| Drug |
rosuvastatin |
1 |
2011 |
| Other |
routine exercises |
1 |
2014 |
| Drug |
rpma) |
1 |
2010 |
| Device |
rsi |
1 |
2018 |
| Radiation |
rt boost |
1 |
2017 |
| Radiation |
rte |
1 |
2018 |
| Drug |
rubitecan |
1 |
2000 |
| Drug |
rucaparib (co-338; formally ag-014699 |
1 |
2008 |
| Drug |
rucaparib (co-338; formally ag-014699/pf-01367338) |
1 |
2008 |
| Drug |
run-in (short pre-surgery course) of endocrine-targeted therapy |
1 |
2013 |
| Drug |
ruta graveolens 5 ch (homeopathic granules) |
1 |
2019 |
| Drug |
ruxolitinib phosphate |
1 |
2017 |
| Biological |
rv-df3 |
1 |
1999 |
| Biological |
rv-df3/muc1 |
1 |
1999 |
| Drug |
s-1 |
1 |
2007 |
| Drug |
s-equol |
1 |
2015 |
| Diagnostic Test |
s2d |
1 |
2017 |
| Radiation |
sabr |
1 |
2018 |
| Other |
safety testing |
1 |
2009 |
| Drug |
sagopilone (bay86-5302, zk 219477) |
1 |
2006 |
| Drug |
sagopilone (zk 219477) |
1 |
2006 |
| Other |
saliva testing |
1 |
2010 |
| Genetic |
salivary kit |
1 |
2012 |
| Drug |
sapacitabine |
1 |
2018 |
| Drug |
sar566658 (act14884) |
1 |
2016 |
| Drug |
saracatinib |
1 |
2007 |
| Drug |
satraplatin |
1 |
2005 |
| Drug |
sb3 (proposed trastuzumab biosimilar) |
1 |
2014 |
| Drug |
sbg (soluble beta-glucan) |
1 |
2007 |
| Device |
scalp cooling system |
1 |
2018 |
| Other |
scapular exercises |
1 |
2016 |
| Procedure |
scar massage. |
1 |
2005 |
| Drug |
sch 727965 |
1 |
2008 |
| Other |
scheduled worry practice |
1 |
2017 |
| Radiation |
scintimammography |
1 |
2016 |
| Diagnostic Test |
screen film mammography |
1 |
2001 |
| Other |
screening advice based on a basic risk assessment |
1 |
2015 |
| Other |
screening advice based on a comprehensive risk assessment |
1 |
2015 |
| Other |
screening mammography |
1 |
2019 |
| Other |
screening questionnaire administration |
1 |
2008 |
| Drug |
sd-101 |
1 |
2009 |
| Drug |
sd-101 / pembrolizumab |
1 |
2009 |
| Dietary Supplement |
seaweed |
1 |
2010 |
| Dietary Supplement |
seaweed/soy protein |
1 |
2010 |
| Drug |
secoisolariciresinol |
1 |
2011 |
| Drug |
second line chemotherapy |
1 |
2007 |
| Behavioral |
sedentary control condition first |
1 |
2020 |
| Device |
selective internal radiation therapy to the liver using yttrium-90 glass microspheres (therasphere) |
1 |
2011 |
| Dietary Supplement |
selenium |
1 |
2007 |
| Dietary Supplement |
selenium supplementation/placebo treatment |
1 |
2019 |
| Other |
selenium supplementation/placebo treatment/diet modification |
1 |
2019 |
| Behavioral |
self-compassion focussed exercises during walking training |
1 |
2019 |
| Behavioral |
self-directed |
1 |
2013 |
| Behavioral |
self-guided lifestyle program (control arm) |
1 |
2020 |
| Behavioral |
self-help materials |
1 |
2015 |
| Behavioral |
self-management |
1 |
2017 |
| Behavioral |
self-management energy conservation |
1 |
2017 |
| Behavioral |
self-management group |
1 |
2014 |
| Procedure |
self-measured arm circumference, therapist-measured arm-circumference, perometer-measured arm circumference |
1 |
2016 |
| Behavioral |
self-regulation |
1 |
2013 |
| Behavioral |
self-regulation/activity monitoring |
1 |
2013 |
| Behavioral |
self-report assessments |
1 |
2012 |
| Other |
self questionnaires |
1 |
2019 |
| Drug |
selicrelumab |
1 |
2018 |
| Drug |
semaxanib |
1 |
2000 |
| Procedure |
sentinel ln in breast cancer recurrence |
1 |
2018 |
| Procedure |
sentinel lymph node procedure |
1 |
2014 |
| Behavioral |
sentinel lymph node technique |
1 |
2006 |
| Procedure |
sentinel node resection |
1 |
2005 |
| Procedure |
sentinel node resection followed by node examination |
1 |
1999 |
| Radiation |
sequential boost radiotherapy |
1 |
2011 |
| Drug |
sequentially) |
1 |
2017 |
| Drug |
serratus |
1 |
2019 |
| Procedure |
serratus plane block with local anesthetic |
1 |
2018 |
| Procedure |
serratus plane block with saline |
1 |
2018 |
| Other |
serum |
1 |
2016 |
| Other |
serum tumor marker directed disease monitoring |
1 |
2018 |
| Drug |
sesame oil |
1 |
2012 |
| Drug |
seviteronel |
1 |
2015 |
| Drug |
sevoflurane group |
1 |
2015 |
| Behavioral |
sexual |
1 |
2018 |
| Behavioral |
sexual/menopausal health resources |
1 |
2018 |
| Other |
sf-12 quality of life survey |
1 |
2015 |
| Drug |
sfx-01 |
1 |
2016 |
| Behavioral |
sg-wlp |
1 |
2015 |
| Drug |
sgn-cd47m |
1 |
2019 |
| Other |
sham acupuncture. |
1 |
2007 |
| Other |
sham apa control |
1 |
2018 |
| Behavioral |
sham art therapy |
1 |
2017 |
| Device |
sham auricular acupressure |
1 |
2015 |
| Procedure |
sham auricular acupressure (sa) |
1 |
2019 |
| Procedure |
sham comparator: control |
1 |
2018 |
| Procedure |
sham electroacupuncture (se) |
1 |
2019 |
| Procedure |
sham electroacupuncture (se)/sham auricular acupressure (sa) |
1 |
2019 |
| Procedure |
sham erector spinae plane block |
1 |
2018 |
| Other |
sham information |
1 |
2018 |
| Other |
sham transcranial direct current stimulation |
1 |
2018 |
| Behavioral |
sham treatment |
1 |
2008 |
| Behavioral |
sham) |
1 |
2009 |
| Other |
shared decision making support tool |
1 |
2020 |
| Behavioral |
shared decision making supported by an in-consultation patient decision aid |
1 |
2019 |
| Procedure |
shave margins |
1 |
2011 |
| Other |
shearwave elastography |
1 |
2015 |
| Behavioral |
short-term diet |
1 |
2018 |
| Behavioral |
short-term diet/exercise intervention |
1 |
2018 |
| Other |
short-term fasting |
1 |
2011 |
| Procedure |
short breast mri (sbmri) |
1 |
2015 |
| Other |
short intervention protocol |
1 |
2017 |
| Other |
shoulder conventional exercises |
1 |
2016 |
| Drug |
shr-1210 / apatinib /fluzoparib |
1 |
2019 |
| Drug |
shr6390 tablets |
1 |
2019 |
| Biological |
sialyl lewisâª-keyhole limpet hemocyanin conjugate vaccine |
1 |
2007 |
| Radiation |
sib 15 fractions if needed |
1 |
2017 |
| Radiation |
sib 5 fractions if needed |
1 |
2017 |
| Drug |
sibp-01 |
1 |
2019 |
| Behavioral |
side effect prevention training (sept) |
1 |
2012 |
| Device |
siemens biograph 40 pet |
1 |
2015 |
| Device |
siennaxp |
1 |
2015 |
| Device |
silk suture |
1 |
2008 |
| Device |
silver leaf dressing |
1 |
2005 |
| Other |
simulated-altitude |
1 |
2017 |
| Device |
single-use injection device |
1 |
2011 |
| Drug |
single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil |
1 |
2016 |
| Drug |
single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil/methotrexate |
1 |
2016 |
| Radiation |
single dose ablative radiotherapy |
1 |
2014 |
| Radiation |
single fraction ioert |
1 |
2015 |
| Procedure |
single injection paravertebral block |
1 |
2016 |
| Radiation |
single pre-operative radiation therapy |
1 |
2012 |
| Radiation |
single pre-operative radiation therapy - with delayed surgery |
1 |
2019 |
| Other |
single rehabilitative treatment |
1 |
2019 |
| Behavioral |
sis.net, routine follow-up |
1 |
2011 |
| Drug |
ski-606 (bosutinib) |
1 |
2006 |
| Procedure |
skin |
1 |
2014 |
| Other |
skin biopsies |
1 |
2016 |
| Other |
skin care |
1 |
2015 |
| Procedure |
skin marking of clip axillary lymph node for localisation |
1 |
2019 |
| Procedure |
skin/nipple sparing mastectomy |
1 |
2014 |
| Other |
sleep diary |
1 |
2007 |
| Behavioral |
sleep education |
1 |
2018 |
| Behavioral |
sleep hygiene training |
1 |
2019 |
| Behavioral |
sleep information |
1 |
2015 |
| Behavioral |
sleep intervention |
1 |
2015 |
| Other |
sleep log |
1 |
2016 |
| Procedure |
sln detection |
1 |
2014 |
| Procedure |
sln detection //- complementary axillary lymphadenectomy |
1 |
2014 |
| Device |
sln procedure (carolires camera) |
1 |
2008 |
| Procedure |
slnb |
1 |
2010 |
| Procedure |
slnb versus completion alnd |
1 |
2015 |
| Procedure |
slnb/complete level i-ii axillary lymphadenectomy |
1 |
2010 |
| Drug |
sm-153 |
1 |
2006 |
| Behavioral |
small group discussion |
1 |
2011 |
| Device |
smartphone |
1 |
2015 |
| placebo |
smartphone application “placebo” |
1 |
2018 |
| Device |
smartphone equipped with application “bouge” = coach group |
1 |
2018 |
| Device |
smartphone/tablet |
1 |
2015 |
| Other |
sms before invitation |
1 |
2016 |
| Other |
sms reminder |
1 |
2015 |
| Other |
sms reminder 1 |
1 |
2016 |
| Drug |
sn132d |
1 |
2019 |
| Drug |
sn2310 injectable emulsion |
1 |
2006 |
| Procedure |
snb |
1 |
2015 |
| Procedure |
sob |
1 |
2016 |
| Behavioral |
social support intervention |
1 |
2016 |
| Diagnostic Test |
sodium (na) magnetic resonance imaging (mri) |
1 |
2018 |
| Drug |
sodium selenite |
1 |
2005 |
| Drug |
solifenacin |
1 |
2012 |
| Drug |
sonazoid; perflubutane for injection |
1 |
2016 |
| Procedure |
sonographically assisted breast surgery |
1 |
2018 |
| Drug |
sonovue |
1 |
2018 |
| Drug |
sonovue (sulphur hexafluoride microbubbles) |
1 |
2005 |
| Diagnostic Test |
sorbstarâ® |
1 |
2018 |
| Biological |
sox2 |
1 |
2014 |
| Drug |
soy isoflavone nutritional supplements |
1 |
2005 |
| Dietary Supplement |
soy milk |
1 |
2005 |
| Dietary Supplement |
soy protein isolate |
1 |
2006 |
| Dietary Supplement |
soy supplement |
1 |
2018 |
| Dietary Supplement |
soy/selenium |
1 |
2007 |
| Drug |
sparc-08-038 |
1 |
2017 |
| Drug |
sparc1613 |
1 |
2017 |
| Procedure |
special studies |
1 |
2011 |
| Diagnostic Test |
spectroscopic photoacoustic imaging |
1 |
2019 |
| Behavioral |
speed of processing training |
1 |
2011 |
| Procedure |
sphygmocor |
1 |
2015 |
| Other |
spinal group |
1 |
2017 |
| Procedure |
spine x-ray |
1 |
2006 |
| Combination Product |
spy-phi |
1 |
2017 |
| Device |
spy elite imaging |
1 |
2013 |
| Radiation |
sr-89 |
1 |
2006 |
| Drug |
sta-9090 |
1 |
2011 |
| Other |
standard-stimulated cohort |
1 |
2019 |
| Drug |
standard adjuvant chemotherapy |
1 |
2007 |
| Drug |
standard anti-emetic treatment (5-ht3 receptor antagonists and |
1 |
2015 |
| Drug |
standard anti-emetic treatment (5-ht3 receptor antagonists and/or dexamethasone) |
1 |
2015 |
| Drug |
standard arm - fulvestrant |
1 |
2017 |
| Procedure |
standard axillary surgery (slnb |
1 |
2016 |
| Procedure |
standard axillary surgery (slnb/alnd) |
1 |
2016 |
| Other |
standard bolus |
1 |
2015 |
| Radiation |
standard breast irradiation |
1 |
2000 |
| Other |
standard care / conversational hypnosis |
1 |
2016 |
| Drug |
standard care after 24 weeks |
1 |
2015 |
| Other |
standard care encouraging family-mediated disclosure of hereditary cancer risk |
1 |
2019 |
| Behavioral |
standard care/verbal counselling |
1 |
2019 |
| Procedure |
standard conservative breast surgery |
1 |
2017 |
| Drug |
standard cyclophosphamide |
1 |
2012 |
| Procedure |
standard decision board |
1 |
2005 |
| Drug |
standard endocrine therapy |
1 |
2019 |
| Other |
standard follow-up |
1 |
2018 |
| Radiation |
standard fractionated radiotherapy |
1 |
2009 |
| Behavioral |
standard genetic counseling |
1 |
2020 |
| Behavioral |
standard health educational booklet |
1 |
2015 |
| Other |
standard information |
1 |
2017 |
| Other |
standard leaflet |
1 |
2017 |
| Procedure |
standard lumpectomy without nonlinear microscopy imaging |
1 |
2016 |
| Device |
standard mammography |
1 |
2016 |
| Device |
standard mammography/tomosynthesis |
1 |
2016 |
| Drug |
standard neoadjuvant cht |
1 |
2017 |
| Behavioral |
standard of care / experimental individualized therapy |
1 |
2018 |
| Behavioral |
standard of care distressed in study arm distressed |
1 |
2018 |
| Behavioral |
standard of care non-distressed |
1 |
2018 |
| Other |
standard of care questionnaire |
1 |
2019 |
| Other |
standard of care schedule variation: sabr |
1 |
2017 |
| Drug |
standard of care single agent chemotherapy |
1 |
2016 |
| Drug |
standard of care: cyclophosphamide |
1 |
2015 |
| Drug |
standard of care: docetaxel |
1 |
2015 |
| Behavioral |
standard oncology care |
1 |
2016 |
| Behavioral |
standard online support group |
1 |
2011 |
| Behavioral |
standard oral information |
1 |
2018 |
| Radiation |
standard per daily radiation therapy |
1 |
2011 |
| Other |
standard perioperative care |
1 |
2020 |
| Other |
standard physical therapy program |
1 |
2017 |
| Drug |
standard preparation |
1 |
2013 |
| Behavioral |
standard printed dietary guidelines |
1 |
2011 |
| Radiation |
standard radiation |
1 |
2015 |
| Radiation |
standard radiation treatment |
1 |
2011 |
| Behavioral |
standard self-regulation |
1 |
2018 |
| Device |
standard silicone-based breast implant |
1 |
2018 |
| Behavioral |
standard support group |
1 |
2020 |
| Behavioral |
standard support group / pedometer |
1 |
2020 |
| Other |
standard supportive care (packed rbc transfusion) |
1 |
2006 |
| Drug |
standard taxane therapy |
1 |
2009 |
| Diagnostic Test |
standard two dimension digital mammogram |
1 |
2017 |
| Other |
standard websites |
1 |
2017 |
| Drug |
standard: aprepitant |
1 |
2017 |
| Drug |
standard: dexamethasone |
1 |
2017 |
| Drug |
standard: ondansetron |
1 |
2017 |
| Procedure |
standardized bcs |
1 |
2016 |
| Procedure |
standardized bcs/cm assessment. |
1 |
2016 |
| Behavioral |
standardized lifestyle management |
1 |
2013 |
| Behavioral |
standardized materials group |
1 |
2008 |
| Behavioral |
standardized, manualized group intervention |
1 |
2013 |
| Device |
starburst xl probe) |
1 |
2007 |
| Behavioral |
starting the conversation video |
1 |
2018 |
| Behavioral |
static care plan |
1 |
2018 |
| Other |
static version of cansort tool |
1 |
2013 |
| Drug |
statins |
1 |
2019 |
| Procedure |
stellate ganglion block |
1 |
2020 |
| Procedure |
stem cell infusion |
1 |
2007 |
| Device |
stereo navigator accessory to pem flex pet scanner |
1 |
2008 |
| Procedure |
stereoscopic digital mammography |
1 |
2005 |
| Radiation |
stereotactic ablative body radiosurgery (sabr) |
1 |
2014 |
| Radiation |
stereotactic ablative breast radiotherapy |
1 |
2020 |
| Radiation |
stereotactic apbi |
1 |
2005 |
| Radiation |
stereotactic body radiation sbrt |
1 |
2017 |
| Radiation |
stereotactic body radiation then surgery |
1 |
2014 |
| Radiation |
stereotactic body radiation therapy (sbrt) |
1 |
2014 |
| Radiation |
stereotactic body radiation therapy (sbrt) (50gy in 5 fractions) |
1 |
2020 |
| Radiation |
stereotactic body radiotherapy ( sbrt) |
1 |
2015 |
| Radiation |
stereotactic body radiotherapy (sbrt) |
1 |
2014 |
| Radiation |
stereotactic body radiotherapy/sbrt |
1 |
2019 |
| Radiation |
stereotactic radiation |
1 |
2016 |
| Radiation |
stereotactic radiation therapy (srt) |
1 |
2015 |
| Procedure |
stereotactic radiosurgery (srs) |
1 |
2018 |
| Radiation |
stereotactic radiotherapy |
1 |
2011 |
| Radiation |
stereotactic radiotherapy delivered by cyberknife |
1 |
2011 |
| Other |
sterile water placement |
1 |
2006 |
| Radiation |
sterotactic body radiotherapy |
1 |
2019 |
| Radiation |
sterotactic body radiotherapy/sbrt |
1 |
2019 |
| Behavioral |
stimulating acupressure |
1 |
2011 |
| Radiation |
stranded palladium seed interstitial implant |
1 |
2014 |
| Other |
stratification |
1 |
2016 |
| Device |
stratticeâ„¢ acellular dermal matrix |
1 |
2015 |
| Behavioral |
strength exercise training |
1 |
2016 |
| Behavioral |
strength training |
1 |
2005 |
| Procedure |
stress management therapy |
1 |
2009 |
| Behavioral |
stress management, in two steps |
1 |
2012 |
| Other |
stretching |
1 |
2007 |
| Behavioral |
stretching control group |
1 |
2007 |
| Other |
stride |
1 |
2019 |
| Combination Product |
study device arm |
1 |
2018 |
| Other |
study group |
1 |
2018 |
| Drug |
su011248/trastuzumab |
1 |
2005 |
| Drug |
su014813 |
1 |
2006 |
| Drug |
su11248 |
1 |
2005 |
| Other |
subclinical cardiac lesions |
1 |
2015 |
| Other |
subclinical cardiac lesions/biomarkers |
1 |
2015 |
| Drug |
suberoylanilide hydroxamic acid (saha, vorinostat) |
1 |
2006 |
| Other |
subjective assessments |
1 |
2014 |
| Behavioral |
subjects are mailed informational |
1 |
2012 |
| Behavioral |
subjects are mailed informational/educational materials |
1 |
2012 |
| Drug |
subserratus plane block with local anesthetic |
1 |
2020 |
| Behavioral |
successful survivorship health education |
1 |
2016 |
| Behavioral |
successful survivorship health education/support group |
1 |
2016 |
| Drug |
sugar pill |
1 |
2014 |
| Drug |
sulbactam |
1 |
2006 |
| Drug |
sulfur colloid |
1 |
2014 |
| Drug |
sunitinib (sutent) |
1 |
2006 |
| Drug |
sunitinib / capecitabine |
1 |
2007 |
| Drug |
sunitinib alone |
1 |
2008 |
| Drug |
sunitinib/paclitaxel |
1 |
2008 |
| Behavioral |
supervised home based training |
1 |
2013 |
| Other |
supervised progressive muscle relaxation training (jacobsen method) |
1 |
2010 |
| Other |
supervised progressive muscle relaxation training (jacobson method) |
1 |
2011 |
| Other |
supervised training |
1 |
2008 |
| Other |
supervised, individualized exercise oncology program |
1 |
2019 |
| Behavioral |
supervision of physical activity |
1 |
2016 |
| Behavioral |
supine position |
1 |
2009 |
| Device |
supine radiotherapy |
1 |
2017 |
| Other |
supplemental oxygen |
1 |
2004 |
| Behavioral |
support |
1 |
2019 |
| Behavioral |
support calls |
1 |
2017 |
| Behavioral |
support program |
1 |
2016 |
| Behavioral |
support psychotherapy |
1 |
2019 |
| Other |
supportive |
1 |
2019 |
| Behavioral |
supportive-expressive group therapy/education |
1 |
2005 |
| Behavioral |
supportive therapy group 2 |
1 |
2016 |
| Other |
supportive/survivorship care program |
1 |
2019 |
| Radiation |
supraclavicular area radiotherapy |
1 |
2018 |
| Procedure |
supraclavicular lymph node dissection |
1 |
2018 |
| Procedure |
surgery (standard of care) |
1 |
2012 |
| Procedure |
surgery after neoadjuvant therapy |
1 |
2016 |
| Procedure |
surgery for breast cancer |
1 |
2005 |
| Procedure |
surgery for standard axillary node dissection |
1 |
2012 |
| Procedure |
surgery on demand |
1 |
2009 |
| Procedure |
surgery: oophorectomy |
1 |
2005 |
| Procedure |
surgical intervention |
1 |
2019 |
| Behavioral |
surgical preparation program |
1 |
2012 |
| Procedure |
surgical wound infiltration |
1 |
2015 |
| Device |
surgimend prs |
1 |
2013 |
| Device |
surgimendâ® acellular dermal matrix |
1 |
2015 |
| Other |
survey questions |
1 |
2015 |
| Other |
surveys |
1 |
2013 |
| Biological |
survivin multi-peptide vaccine |
1 |
2007 |
| Other |
survivorship care program |
1 |
2019 |
| Behavioral |
survivorship education |
1 |
2015 |
| Behavioral |
survivorship intervention |
1 |
2009 |
| Device |
suture |
1 |
2008 |
| Behavioral |
symptom management |
1 |
2015 |
| Behavioral |
symptom management group |
1 |
2014 |
| Behavioral |
symptoms via study app |
1 |
2018 |
| Biological |
syn004 |
1 |
2015 |
| Drug |
syndros |
1 |
2018 |
| Biological |
synthetic breast cancer peptides-tetanus toxoid-montanide isa-51 vaccine |
1 |
2006 |
| Radiation |
synthetic mammography / digital breast tomosynthesis |
1 |
2016 |
| Biological |
synthetic tumor-associated peptide vaccine therapy |
1 |
2006 |
| Diagnostic Test |
systematic axillary ultrasound imaging |
1 |
2019 |
| Radiation |
systemic |
1 |
2014 |
| Drug |
systemic therapy |
1 |
2019 |
| Drug |
systemic therapy/standard of care |
1 |
2019 |
| Drug |
t-dm1/pertuzumab |
1 |
2009 |
| Other |
t-pat |
1 |
2013 |
| Drug |
t / trastuzumab followed by cef / trastuzumab |
1 |
2011 |
| Biological |
taa-specific ctls |
1 |
2017 |
| Device |
tablet |
1 |
2015 |
| Drug |
tac chemotherapy |
1 |
2011 |
| Drug |
tachosilâ® patches |
1 |
2014 |
| Drug |
tacrolimus |
1 |
2005 |
| Procedure |
tagged axillary metastatic node |
1 |
2018 |
| Behavioral |
tai chi |
1 |
2017 |
| Procedure |
tailored axillary surgery |
1 |
2018 |
| Other |
tailored education |
1 |
2015 |
| Behavioral |
tailored email |
1 |
2013 |
| Behavioral |
tailored lifestyle intervention (tli) |
1 |
2012 |
| Behavioral |
tailored program of pa |
1 |
2011 |
| Behavioral |
tailored program of pa/nutritional counseling |
1 |
2011 |
| Other |
tailored screening according to breast density |
1 |
2015 |
| Other |
tailored support |
1 |
2013 |
| Behavioral |
tailored, interactive intervention for mammography screening |
1 |
2006 |
| Drug |
tak-117 |
1 |
2017 |
| Drug |
tak-165 |
1 |
2002 |
| Drug |
tak-228/tak-117 |
1 |
2017 |
| Drug |
tak-573 |
1 |
2019 |
| Drug |
tak700 |
1 |
2013 |
| Drug |
talazoparib tosylate |
1 |
2015 |
| Drug |
talazoparib/irinotecan |
1 |
2009 |
| Drug |
tam |
1 |
2015 |
| placebo |
tamoxifen (nolvadex) placebo |
1 |
2009 |
| Drug |
tamoxifen (post-operative) |
1 |
2011 |
| Drug |
tamoxifen / aminoglutethimide |
1 |
2006 |
| Drug |
tamoxifen / exemestane |
1 |
2002 |
| Drug |
tamoxifen / palbociclib |
1 |
2015 |
| Drug |
tamoxifen 20mg tablet |
1 |
2017 |
| Drug |
tamoxifen 40mg qd |
1 |
2010 |
| Drug |
tamoxifen alone |
1 |
2006 |
| Drug |
tamoxifen citrate (tamoxifen) |
1 |
2006 |
| Drug |
tamoxifen citrate 20mg tab |
1 |
1999 |
| Drug |
tamoxifen dose adjustment |
1 |
2020 |
| Drug |
tamoxifen oral product |
1 |
2017 |
| Drug |
tamoxifen pill |
1 |
2019 |
| Drug |
tamoxifen stim in early follicular phase |
1 |
2016 |
| Drug |
tamoxifen stim in late follicular phase |
1 |
2016 |
| Drug |
tamoxifen stim in luteal phase |
1 |
2016 |
| Drug |
tamoxifen, |
1 |
2011 |
| Drug |
tamoxifen, letrozole , anastrozole, exemestane |
1 |
2012 |
| Drug |
tamoxifen, letrozole, anastrozole |
1 |
2010 |
| Drug |
tamoxifen, letrozole, anastrozole, |
1 |
2020 |
| Drug |
tamoxifen, letrozole, anastrozole,/exemestane |
1 |
2020 |
| Drug |
tamoxifen, letrozole, anastrozole/exemestane |
1 |
2010 |
| Drug |
tamoxifen/aromatase inhibitor/aromatase inhibitor / goserelin |
1 |
2015 |
| Drug |
tamoxifen/gnrh analogue |
1 |
2012 |
| Drug |
tamoxifen/prometrium |
1 |
2018 |
| Other |
tandem mass spectometry |
1 |
2009 |
| Procedure |
tangential radiation |
1 |
2005 |
| Drug |
tap-144-sr(3m) |
1 |
2012 |
| Drug |
tap-144-sr(6m) |
1 |
2012 |
| Other |
taping |
1 |
2018 |
| Behavioral |
targeted |
1 |
2012 |
| Behavioral |
targeted email |
1 |
2013 |
| Behavioral |
targeting the teachable moment |
1 |
2013 |
| Drug |
tas-102 oral solution |
1 |
2013 |
| Drug |
tas-102 tablets |
1 |
2013 |
| Drug |
tas-108 |
1 |
2005 |
| Drug |
tas-120 |
1 |
2019 |
| Procedure |
tattooing of biopsied node |
1 |
2018 |
| Biological |
tavokinogene telseplasmid |
1 |
2018 |
| Drug |
taxane-based chemotherapy |
1 |
2007 |
| Drug |
taxane (docetaxel |
1 |
2007 |
| Drug |
taxane (docetaxel/paclitaxel) |
1 |
2007 |
| Drug |
taxane based chemotherapy |
1 |
2015 |
| Drug |
taxane/carboplatin |
1 |
2015 |
| Drug |
taxanes/carboplatin |
1 |
2015 |
| Drug |
taxotere (docetaxel) |
1 |
2010 |
| Drug |
taxotere , epirubicin |
1 |
2008 |
| Drug |
taxotere, carboplatin, herceptin |
1 |
2017 |
| Drug |
taxotere, carboplatin, herceptin / pertuzumab |
1 |
2017 |
| Drug |
taxotere/docetaxel |
1 |
2005 |
| Drug |
taxotereâ® |
1 |
2014 |
| Drug |
taxotereâ® (100 mg |
1 |
2018 |
| Drug |
taxotereâ® (100 mg/m2) |
1 |
2018 |
| Drug |
tc-h x paclitaxel (p) |
1 |
2018 |
| Drug |
tc-h x paclitaxel (p) / trastuzumab(t) |
1 |
2018 |
| Drug |
tc (docetaxel |
1 |
2017 |
| Drug |
tc (docetaxel/carboplatin) versus ec followed by t (epirubicin/cyclophosphamide followed by docetaxe) |
1 |
2017 |
| Drug |
tc 99m filtered sulfur colloid |
1 |
2017 |
| Drug |
tc 99m tilmanocept |
1 |
2017 |
| Drug |
tc chemotherapy |
1 |
2011 |
| Drug |
tc2 cells |
1 |
2004 |
| Drug |
tc99m sestamibi |
1 |
2014 |
| Drug |
tch |
1 |
2009 |
| Drug |
tch (docetaxel |
1 |
2017 |
| Drug |
tch (docetaxel/carboplatin/trastuzumab) versus ec-th(epirubicin/cyclophosphamide followed by docetaxe/trastuzumab) |
1 |
2017 |
| Drug |
tch chemotherapy |
1 |
2011 |
| Device |
tdcs |
1 |
2017 |
| Drug |
tdm1 |
1 |
2014 |
| Device |
tds-im system (inchor medical systems) |
1 |
2017 |
| Genetic |
tdt-mediated dutp nick end labeling assay |
1 |
2006 |
| Drug |
te iodine |
1 |
2018 |
| placebo |
te placebo |
1 |
2018 |
| Dietary Supplement |
tea capsule |
1 |
2009 |
| Behavioral |
team based care |
1 |
2018 |
| Other |
teamwork app |
1 |
2018 |
| Drug |
technetium tc-99m sestamibi |
1 |
2016 |
| Radiation |
technetium tc-99m sulfur colloid |
1 |
2015 |
| Drug |
technetium tc99m sulfur colloid |
1 |
2015 |
| Drug |
technetium99 |
1 |
2016 |
| Behavioral |
technology-based information |
1 |
2016 |
| Behavioral |
technology-based information/coaching/support program |
1 |
2016 |
| Behavioral |
technology-based physical activity promotion |
1 |
2013 |
| Other |
telehealth |
1 |
2019 |
| Behavioral |
telephone booster |
1 |
2018 |
| Other |
telephone coaching |
1 |
2017 |
| Behavioral |
telephone counseling. |
1 |
2012 |
| Device |
telerehabilitation ecuidate system |
1 |
2015 |
| Behavioral |
telerehabilitation group |
1 |
2013 |
| Biological |
telomerase: 540-548 peptide vaccine |
1 |
2004 |
| Drug |
temsirolimus (cci-779) |
1 |
2003 |
| Drug |
tesetaxel/capecitabine |
1 |
2017 |
| Drug |
tesmilifene (ymb 1002) |
1 |
2006 |
| Drug |
tesmilifene (ymb1002) |
1 |
2006 |
| Device |
test - standard closure with tissuglu surgical adhesive |
1 |
2016 |
| Behavioral |
testimonials from breast cancer survivors |
1 |
2013 |
| Drug |
tetrahydrouridine (thu) |
1 |
2009 |
| Drug |
tetrathiomolybdate |
1 |
2005 |
| Behavioral |
text message application |
1 |
2014 |
| Behavioral |
text message management prompts |
1 |
2014 |
| Behavioral |
text message reminder |
1 |
2012 |
| Other |
tezel method of breast volume measurement |
1 |
2015 |
| Drug |
tf2 - 68 ga-imp-288: |
1 |
2012 |
| Drug |
tgfbetarii fusion protein m7824 |
1 |
2018 |
| Drug |
th2 |
1 |
2004 |
| Drug |
th2/tc2 cells |
1 |
2004 |
| Behavioral |
the-optimal-lymph-flow |
1 |
2015 |
| Behavioral |
the behavioral activation |
1 |
2019 |
| Behavioral |
the behavioral activation/ problem solving intervention |
1 |
2019 |
| Drug |
the fec75 |
1 |
2006 |
| Drug |
the fec75/95 regimen |
1 |
2006 |
| Behavioral |
the guided imagery |
1 |
2019 |
| Behavioral |
the guided imagery/music method |
1 |
2019 |
| Other |
the health education |
1 |
2019 |
| Device |
the mixture including indocyanine green |
1 |
2013 |
| Procedure |
therapeutic |
1 |
2016 |
| Procedure |
therapeutic dietary intervention |
1 |
1999 |
| Behavioral |
therapeutic education program |
1 |
2014 |
| Other |
therapeutic exercise-physiotherapy |
1 |
2016 |
| Behavioral |
therapeutic group by teleconference |
1 |
2011 |
| Procedure |
therapeutic mammoplasty |
1 |
2018 |
| Drug |
therapeutic testosterone |
1 |
2004 |
| Procedure |
therapeutic touch |
1 |
2007 |
| Procedure |
therapy |
1 |
2005 |
| Biological |
theratope stn-klh vaccine |
1 |
1999 |
| Drug |
theratopeâ® vaccine |
1 |
2002 |
| Procedure |
thermic destruction of tissue by laser using the novilase device |
1 |
2012 |
| Drug |
thermodox in combination with microwave hyperthermia (heat) |
1 |
2009 |
| Dietary Supplement |
thl-p |
1 |
2009 |
| Procedure |
thoracic paravertebral block |
1 |
2015 |
| Procedure |
thoracic paravertebral block (tpvb) |
1 |
2010 |
| Procedure |
thoracic paravertebral block under ultrasound guidance |
1 |
2019 |
| Procedure |
thoracoscopic surgery |
1 |
2007 |
| Radiation |
three fraction accelerated partial breast irradiation |
1 |
2018 |
| Other |
thunbergia cream |
1 |
2016 |
| Behavioral |
tibetan meditation program |
1 |
2007 |
| Drug |
tigatuzumab |
1 |
2011 |
| Behavioral |
tips for making exercise enjoyable |
1 |
2013 |
| Behavioral |
tips for making exercise enjoyable/personally-valued |
1 |
2013 |
| Biological |
tislelizumab |
1 |
2020 |
| Procedure |
tissue |
1 |
2010 |
| Genetic |
tissue biopsy, blood sample |
1 |
2017 |
| Procedure |
tissue sample collection |
1 |
2019 |
| Other |
titanium marker |
1 |
2013 |
| Drug |
tiva-tci |
1 |
2016 |
| Drug |
tivantinib |
1 |
2012 |
| Drug |
tivozanib (av-951) |
1 |
2008 |
| Drug |
tivozanib (av-951) / paclitaxel |
1 |
2008 |
| Behavioral |
tiweb |
1 |
2017 |
| Behavioral |
tiweb/csc |
1 |
2017 |
| Drug |
tlk286 |
1 |
2002 |
| Device |
tm |
1 |
2017 |
| Device |
tmem-mri |
1 |
2018 |
| Drug |
tmz |
1 |
2017 |
| Other |
tobacco cessation counseling |
1 |
2017 |
| Device |
tobi |
1 |
2014 |
| Device |
tobi / dbt |
1 |
2014 |
| Drug |
tocosol(r) paclitaxel |
1 |
2004 |
| Dietary Supplement |
tocotrienol-rich fraction (trf) |
1 |
2019 |
| Dietary Supplement |
tocotrienol 300 mg x 3 daily |
1 |
2016 |
| Dietary Supplement |
tocotrienol rich fraction (trf) |
1 |
2010 |
| Radiation |
tomosynthesis breast scanning |
1 |
2012 |
| Radiation |
tomosynthesis imaging |
1 |
2008 |
| Radiation |
tomotherapy |
1 |
2016 |
| placebo |
topical approved placebo |
1 |
2019 |
| Drug |
topical calcipotriene ointment |
1 |
2018 |
| Device |
topical keratin |
1 |
2017 |
| Drug |
topical liquid lidocaine |
1 |
2011 |
| Drug |
topical saline |
1 |
2011 |
| Other |
topical vaseline |
1 |
2018 |
| Drug |
toremifine |
1 |
2014 |
| Drug |
toripalimab |
1 |
2020 |
| Drug |
toripalimab 240mg |
1 |
2020 |
| Procedure |
total submuscular coverage |
1 |
2014 |
| Drug |
tp |
1 |
2010 |
| Drug |
tpc |
1 |
2017 |
| Drug |
tpi 287 |
1 |
2011 |
| Drug |
tqb2450 injection |
1 |
2019 |
| Drug |
tqb2450 injection/anlotinib hydrochioride capsules |
1 |
2019 |
| Drug |
trabectedin |
1 |
2007 |
| Other |
tracking |
1 |
2012 |
| Other |
tracking/feedback |
1 |
2012 |
| Other |
traditional biomedical educational program |
1 |
2017 |
| Drug |
traditional chinese medicine formulation |
1 |
2020 |
| Other |
traditional massage |
1 |
2019 |
| Other |
traditional mld |
1 |
2015 |
| Behavioral |
training group |
1 |
2020 |
| Drug |
tramadol |
1 |
2016 |
| Drug |
tranexamic acid |
1 |
2015 |
| Other |
transcranial direct current stimulation |
1 |
2018 |
| Biological |
trastuxumab |
1 |
2002 |
| Biological |
trastuzumab-eu |
1 |
2014 |
| Drug |
trastuzumab - emtansine |
1 |
2013 |
| Drug |
trastuzumab (9 weeks) |
1 |
2008 |
| Drug |
trastuzumab (9 weeks) / docetaxel |
1 |
2008 |
| Drug |
trastuzumab (9 weeks) / docetaxel / cef / trastuzumab (up to 51 weeks) |
1 |
2008 |
| Drug |
trastuzumab (up to 51 weeks) |
1 |
2008 |
| Drug |
trastuzumab / letrozole |
1 |
2005 |
| Drug |
trastuzumab / paclitaxel |
1 |
2018 |
| Drug |
trastuzumab [herceptinâ®] |
1 |
2019 |
| Drug |
trastuzumab 8 mg |
1 |
2016 |
| Drug |
trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (her2 positive patients only) |
1 |
2016 |
| Drug |
trastuzumab 8mg |
1 |
2018 |
| Drug |
trastuzumab 8mg/kg/6 mg/kg |
1 |
2018 |
| Drug |
trastuzumab emtansin |
1 |
2015 |
| Drug |
trastuzumab emtansine [kadcyla] 3.0 mg |
1 |
2009 |
| Drug |
trastuzumab emtansine [kadcyla] 3.0 mg/kg |
1 |
2009 |
| Drug |
trastuzumab emtansine [kadcyla] 3.6 mg |
1 |
2009 |
| Drug |
trastuzumab emtansine [kadcyla] 3.6 mg/kg |
1 |
2009 |
| Drug |
trastuzumab fdc sc |
1 |
2018 |
| Drug |
trastuzumab followed by cef |
1 |
2011 |
| Drug |
trastuzumab maintenance therapy |
1 |
2006 |
| Drug |
trastuzumab monotherapy |
1 |
2009 |
| Drug |
trastuzumab phase l |
1 |
2011 |
| Drug |
trastuzumab(t) |
1 |
2018 |
| Drug |
trastuzumab) |
1 |
2017 |
| Drug |
trastuzumab) versus ec-th(epirubicin |
1 |
2017 |
| Drug |
trastuzumab, 4 cycles |
1 |
2008 |
| Drug |
trastuzumab, 4 cycles, followed by docetaxel |
1 |
2008 |
| Drug |
trastuzumab, docetaxel, bevacizumab |
1 |
2011 |
| Drug |
trastuzumab, docetaxel/carboplatin in dose dense regimen |
1 |
2005 |
| Drug |
trastuzumab, followed by postoperative trastuzumab |
1 |
2008 |
| Drug |
trastuzumab/chemotherapy |
1 |
2009 |
| Drug |
trastuzumab/docetaxel (for 4 21-day cycles) after four 14-day cycles of doxorubicin/cyclophosphamide |
1 |
2017 |
| Drug |
trastuzumab/docetaxel/npld |
1 |
2011 |
| Drug |
trastuzumab/docetaxel/npld/bevacizumab |
1 |
2011 |
| Drug |
trastuzumab/non-pegylated liposomal doxorubicin |
1 |
2015 |
| Other |
treated recommended |
1 |
2013 |
| Procedure |
treatment |
1 |
2010 |
| Behavioral |
treatment as usual |
1 |
2015 |
| Other |
treatment of cancer-quality of life questionnaire |
1 |
2016 |
| Other |
treatment of cancer-quality of life questionnaire (eortc qlq-c30) |
1 |
2017 |
| Drug |
treatment of physician’s choice |
1 |
2011 |
| Drug |
treatment of physician’s choice (tpc) |
1 |
2011 |
| Other |
treatment recommendation |
1 |
2016 |
| Other |
treatment suggestion |
1 |
2013 |
| Device |
trecam |
1 |
2014 |
| Drug |
trental pill |
1 |
2019 |
| Procedure |
trephine biopsy |
1 |
2016 |
| Device |
tri-modal imaging |
1 |
2016 |
| Combination Product |
triamcinolone |
1 |
2019 |
| Biological |
tricom-cea(6d) |
1 |
2001 |
| Drug |
triiodothyronine (t3) |
1 |
2018 |
| Drug |
trilaciclib |
1 |
2016 |
| Drug |
trimix |
1 |
2018 |
| Other |
trip patient navigation intervention |
1 |
2018 |
| Device |
true auricular acupressure |
1 |
2015 |
| Drug |
trx518 |
1 |
2019 |
| Drug |
ts-1 |
1 |
2007 |
| Drug |
ts-1/eloxatin |
1 |
2007 |
| Drug |
tt-00420 |
1 |
2018 |
| Drug |
ttac-0001 |
1 |
2018 |
| Drug |
ttac-0001/pembrolizumab combination |
1 |
2018 |
| Drug |
ttc-352 |
1 |
2017 |
| Drug |
tucatinib (ont-380) |
1 |
2013 |
| Drug |
tucatinib in combination with palbociclib |
1 |
2017 |
| Drug |
tucatinib in combination with palbociclib/letrozole |
1 |
2017 |
| Procedure |
tumor biopsies |
1 |
2013 |
| Procedure |
tumor biopsy (optional) |
1 |
2016 |
| Procedure |
tumor biopsy/blood draw |
1 |
2010 |
| Biological |
tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine |
1 |
2015 |
| Other |
tumor exome analysis |
1 |
2016 |
| Drug |
tumor infiltrating lymphocytes (til) ln-145 |
1 |
2019 |
| Device |
tumor rda biopsy |
1 |
2014 |
| Biological |
tumor sample |
1 |
2011 |
| Procedure |
tumorectomy |
1 |
2015 |
| Genetic |
tunel assay |
1 |
2008 |
| Radiation |
twi 15 fractions |
1 |
2017 |
| Radiation |
twi 5 fractions |
1 |
2017 |
| Radiation |
twice daily apbi |
1 |
2018 |
| Drug |
two complex naturopathic add-on therapies, leaflet 5-a-day |
1 |
2005 |
| Procedure |
two steps axillary node clearance |
1 |
2019 |
| Device |
tx-plore |
1 |
2006 |
| Drug |
tykerb |
1 |
2007 |
| Biological |
typhoid vaccine |
1 |
2015 |
| Drug |
u3-1402 |
1 |
2016 |
| Biological |
ub-921 |
1 |
2017 |
| Behavioral |
uc |
1 |
2017 |
| Drug |
uft (uracil, tegafur)/tamoxifen |
1 |
2005 |
| Device |
uincare |
1 |
2019 |
| Device |
uincare homeplus |
1 |
2020 |
| Drug |
ulipristal acetate |
1 |
2015 |
| Drug |
ulixertinib |
1 |
2015 |
| Radiation |
ultrahypofractionation |
1 |
2020 |
| Procedure |
ultrasonic knife (ultracisionâ®, ethicon endo surgery) |
1 |
2009 |
| Procedure |
ultrasonography after removal of the drains |
1 |
2014 |
| Device |
ultrasound- virtual touch tissue imaging quantification |
1 |
2015 |
| Procedure |
ultrasound-guided biopsy |
1 |
2015 |
| Procedure |
ultrasound-guided core needle biopsy |
1 |
2018 |
| Procedure |
ultrasound (us) bi-level erector spinae block |
1 |
2020 |
| Drug |
ultrasound guided serratus anterior block with ropivacaine |
1 |
2015 |
| Device |
ultrasound image manual review |
1 |
2018 |
| Device |
ultrasound image review with cade |
1 |
2018 |
| Device |
ultrasound image review with cadx |
1 |
2018 |
| Device |
ultrasound sagittal scan |
1 |
2017 |
| Procedure |
ultrasound scan |
1 |
2008 |
| Device |
ultrasound transverse scan |
1 |
2017 |
| Procedure |
umbilical cord blood transplantation |
1 |
2006 |
| Other |
upper limb function |
1 |
2015 |
| Drug |
urea |
1 |
2006 |
| Drug |
urea/lactic acid-based topical cream |
1 |
2006 |
| Other |
us diagnostic group |
1 |
2014 |
| Other |
us neoadjuvant chemotherapy group |
1 |
2014 |
| Other |
us process validation group |
1 |
2014 |
| Device |
use of a picc line for chemo administration (powerpicc soloâ²) |
1 |
2013 |
| Procedure |
usg pecs2 with drug a (active) |
1 |
2018 |
| placebo |
usg pecs2 with drug p (placebo) |
1 |
2018 |
| Other |
usual care - written materials |
1 |
2009 |
| Behavioral |
usual care (wait-list control) |
1 |
2017 |
| Other |
usual care / acupuncture |
1 |
2012 |
| Behavioral |
usual care arm |
1 |
2017 |
| Other |
usual care disease monitoring |
1 |
2018 |
| Other |
usual care during neoadjuvant chemotherapy |
1 |
2016 |
| Other |
usual care during neoadjuvant chemotherapy/exercise after surgery |
1 |
2016 |
| Other |
usual clinical |
1 |
2011 |
| Other |
usual clinical/radiological criteria |
1 |
2011 |
| Dietary Supplement |
usual intake pre-op |
1 |
2020 |
| Dietary Supplement |
usual intake pre-op / ons post-op |
1 |
2020 |
| Drug |
utd1 injection |
1 |
2014 |
| Drug |
utd1 injection/capecitabine |
1 |
2014 |
| Biological |
v3-mommo |
1 |
2018 |
| Biological |
vaccination with mimotope p10s-padre |
1 |
2011 |
| Biological |
vaccination with mimotope p10s-padre/montanide isa 51 vg |
1 |
2011 |
| Biological |
vaccine therapy |
1 |
2019 |
| Biological |
vaccinia-cea vaccine |
1 |
1999 |
| Drug |
vagifemâ® (vaginal 17î²-estradiol) questionnaire |
1 |
2009 |
| Drug |
vagifemâ® (vaginal 17î²-estradiol) questionnaire/menopause symptom checklist |
1 |
2009 |
| Other |
vaginal lubricant |
1 |
2012 |
| Drug |
valacyclovir |
1 |
2016 |
| Drug |
valproic acid |
1 |
2012 |
| Behavioral |
values |
1 |
2019 |
| Drug |
vandetanib (zd6474) |
1 |
2007 |
| Drug |
vantictumab |
1 |
2013 |
| Drug |
vantictumab/with paclitaxel |
1 |
2013 |
| Procedure |
vascularized lymph node transfer |
1 |
2019 |
| Drug |
vectibix |
1 |
2009 |
| Other |
vegetable, low fat |
1 |
2003 |
| Drug |
velcade |
1 |
2005 |
| Genetic |
veledimex |
1 |
2012 |
| Device |
venous access port |
1 |
2016 |
| Device |
venous access port/picc |
1 |
2016 |
| Procedure |
venous blood draw |
1 |
2009 |
| Procedure |
venous occlusion plethysmography |
1 |
2015 |
| Device |
ventilator |
1 |
2019 |
| Behavioral |
verbal counselling |
1 |
2019 |
| Behavioral |
verbal support |
1 |
2017 |
| Procedure |
vibrant-de |
1 |
2007 |
| Device |
vicryl* |
1 |
2008 |
| Device |
vicryl*/suture |
1 |
2008 |
| Drug |
vidaza |
1 |
2014 |
| Behavioral |
video |
1 |
2015 |
| Other |
video game program |
1 |
2016 |
| Behavioral |
video/booklet |
1 |
2015 |
| Behavioral |
videoconferencing support group |
1 |
2010 |
| Behavioral |
videos |
1 |
2016 |
| Drug |
vinca alkaloids |
1 |
2014 |
| Drug |
vinflunine/capecitabine |
1 |
2010 |
| Drug |
vinorebine, everolimus |
1 |
2012 |
| Drug |
vinorelbin |
1 |
2020 |
| Drug |
vinorelbine 25 mg |
1 |
2011 |
| Drug |
vinorelbine 25 mg/m2 weekly |
1 |
2011 |
| Drug |
vinorelbine 40mg |
1 |
2020 |
| Drug |
vinorelbine injection |
1 |
2014 |
| Drug |
vinorelbine oral |
1 |
2008 |
| Drug |
vinorelbine weekly |
1 |
2011 |
| Drug |
vinorelbine, paclitaxel, nab-paclitaxel , docetaxel, capecitabine |
1 |
2014 |
| Drug |
vinorelbine/capecitabine |
1 |
2008 |
| Drug |
vinorelbine/epirubicin |
1 |
2015 |
| Other |
virtual reality |
1 |
2013 |
| Drug |
viscum album pini |
1 |
2005 |
| Device |
visica 2 treatment system |
1 |
2013 |
| Device |
visionrt |
1 |
2016 |
| Drug |
vismodegib |
1 |
2015 |
| Drug |
vistusertib |
1 |
2014 |
| Drug |
vitablueâ„¢ |
1 |
2013 |
| Dietary Supplement |
vitamin b12 |
1 |
2010 |
| Biological |
vm206ad |
1 |
2013 |
| Biological |
vm206dna |
1 |
2013 |
| Biological |
vrp-her2 |
1 |
2018 |
| Behavioral |
wait list |
1 |
2017 |
| Other |
waitlist |
1 |
2012 |
| Behavioral |
waitlist control group |
1 |
2007 |
| Behavioral |
walk with ease |
1 |
2016 |
| Behavioral |
walk with ease arm a |
1 |
2015 |
| Behavioral |
walk with ease program |
1 |
2014 |
| Behavioral |
walking (control) |
1 |
2017 |
| Behavioral |
walking exercise |
1 |
2015 |
| Behavioral |
walking program |
1 |
2016 |
| Behavioral |
walking training |
1 |
2019 |
| Other |
walking/simulated-altitude |
1 |
2017 |
| Behavioral |
watch dvd |
1 |
2011 |
| Behavioral |
watch dvd/small group discussion |
1 |
2011 |
| Biological |
water for injection |
1 |
2011 |
| Radiation |
wbi 15 fractions |
1 |
2017 |
| Radiation |
wbi 5 fractions |
1 |
2017 |
| Device |
wearable device (fitbit charge hrâ® |
1 |
2017 |
| Device |
wearable device (fitbit charge hrâ®/fitbit alta â®) |
1 |
2017 |
| Behavioral |
web-based counseling |
1 |
2016 |
| Other |
web-based decision aid |
1 |
2017 |
| Behavioral |
web-based decision support |
1 |
2009 |
| Behavioral |
web-based health planner on diet |
1 |
2012 |
| Behavioral |
web-based health planner on diet/exercise |
1 |
2012 |
| Other |
web-based screening |
1 |
2013 |
| Other |
web-based screening/tailored support |
1 |
2013 |
| Behavioral |
website |
1 |
2012 |
| Drug |
weekly paclitaxel |
1 |
2018 |
| Behavioral |
weight gain prevention program |
1 |
2007 |
| Behavioral |
weight loss |
1 |
2010 |
| Other |
weight management classes |
1 |
2016 |
| Procedure |
weight measurement |
1 |
2017 |
| Other |
wellness seminar series |
1 |
2008 |
| Genetic |
western blotting |
1 |
2008 |
| Drug |
white button mushroom extract |
1 |
2008 |
| Other |
whole-body fdg pet-ct alone |
1 |
2016 |
| Radiation |
whole-brain radiotherapy |
1 |
2012 |
| Device |
whole body mri |
1 |
2016 |
| Procedure |
whole brain radiation |
1 |
2007 |
| Radiation |
whole brain radiation therapy (wbrt) |
1 |
2004 |
| Radiation |
whole brain radiotherapy (wbrt) |
1 |
2012 |
| Radiation |
whole breast |
1 |
2017 |
| Radiation |
whole breast irradiation (wbi) |
1 |
2014 |
| Radiation |
whole breast irradiation / boost/hypofractionated irradiation |
1 |
2010 |
| Radiation |
whole breast irradiation delivered by 3-dimensional conformal radiation therapy |
1 |
2011 |
| Radiation |
whole breast irradiation delivered by 3-dimensional conformal radiation therapy/intensity modulated radiation therapy |
1 |
2011 |
| Radiation |
whole breast radiation |
1 |
2015 |
| Radiation |
whole breast radiotherapy |
1 |
2005 |
| Device |
whole breast ultrasound |
1 |
2015 |
| Radiation |
whole breast/nodal irradiation |
1 |
2017 |
| Procedure |
wide excision |
1 |
2017 |
| Procedure |
wire-guided lesion localization |
1 |
2013 |
| Procedure |
wire-localized abnormal node |
1 |
2013 |
| Drug |
with carboplatin followed by epirubicin |
1 |
2019 |
| Drug |
with fulvestrant |
1 |
2019 |
| Procedure |
with meditation |
1 |
2012 |
| Biological |
with obi-821 |
1 |
2018 |
| Drug |
with paclitaxel |
1 |
2013 |
| Drug |
with trastuzumab |
1 |
2013 |
| Drug |
with weekly paclitaxel. |
1 |
2012 |
| Procedure |
without preoperative access to lymphoscintigraphy findings |
1 |
2015 |
| Drug |
without trastuzumab |
1 |
2009 |
| Biological |
wokvac vaccine |
1 |
2017 |
| Behavioral |
workshop |
1 |
2015 |
| Procedure |
wound care management |
1 |
2019 |
| Procedure |
wound infiltration with drug a (active) |
1 |
2018 |
| placebo |
wound infiltration with drug p (placebo) |
1 |
2018 |
| Drug |
wx-671 |
1 |
2008 |
| Radiation |
x |
1 |
2011 |
| Device |
x-ray computed tomography |
1 |
2016 |
| Device |
x-ray computed tomography (ct) |
1 |
2016 |
| Drug |
xianlinggubao |
1 |
2015 |
| Drug |
xinmailong injection |
1 |
2018 |
| Drug |
xl765 (sar245409) |
1 |
2010 |
| Biological |
xmab20717 |
1 |
2018 |
| Biological |
xmabâ®23104 |
1 |
2018 |
| Drug |
xmt-1522 |
1 |
2016 |
| Drug |
xrp9881 |
1 |
2004 |
| Biological |
yb-1 |
1 |
2014 |
| Other |
yes portal |
1 |
2019 |
| Drug |
ym155 |
1 |
2009 |
| Other |
yoga classes |
1 |
2013 |
| Behavioral |
yoga group |
1 |
2007 |
| Behavioral |
yoga intervention |
1 |
2015 |
| Other |
yogic |
1 |
2014 |
| Other |
yogic/routine exercises |
1 |
2014 |
| Biological |
young til |
1 |
2010 |
| Behavioral |
young women’s intervention (ywi) |
1 |
2012 |
| Radiation |
yttrium y 90 monoclonal antibody b3 |
1 |
2001 |
| Radiation |
yttrium y 90 monoclonal antibody bre-3 |
1 |
2001 |
| Radiation |
yttrium y 90 monoclonal antibody mn-14 |
1 |
1999 |
| Behavioral |
ywi |
1 |
2011 |
| Drug |
za |
1 |
2006 |
| placebo |
za matching placebo |
1 |
2006 |
| Drug |
zactima |
1 |
2008 |
| Drug |
zarnestra, tipifarnib, r115777 |
1 |
2002 |
| Drug |
zd1839 |
1 |
2007 |
| Drug |
zd1839 in combination with docetaxel |
1 |
2003 |
| Drug |
zd6474 |
1 |
2002 |
| Drug |
zd9393 (zoladex) 10.8 mg |
1 |
2010 |
| Drug |
zd9393 (zoladex) 3.6 mg |
1 |
2010 |
| Device |
zemy software |
1 |
2018 |
| Drug |
zen003694 |
1 |
2019 |
| Drug |
zhongyaofufang |
1 |
2015 |
| Biological |
ziv-aflibercept |
1 |
2006 |
| Drug |
zn-c3 |
1 |
2019 |
| Drug |
zo-nantax |
1 |
2011 |
| Drug |
zofran |
1 |
2015 |
| Drug |
zoledronic acid i.v. 2 years |
1 |
2014 |
| Drug |
zoledronic acid i.v. 5 years |
1 |
2014 |
| Drug |
zoledronic acid; letrozole |
1 |
2005 |
| Drug |
zolpidem tartrate |
1 |
2004 |
| Drug |
zometa / neoadjuvant therapy |
1 |
2010 |
| Radiation |
zometaâ„¢ |
1 |
2007 |
| Drug |
zr89-trastuzumab |
1 |
2011 |